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The desmosome is an inter-cellular complex required for strong cell-cell adhesion in skin and 
heart tissue. The plakin family of proteins are important to the desmosome as their main function 
is to act as linkers between the cell surface and cytoskeleton. Plakin proteins are defined by the 
presence of a plakin domain which is composed of spectin repeats, a central coiled coil rod 
domain and a C-terminal tail containing plakin repeat domains and a linker domain. The 
structures, dynamics and interactions of these component domains have remained largely 
unknown.  Moreover, many mutations in the desmosomal genes that cause arrhythmogenic right 
ventricular cardiomyopathy (ARVC) and various skin blistering diseases are known but their 
consequences remain undefined. Consequently this thesis used biophysical techniques to better 
understand plakin family function but also to shed light into the specific effects of pathological 
mutations.  
The primary aims of the thesis were to investigate the plakin domain structure in solution, 
whether the linker domain constituted a structured domain and whether there were structural 
differences between plakin repeat domains. In order to achieve this complementary biophysical 
techniques including nuclear magnetic resonance (NMR) spectroscopy, small angle X-ray 
scattering (SAXS) and X-ray crystallography were used. Specifically, the N and C termini from 
plakin family members desmoplakin, envoplakin and periplakin were explored.  
The study generated novel insights into a variety of areas. These included the modular 
organization of plakin domains in solution. The non-linearity and flexibility of serial spectrin 
repeat constructs in the N-terminal plakin domain was established, contrary to previous 
predictions. The envoplakin C-terminal plakin repeat domain (PRD) was successfully 
crystallized, with the structure revealing novel features including a putative alternative binding 
groove. The discovery of a novel structural domain at the C-terminal tail of desmoplakin, 
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envoplakin and periplakin was made, revealing a possible mechanism in cytoskeletal 
preference. Finally the molecular consequences of a series of pathogenic point mutations known 
to cause ARVC were defined, including dramatic destabilisation and subtle conformational 
effects.   
Together this provides a better understanding of the specific roles of the plakin family’s N- and 
C- termini in linking to the desmosomal machinery on the cell membrane and in intermediate 
filaments, respectively.  The conservation and divergences of the key features across the plakin 
family illustrates how desmosomal domain structure, dynamics, stability and interactions play 
essential yet specialised roles in preserving the integrity and flexibility of strong cell-cell junctions 
within distinct tissues. The results set out a foundation of work to better understand how the 
functional N and C termini “arms” of plakin proteins allow desmosomal assembly and 
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Chapter 1 - Introduction 
The following introduction will give a broad overview of the desmosomal field. The introductions 
of the following results chapters will then expand on the information presented in this chapter.  
1.1 Cell adhesion 
In order for a multicellular organism to develop fully functioning organs, tissues are required and 
these in turn are made up of specialized differentiated cells. For cells to become part of a 
specific tissue they must adhere to one another. Adhesion amongst cells is therefore critical in 
maintaining tissue integrity. How the cells adhere to one another is based on the tissue and 
organ and is maintained by adhesion molecules in cell junctions. There are two types of cell 
junctions; cell-cell (or intercellular) and cell-matrix junctions (Wegener, 2001). Cell junctions are 
found in abundance in epithelial tissues (such as the skin, intestine, stomach, bladder, uterus 
and pancreas) and the myocardium. They maintain the strength and flexibility of epithelial and 
myocardial tissues. Intercellular junctions, as their name implies, connect one cell to another. 
Cell-matrix junctions on the other hand adhere cells to the extracellular matrix. Cell junctions are 
further divided into three groups: occluding junctions, anchoring junctions and communicating 
junctions (Wegener, 2001). Occluding junctions which include tight junctions are specialized to 
create a diffusion barrier by sealing cells together. Communicating junctions such as gap 
junctions allow free transfer of small molecules and solutes between adjacent cells. Anchoring 
junctions are specialized to confer strong cell to cell and cell to extracellular matrix adhesion and 





Figure 1.1 Schematic diagram of cell-cell and cell-matrix adhesion junctions 
Tight junctions (yellow), adherens junctions (blue), desmosomes (red) and gap junctions (purple) 
are all cell-cell junctions which connect two basal epithelial cells. Hemidesmosomes (green) and 
focal adhesions (purple) represent cell-matrix junctions and connect epithelial cells to the 
basement membrane zone. Also shown are elements of the cell cytoskeleton including 
intermediate filaments (cyan) and actin microfilaments (dark green). Actin microfilaments are 
connected to adherens junctions and focal adhesions. Desmosomes and hemidesmosomes are 
connected to intermediate filaments. Integrins (dark blue) anchor hemidesmosomes and focal 
adhesions to the basement membrane zone via the plasma membrane. Adhesion between 
desmosomes and adherens junctions are mediated by cadherins (black) in the extracellular 






1.11 Anchoring junctions 
Anchoring junctions have an adhesive interface in the intercellular space between adjacent cells 
that is mediated by transmembrane molecules (discussed below) which interact to seal the 
adjacent cells together. These transmembrane molecules are often connected to the 
cytoskeleton or to signalling molecules by “adaptor proteins”. Anchoring junctions are further 
subdivided into four classes, adherens junctions, desmosomes, hemidesmosomes and focal 
adhesions (Alberts et al., 2002). Adherens junctions and desmosomes engage in intercellular 
adhesion and contain transmembrane proteins from the cadherin family. Hemidesmosomes and 
focal adhesions engage in cell-matrix adhesion with their transmembrane proteins from the 
integrin family. The cytoskeletal network binds to both desmosomes and hemidesmosomes 
while adherens junctions and focal adhesions are connected to the actin microfilament 
cytoskeleton (discussed further in 1.2) (Alberts et al., 2002). Although architecturally similar, 










1.2 The cell cytoskeleton  
The cytoskeleton is a eukaryotic cell structure that provides the cell with mechanical strength 
and maintains its shape and integrity (Insall and Machesky, 2001). It is made up of three major 
components, actin microfilaments, microtubules and intermediate filaments (IFs). These 
components are assembled from soluble precursors to form larger complex networks. Assembly 
is carefully controlled by a variety of different cellular processes. Actin microfilaments have 
important roles in cell migration, contraction and polarity (Insall and Machesky, 2001). 
Microtubules are essential for processes such as intracellular vesicle, organelle and protein 
delivery, and are the largest filaments with a diameter of 25 nm. IFs play important roles in 
intracellular mechanical strength and are therefore present in tissues that encounter frequent 
mechanical stress such as the epidermis and muscles (Foisner, 2001). Plakin family members 
are known to act as cytolinkers, connecting elements of the cytoskeleton to each other and to 
junctional complexes at the membrane, and will be discussed further in section 1.4. 
1.21 Intermediate filaments 
Intermediate filaments are unique relative to other cytoskeletal family members (Herrmann and 
Aebi, 2004). They are made up of elongated α-helical protein building blocks. The α-helical 
“building blocks” are unstable in solution and multimerize to create a hydrophobic core in order 
to stabilize the IF whilst exposing their hydrophilic amino acids on the surface. This in turn 
makes IFs fibrous and rope-like, which makes them flexible and more resistant to mechanical 
stress than the other cytoskeletal elements (Foisner, 2001).   
Intermediate filament proteins are expressed in a tissue-specific manner and are encoded by a 
total of 70 genes (Hesse et al., 2001). They are divided into six sequence homology classes 
(SHC) based on their primary structure, gene structure, assembly properties and tissue 
expression patterns. These are acidic keratins (SHC I), basic keratins (SHC II), desmin-vimentin-
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type proteins (SHC III), neurofilaments (SHC IV), nuclear lamins (SHC V) and eye-lens filaments 
(SHC VI). Plakin family members have been shown to bind to keratins, vimentin and desmin 
(Favre et al., 2011, Fontao et al., 2003, Kazerounian et al., 2002, Meng et al., 1997b, 
Stappenbeck et al., 1993, Lapouge et al., 2006). This study is particularly interested in the 
SHCIII desmin-vimentin type proteins given their relevance to plakin family binding. 
There are several features of IFs that are revealed by primary sequence analysis. Firstly, the 
heptad repeat (a-b-c-d-e-f-g)n is observed which are typical of α-helical two stranded coiled coils 
like that observed for IFs. The a and d positions are typically occupied by hydrophobic residues 
such as leucine, isoleucine or valine. There are 3.5 residues per turn and is left-handed to 
compensate for a small structural difference of the parallel α-helix. IFs are made up of a tripartite 
structure with a central ~310 amino acid α-helical rod domain which is flanked by N (head) and 
C (tail)-termini of variable length. It is thought that while the C-terminus is dispensable (Hatzfeld 
and Weber, 1990), the N-terminus is essential for filament assembly (Herrmann and Aebi, 2004). 
1.22 Intermediate filament assembly 
Keratins (SHC I and II) form heterodimers while the desmin/vimentin type (SHC III) and 
nuerofilaments (SHC IV) form homopolymers in vitro. Denatured vimentin filaments form dimers 
at a concentration of 6 M urea. Vimentin assembles into a mix of dimers and tetratmers under 
further dilution to 4.5 M urea. In buffers of low ionic strength (e.g. 5mM Tris-HCl) and in the 
absence of urea, vimentin forms long and uniform filaments (Herrmann and Aebi, 2004). 
Increasing the ionic strength (≥130 mM) by the addition of salts initiates multimeric filament 
formation. In vivo, vimentin is generally observed in the polymerized state although there are 
reports of an unpolymerized pool of unknown significance (Blikstad, 1983). Furthermore, it is 





Desmosomes were first discovered by Giulio Bizzozero in 1864 (Bizzozero, 1864) and were 
named desmosomes by Josef Schaffer in 1920 (Schaffer, 1920). In 1974 the molecular 
components of the desmosome were characterized by Skerrow and Matoltsy (Skerrow and 
Matoltsy, 1974) who identified 8 proteins by SDS-PAGE analysis. They also correctly assumed 
that the cadherins were responsible for intercellular adhesion.  Desmosomes are known for their 
important role in strong intercellular adhesion and the maintenance of tissue integrity. Since 
desmosomes are connected to the IF cytoskeletal network, they are thought to have a role in 
resisting mechanical stress imparted on the cell from intracellular and extracellular sources 
(Green and Gaudry, 2000). This is inferred from the plethora of studies which show that 
breakage of the links of the desmosome to the cytoskeletal network cause a variety of different 
diseases (Russell et al., 2004, Vasioukhin et al., 2001, Bierkamp et al., 1996, Thomason et al., 
2010).  
The desmosome is typically described as containing three ordered regions: 1) the extracellular 
core domain (ECD), 2) the outer dense plaque (ODP) and 3) the inner dense plaque (IDP). The 
cytoskeletal network is connected to the desmosome via the IDP (Garrod and Chidgey, 2008). 
While the thickness of both the ODP and IDP combined is approximately 15-20 nm, the diameter 
of an entire desmosome is less than 1 µm. However, the actual size and morphology may also 
vary within and between different tissues.  
1.31 Desmosome composition  
The desmosome is comprised of proteins from three distinct families, the cadherin family, the 
armadillo family and the plakin family (figure 1.2) (Garrod and Chidgey, 2008). Depending on 
tissue location, expression patterns from within the families vary. These include the cadherin 
proteins desmoglein (DSG1-4), desmocollin (DSC1-3) and the armadillo proteins: plakophilin 
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(PKP1-3) and plakoglobin. The armadillo protein plakoglobin only has one isoform while 
desmoplakin has two isoforms DSPI and DSPII. Although these proteins form the minimal 
requirement for desmosomal formation, additional proteins such as periplakin and envoplakin 










Figure 1.2 Molecular composition of the desmosome 
A schematic diagram of the desmosome joining two adjacent cells (only one shown in detail) 
showing the relative positions of the armadillo proteins plakophilin (PKP) and plakoglobin (PG) 
(both purple), the cadherin proteins desmocollin (DSC) (green) and desmoglein (DSG) (red) and 
the obligatory plakin protein desmoplakin (N and C-terminal domains shown in yellow separated 
by a coiled coil domain). Also indicated is the location of what is termed the “outer dense plaque” 
and the “inner dense plaque”. Plakin proteins bind to intermediate filaments (dark blue) at their 







1.32 Cadherin family 
In humans the desmosomal cadherin family are made up of seven proteins DSC1-3 and DSG1-
4. The cadherin family form the “molecular glue” of two inter-cellular desmosomes. They are 
single-pass membrane spanning proteins. Their N-terminal extracellular domain made up of 5 
homologous cadherin domains. The cadherin domains are separated by putative flexible linkers 
which accommodate 3 calcium ions (Garrod et al., 2005). Studies have shown interactions in a 
homophilic (i.e. between desmoglein and desmoglein) and heterophilic (i.e. between desmoglein 
and desmocollin) fashion both in cis (between cadherins of the same cell) and trans (between 
cadherins of adjacent cells) (Nie et al., 2011). Since the N-terminal domains contain multiple 
cadherin modules and are highly homologous, it is likely this portion of the protein is 
predominantly folded. 
Their second domain is their transmembrane domain which anchors the proteins in the 
membrane. Finally, the cadherin family have a cytoplasmic tail domain which interacts with the 
intra-cellular components of the desmosome (Garrod and Chidgey, 2008). The C-terminal tails 
(which contain the least homology amongst one another) are intrinsically disordered and form a 
“hub” for interacting with a variety of different desmosomal proteins (Kami et al., 2009), a typical 
feature of intrinsically disordered regions (Haynes et al., 2006).  It is still unclear how this 
desmosomal “hub” correctly assembles with multiple protein partners to form a characteristic 
desmosome. However, multiple interactions have been characterized between different 
desmosomal proteins and these are currently under further investigation by Martyn Chidgey’s 
lab.  
1.33 Armadillo family 
Armadillo family proteins are characterized by their highly conserved and alpha helical central 
ARM repeat domains. The arm repeats (of which there are a variable number depending on the 
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armadillo family member) typically consist of 42 amino acids resulting in one alpha helix (Choi 
and Weis, 2005). The central Arm repeat domain is flanked by unstructured N and C-termini 
(JK3rd et al., 2000). The most characterized of all the armadillo family members is β-catenin 
(Choi and Weis, 2005, Haegel et al., 1995, Zhurinsky et al., 2000). The armadillo desmosomal 
components homologous to β-catenin are plakoglobin and plakophilin. β-catenin localizes to 
adherens junctions only and is unable to interact with the desmosome (Troyanovsky et al., 
1996). Crystal structures are available for β-catenin (Huber et al., 1997), PKP1 (Choi and Weis, 
2005), PKP2a (Kirchner et al., 2012) and plakoglobin (Choi et al., 2009). They reveal multiple 
motifs consisting of 3 α-helices organised into the shape of a right handed helix superhelix. In 
turn, this creates a positively charged groove on its surface which interacts with ligands.  
Plakoglobin interactions occur via its conserved central ARM repeat domain for which repeats 1-
3 are required for interaction with the C-terminal tail of DSG1 and DSC2a (Chitaev et al., 1998). 
Other protein interactions include desmoplakin (Kowalczyk et al., 1997), PKP2 and PKP3 
(Bonné et al., 2003, Chen et al., 2002), however, the binding sites have not been identified. A 
study investigating the deletion of the plakoglobin C-terminus observed larger desmosomes 
which suggested that plakoglobin regulates the control of desmosome size by its interactions 
with other desmosomal proteins (Palka and Green, 1997). Plakoglobin is also implicated in 
signal transduction (Garrod and Chidgey, 2008). Plakoglobin is highly homologous to β-catenin 
(a modulator of the Wnt/ β-catenin pathway) and the two molecules are thought to compete for 
proteins involved in this pathway. Whether plakoglobin activates or represses this pathway is 
unclear as is whether it plays a distinct role to that of β-catenin (Zhurinsky et al., 2000). β-
catenin knock out studies show that plakoglobin cannot compensate for the lack of β-catenin 
(Bierkamp et al., 1996, Haegel et al., 1995, Ruiz, 1996). Suppression of desmoplakin in cardiac 
myocytes results in translocation of plakoglobin to the nucleus. This in turn leads to suppression 
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of the Wnt/ β-catenin pathway (Garcia-Gras et al., 2006). Interestingly plakoglobin had been 
suggested to bind to the N-terminal of desmoplakin (Bornslaeger et al., 2001, Kowalczyk et al., 
1997) however unpublished results from our lab have shown that a direct interaction between 
the two is unlikely to occur in vitro. Therefore it appears that plakoglobin interaction with the 
desmosome is likely to be more complex than originally thought.  
There are three plakophilins (PKP): PKP1, PKP2 and PKP3. They each contain a central 9 ARM 
repeat domain, a large unstructured N-terminal domain and a short unstructured C-terminal 
domain. Unlike plakoglobin they contain a large and putative flexible region between repeats 5 
and 6 (Choi and Weis, 2005). PKP members are localized to the desmosome and nucleus and 
bind a wide variety of proteins including desmoplakin, cadherins, β-catenin, plakoglobin and 
intermediate filaments (Zhurinsky et al., 2000). Recently it was also discovered that PKP can 
bind to single stranded DNA (Sobolik-Delmaire et al., 2010) as well as other DNA associated 
proteins; RNA polymerase III and transcription factor TFIIIB (Mertens et al., 2001). Hence it is 
possible that they play both a structural and signalling role in association with desmosomes. 
Interestingly, all interactions of PKP so far documented are mediated via its unstructured head 
domain (Choi and Weis, 2005).   
1.4 Plakin family 
The plakin family typically provide a link between cytoskeletal proteins and junctional complexes. 
So far seven members have been identified including desmoplakin, periplakin, envoplakin, 
plectin, bullous pemphigoid antigen-1 (BPAG1), epiplakin and microtubule-actin crosslinking 
factor (MACF) (Sonnenberg and Liem, 2007a). Four of these proteins (desmoplakin, periplakin, 
envoplakin and plectin) are known to localize to the desmosome but of the four only 
desmoplakin is essential for desmosomal adhesion. Typically, plakin proteins consist of a N-
terminal head domain including a globular plakin domain (which itself is made up of spectrin 
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repeat (SR) modules), a central coiled coil rod domain and a C-terminal tail with a “linker” 
domain and variable numbers of plakin repeat domains (PRDs) (discussed in further detail in 
1.62). The focus of the thesis was to investigate the biophysical properties of the proteins 
desmoplakin, envoplakin and periplakin and will therefore be discussed in further detail. A 













Figure 1.3 Schematic diagram of plakin family members that are associated with 
desmosomes 
A: The tripartite structures of desmoplakin, envoplakin, periplakin and plectin are shown. At the 
N-terminal (head) region a plakin domain (Plakin) is present in all plakin family members with the 
exception of epiplakin. The middle rod domain (Rod) consists of a coiled coil. Finally the C-
terminal (tail) region consists of a variable number of PRDs (termed A, B and C) and a linker 
domain (L). Additionally, plectin contains a unique N-terminal actin binding domain (ABD). B: 
The plakin domain of desmoplakin consists of 6 SRs and an SH3 domain. This represents a 
typical plakin domain of a plakin family member although the number of SRs can vary between 
family members. Also indicated is a hinge located between SR6 and SR7 and a flexible “CT” 






Desmoplakin is an obligatory component of the desmosomal complex. Its N-terminal head 
region interacts with plakoglobin and plakophilin (Bornslaeger et al., 2001, Kowalczyk et al., 
1997). Its coiled coil rod domain region facilitates homo-dimerization (Green et al., 1990), 
whereas the C-terminal tail interacts with intermediate filament proteins and contains 3 PRDs 
(designated A, B and C). Two isoforms created by alternative splicing are known; DPI (~332 
kDa) and DPII (~260 kDa). They are essentially identical except that DPII has a shorter rod 
domain. The reason why two splice variants are required is currently unknown. Both are 
expressed widely and abundantly with the exception of the heart where DPII is only expressed at 
very low levels (Garrod and Chidgey, 2008). Using antibodies against the N and C-termini of 
desmoplakin the orientation of molecule was determined which suggested the N-terminal end 
orientates towards the membrane region while the C-terminal end orientates towards the 
intracellular region (North et al., 1999). This corroborated previous findings which suggested the 
N-terminal end of the protein is required for desmosomal assembly whereas the C-terminal end 
is required for binding to cytoskeletal proteins. Desmoplakin’s role is thus primarily to mediate 
interactions between a variety of intermediate filaments (keratin, desmin and vimentin) and the 
desmosome. A putative phosphorylation site at the extreme C-terminal tail (S2849) has also 
been shown to weaken interaction with keratin when phosphorylated as indicated by a point 
mutation (S2849G) disrupting assembly into desmosomes (Stappenbeck et al., 1994). 
1.42 Envoplakin and periplakin 
Both envoplakin (~210 kDa) and periplakin (~195 kDa) were identified as protein constituents of 
the epidermal cornified envelope (Ruhrberg et al., 1997). This is an area that is found in the 
outermost layers of the skin that contributes to its barrier function. Both proteins are found 
localized to desmosomes and the interdesmosomal membrane where they contribute to a 
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scaffold upon which the cornified envelope assembles (Sonnenberg and Liem, 2007a). 
Periplakin and envoplakin form a functional dimeric unit through heterodimerization facilitated by 
their rod domain (Ruhrberg et al., 1997). Periplakin is also thought to form homodimers via its 
rod domain based on a scoring method described by (Parry et al., 1977) which correctly 
deduced that keratin would form heterodimers. In addition, heterodimerization is thought to be 
facilitated by the linker domains at the C-terminal tails of both envoplakin and periplakin 
(Karashima and Watt, 2002). Surprisingly when the periplakin or envoplakin genes were 
disrupted in mice, cornified envelope assembly remained intact with little observable differences 
(Aho et al., 2004, Määttä et al., 2001). A triple gene disruption of envoplakin, periplakin and 
involucrin revealed impairment to the epidermal barrier including cornified envelopes that were 
ultrastructurally abnormal with impaired desquamation (Sevilla et al., 2007). Therefore it appears 
that the three proteins work together for effective cornified envelope formation. Autoantibodies 
have also been found targeting the linker domains of envoplakin and periplakin in the skin 
disease paraneoplastic pemphigus (Kiyokawa et al., 1998, Mahoney et al., 1998); whether the 
antibodies are important in the aetiology of the disease is unknown.  
Binding partners of envoplakin and periplakin have been identified. Kazrin (a desmosomally 
localized protein of unknown significance and structure) binds to the first 131 amino acids of 
periplakin, a likely unstructured region (Groot et al., 2004). Plectin has also been shown to bind 
to periplakin at the extreme N-terminal (Boczonadi et al., 2007). However, no binding partners 
have been identified for the N-terminal region of envoplakin. The linker domain is the sole 
domain of the periplakin C-terminal tail and is known to bind keratin 8 and vimentin (Kazerounian 
et al., 2002). The binding propensity of the envoplakin C-terminal tail (which consists of a linker 
domain and one PRD) is less clear as to whether it can bind vimentin with or without the 
presence of periplakin (Karashima and Watt, 2002).  
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1.5 Biophysical properties of plakin proteins 
1.51 The N-terminal head domain of plakin proteins 
The N-terminal head region of plakin proteins contain a N-terminal tail of variable length followed 
by a globular region called the plakin domain. Unpublished results from our lab showed that the 
extreme N-terminal region of desmoplakin contained a predominantly α-helical secondary 
structure however, was unable to form a folded tertiary structure as shown by 1D-NMR 
(Unpublished results Dr Keichiro Kami, 2008). Conversely, the preceeding plakin domain is 
relatively well studied. It was originally proposed to contain 6 α-helical fragments (NN, Z, Y, X, 
W, V) which formed α-helical bundles (Virata, 1992). However, in 2007 the α-helical bundles 
were identified as being members of the spectrin superfamily (Jefferson et al., 2007). Also 
present are a SH3 domain and CT region (Sonnenberg et al., 2007, Al-Jassar et al., 2011). 
Unfortunately, the previously outdated nomenclature is still being used in very recent 
publications despite the proven presence of spectrin repeats in multiple plakin family members.  
1.52 The plakin domain is a member of the spectrin superfamily  
1.53 The spectrin repeat 
To date, spectrin, dystrophin, utrophin, α-actinin and plakin proteins are known members of the 
spectrin superfamily (Broderick and Winder, 2005, Jefferson et al., 2007). Spectrin repeats 
(SRs) form the structural  platform of the spectrin superfamily (Djinovic-Carugo et al., 2002). 
Interestingly, the SR is unique to the animal kingdom (Broderick and Winder, 2005). A SR is a 
left-handed anti-parallel triple helical coiled often found in proteins with multiple copies (4-20 
plus) (Yan et al., 1993). They are characterized by a typical heptad repeat structure termed 
a,b,c,d,e,f,g where a and d are usually occupied by apolar residues involved in hydrophobic 
packing of the SR similarly to those observed in IFs. In addition to these interactions, charged 
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side chains at positions g and e from adjacent coils stabilize the fold of the domain. SRs are 
often found in tandems connected through a linker region (Law et al., 2003). The linker region is 
often an α-helical structure which contributes to their linear and non-globular structure (Law et 
al., 2003). Serial chains of SRs are therefore thought to form linear structures, which is 
corroborated by the multitude of crystal and NMR structures of SRs (Ylänne et al., 2001). 
However, a paper published with my colleagues based on data presented in this thesis (chapter 
4) showed that the desmoplakin plakin domain is non-linear (appendix A1). The study was the 
first of its kind to investigate the solution structure of a protein containing over 3 spectrin repeats, 
and contrasts with the exclusively linear conformation of previous structures solved by X-ray 
crystallography (Al-Jassar et al., 2011).  
The main function of SRs is to withstand mechanical stress (Law et al., 2003). This is 
unsurprising given that SRs are located in proteins expressed in tissues known to encounter 
mechanical and/or abrasive forces. For instance spectrin is known to withstand mechanical 
stress which the red blood cell encounters and plakin family members are tethered to 
cytoskeletal proteins which function to resist mechanical stress. Furthermore they are known to 
bind a diverse range of ligands including (and not limited to) ankyrin, F-actin, α-catenin and titin 
(Broderick and Winder, 2005).       
1.54 The SH3 domain  
The SH3 domain is a well characterized protein module known to bind proline rich motifs 
(Kaneko et al., 2008). First characterized from the protein spectrin, it was reported as being an 
independent unit with no preference of location on its host protein (Musacchio et al., 1992). This 
has a bearing on the plakin domain SH3 domains which is discussed further in 1.61. They are 
small (55-70 amino acids) β barrel domains made up of 5 anti parallel β-sheets that are tightly 
compacted to form a spherical structure. SH3 domains contain a highly variable RT (arginine-
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threonine) loop. This is located between the first and second β-strands and contains an irregular 
anti parallel structure separated by acidic residues. The RT loop is often the site of ligand 
interaction which binds to motifs typically with PxxP (proline rich) motifs (Musacchio et al., 1994, 
Yu et al., 1994).   
1.6 Biophysical data on plakin proteins  
1.61 X-ray crystallography data of constructs from plakin domains 
To date four crystal structures have been elucidated for the plakin domains from BPAG1 
(Jefferson et al., 2007), plectin (Ortega et al., 2011, Sonnenberg et al., 2007) and desmoplakin 
(Choi and Weis, 2011) some of which were published during the collection of data on similar 
constructs for this study. Published findings including the solution structure of the entire plakin 
domain and its modular organization is discussed in detail in chapters 3 and 4 and will therefore 
not be discussed in this chapter.  
The structures elucidated from various segments of the plakin domain from BPAG1, plectin and 
desmoplakin reveal a high level of structural homology to typical SR structures. Early studies 
also revealed the presence of a SH3 domain within the plakin domain located within SR5 
(Sonnenberg et al., 2007). This was not surprising as the protein α-spectrin also contains a SH3 
domain (Musacchio et al., 1992). In 2011, two crystal structures revealed that the SH3 domain of 
plectin and desmoplakin is located within loop B of SR5 and interacts with SR4 in a fashion that 
rigidifies the plakin domain (Choi and Weis, 2011, Ortega et al., 2011). The result was a non-
canonical SH3 domain incapable of binding ligands through the conventional method of the RT 
loop. It is unlikely the SH3 domain is capable of binding ligands as its primary function appears 
to be rigidification of the SR3-6 region of the plakin domain. Although crystal structures of the 
more homologous N-terminal region from several plakin domains have been published the more 
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divergent C-terminal region remained uncharacterized. Furthermore SR6 from desmoplakin, the 
most C-terminal SR characterized to date at atomic resolution was revealed to be only “spectrin 
repeat like” according to the authors (Choi and Weis, 2011).  
1.61 The central coiled coil rod domain 
The coiled coil central domain has yet to be structurally elucidated in any plakin protein, despite 
its importance in protein multimerization and extension (Green et al., 1990).  
1.62 X-ray crystallographic data on plakin C-terminal tails       
The C-terminal tail is comprised of a highly homologous linker domain and variable numbers of 
PRDs. To date no biophysical data is available on the linker domains however are implicated in 
binding to cytoskeletal proteins (discussed previously in 1.2). The PRDs of desmoplakin 
however have been characterized by Bill Weis and his group (2002) . Through sequence 
homology they were originally predicted to resemble ankyrin repeats which are 30-34 amino acid 
motifs in a helix-turn-helix conformation which are packed in a linear array by intra and inter-
domain interactions (Li et al., 2006). Bill Weis’ group elucidated the crystal structures of 
desmoplakin PRDs B and C, revealing a novel structure containing 4.5 repeats of a 38 amino 
acid motif and termed it the plakin repeat (PR) motif. The motif itself consists of a β-hairpin 
followed by two anti parallel α-helices. Additionally a negatively charged residue at position 4 on 
the first β-strand of the β-hairpin interacts with a positively charged residue at position 19 of helix 
1 to “fix” the β-hairpin into place. Furthermore, multiple hydrophobic contacts are used to 
stabilize the two anti parallel α-helices. The entire PRD forms a globular and compact structure 
by further inter domain hydrophobic contacts. A positively charged groove was located in both 
molecular surfaces of desmoplakin PRDs B and C (Choi et al., 2002). This was proposed to be 
the putative binding site for vimentin. Manual docking revealed that the crystal structure of 
vimentin (PDB code: 1GK4) was able to fit into this groove (Choi et al., 2002). However, 
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although polymerized vimentin bound to variable constructs from the desmoplakin C-terminal tail 
including PRDs B and C, the presence of high salt (>1 M) was unable to disrupt interaction 
between the two proteins implying other interactions may play a more significant role in complex 
formation (Choi et al., 2002).  
1.7 Inherited diseases that affect desmosomes 
Mutations across all protein families of the desmosome have been identified as causative agents 
of inherited human skin and heart diseases (with the exception of envoplakin, periplakin, DSG3, 
DSC1 and PKP3). Disease causing mutations in many of the proteins that make up the 
desmosome are sufficient to impair desmosomal function (summarized in table 1.1). In turn this 
would weaken adhesive strength and tissue integrity. Since mutations often cause any 
combination of skin, hair and heart defects they are referred to as cardio-cutaneous syndromes 
(Bolling and Jonkman, 2009).  
Gene Mode of 
inheritance 
Phenotypes 
Skin Hair Heart 
DSG1 Dominant SPPK   
DSG2 Dominant   ARVC 
Recessive   ARVC 
DSG4 Recessive  Hypotrichosis  
DSC2 Dominant   ARVC 
DSC2 Recessive PPK, woolly hair and ARVC 
DSC3 Recessive Hypotrichosis  
Desmoplakin Dominant SPPK  ARVC 
Dominant SPPK, woolly hair and ARVC 
Recessive Carvajal syndrome 
Recessive Bullous dermatosis, PPK, total alopecia 
and ARVC 
Recessive Focal and diffuse PPK and woolly hair 
Plakoglobin Dominant   ARVC 
Recessive Naxos disease  




PKP2 Dominant   ARVC 
Recessive   ARVC 
Table 1.1 Dominant and recessive mutations in desmosomal genes and their disease outcomes 
Desmosomal genes which give rise to a variety of different skin and/or heart diseases. SPPK: 
Striate Palmoplantar Keratoderma. ARVC: Arrhythmogenic Right Ventricular Cardiomyopathy. 
PPK: Palmoplantar Keratoderma. 
1.71 Skin diseases and the desmosome 
Striate palmoplantar keratoderma (SPPK) and pemphigus vulgaris are two of the skin diseases 
known to affect the desmosome. Hereditary PPKs are a clinically heterogenous group which 
cause thickening of the epidermis in the palms and soles of the feet. They are usually caused by 
autosomal dominant mutations from multiple desmosomal genes. They are further subdivided 
into 3 groups – focal, diffuse and punctate PPK. Focal PPK is restricted to areas which 
encounter mechanical and frictional stress. In diffuse PPK a more uniform thickening of the 
epidermis is observed. Finally punctate PPKs are characterized by numerous pinhead-sized 
hyperkeratotic papules that are irregularly distributed and localized to the palms and soles. 
Pemphigus vulgaris is a potentially fatal autoimmune disease whereby autoantibodies are 
generated against proteins of the desmosome, typically DSG3 and DSG1. The underlying cause 
of autoantibody generation is unknown although genetic or environmental factors may contribute 
(Amagai et al., 1991). The disease is characterized by skin blistering deep in the epidermis 
which can lead to fluid loss and infection. The link between autoantibody generation and skin 
blistering is unclear. It has been postulated that autoantibody binding to extracellular domains of 




 1.72 Cardio-cutaneous diseases and the desmosome 
Naxos disease and Carvajal syndrome are both genetic diseases of the skin and heart that are 
caused by autosomal recessive mutations in the desmoplakin and plakoglobin genes 
respectively. They are characterized by PPK, woolly hair and heart disease. Whereas some 
suggest both diseases are a single entity caused by mutations in two different proteins, others 
suggest they are slightly different with Naxos disease causing right ventricular effects and 
Carvajal syndrome causing left-dilated cardiomyopathy. A similar syndrome caused by 
mutations in desmoplakin whereby the patients exhibited PPK and woolly hair but no cardiac 
defects was called “skin fragility woolly hair syndrome” described by Whittock et al (2002).  
1.73 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
ARVC is a genetic heart disease resulting in fibro-fatty tissue replacement in the right ventricule 
which leads to ventricular arrhythmias. Although its prevalence is reportedly low (estimates 
range from 1/1000-5000) it is one of the most common causes of unexpected sudden cardiac 
death in the young, particularly in young fit athletes (Awad et al., 2008). The prevalence may 
even be higher based on a recent study from Finland which suggested that as many as 1/200 
may be carriers of a mutation predisposing them to ARVC (Lahtinen et al., 2011). Furthermore, 
low reported prevalence in the general population may be due to inadequate autopsies in which 
pathologists are not required to delve further into the underlying genetic cause (Papadakis et al., 
2009). A genetic cause is thought to be the main cause in 50% of the cases and to date 7 genes 
have been implicated of which 5 encode cardiac desmosomal proteins (Awad et al., 2008). 
Studies have revealed that mutations in the cardiac desmosomal genes account for most of the 
reported cases of ARVC in the order of: (from high to low) PKP2>DP>DSG2>DSC2>PG (van 
Tintelen et al., 2006). 
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Historically ARVC was not officially described clinically until 1982 when Marcus et al reported 24 
cases in which the electrophysiological effects (i.e. on electrocardiograms) were first described 
(Marcus et al., 1982). It was not until 1994 when McKenna et al set out a number of clinical 
criteria known as the “Task force criteria” designed to aid diagnosis of ARVC (McKenna et al., 
1994). Criteria were separated as major and minor criterions in which, two major, four minor, or 
one major plus two minor criteria constituted diagnosis of ARVC in a patient. Major criteria 
included: reduced right ventricular ejection, fibrofatty replacement in the myocardium by biopsy, 
and “familial disease confirmed at necropsy or surgery”. Minor criteria included: altered 
electrocardiogram waves and familial history of sudden cardiac death. Despite these efforts to 
improve ARVC diagnosis it remains notoriously difficult to diagnose given the similarities to other 
cardiomyopathies (such as long QT syndrome). Differentiation between other cardiomyopathies 
often requires specialist examination and may still be ambiguous (Personal communication: 
Professor William McKenna, 2011). McKenna and colleagues recently updated the taskforce 
criteria further to facilitate diagnosis in which, amongst other suggestions, desmosomal 
mutations were upgraded to a major criterion (Marcus et al., 2010). A further study by an 
independent group found that these recent modifications significantly improved diagnosis of 
ARVC in patients when compared to the old taskforce criteria (Protonotarios et al., 2011).  
Despite improvements to ARVC diagnosis, the molecular underpinning of the disease remains 
poorly understood. Two main theories have been proposed to explain the link between 
desmosomal gene mutations and the formation of fibrofatty tissue and subsequent 
cardiomyopathy. The first and simplest theory is an entirely structural model which proposes that 
a defective myocyte adhesion leads to cell death. It has been suggested that right ventricular 
scar formation can lead to arrhythmias such as those experienced during ARVC. The model also 
proposes that environmental factors such as exercise or virally induced inflammation could 
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exacerbate the already impaired myocyte adhesion. The second theory is more complex, and 
involves the Wnt/β-catenin signalling pathway. Disruption of desmosomal protein binding to one 
another is thought to be a major contributor to ARVC (Yang et al., 2006, Awad et al., 2008)). 
Plakoglobin, a desmosomal armadillo family member was shown to translocate to the nucleus 
upon disruption of binding to desmoplakin and suppress canonical Wnt/β-catenin signalling 
(Garcia-Gras et al., 2006). As a result of nuclear localization of plakoglobin Wnt signalling 
mediated inhibition of adipogenesis (the differentiation of cells into fatty tissue) was prevented.  
Genetic screening of ARVC patients is becoming more important. The main benefit is that 
relatives of those affected, who have a higher risk of developing ARVC are forewarned. Genetic 
screening is an additional aid for diagnosis with mutations resulting in insertions, deletions, 
frameshift or premature termination which result in significantly altered protein products, 
frequently observed in those affected by ARVC. However, those with missense mutations are 
harder to interpret given proteins adopt tertiary structures and potentially altered binding sites to 
desmosomal ligands have not been localized comprehensively. Figure 1.4 summarizes all the 






Figure 1.4 Pathogenic missense mutations in desmoplakin that have been 
reported in the ARVC database 
Highlighted are the SRs of the plakin domain (red), the SH3 domain (cyan), the CT region 
(green), the rod domain (orange), the PRDs (purple) and the linker domain (blue). Most (~50%) 
of the reported mutations are located in the plakin domain. Image created by Domain Graph 













A number of hypotheses prompted the work in this study. They are based on previous studies of 
plakin family members.  
The first assumed that by ascertaining the structure of the plakin domain it would help explain its 
essential role in tethering the desmosome to the cytoskeletal network. The desmoplakin N-
terminal region which includes the plakin domain is known to bind both plakophilin and 
plakoglobin (Bornslaeger et al., 2001). Through this mechanism it is thought that the 
desmosome assembles correctly, since it was previously shown that disruption of these 
interactions led to improper desmosomal development (Russell et al., 2004). Prior to this study 
being conducted the structures of only the first 2 SRs of BPAG1 (Jefferson et al., 2007) and 
plectin (Sonnenberg et al., 2007) were known (these are homologous to the first 2 SRs of 
desmoplakin’s plakin domain). However, 4 more C-terminal spectrin repeats (and a SH3 
domain) of unknown significance are present in the desmoplakin plakin domain. How the entire 
plakin domain folded in light of these additional domains was unknown.  
The second hypothesis assumed that there would be subtle structural differences between 
plakin family members which gave them their specialized roles in the cell. Desmoplakin is 
essential for murine embryonic development (Gallicano et al., 1998), Conversely, single or 
double gene disruptions of envoplakin and periplakin, plakin proteins also localized to the 
desmosome, produced little observable effects (Aho et al., 2004, Määttä et al., 2001). By 
comparing domains from throughout the full length sequences (particularly from the plakin 
domains and C-terminal tails) of the plakin family members desmoplakin, periplakin and 




The third hypothesis presumed that specialized domains at the C-terminal tail give rise to 
specific cytoskeletal binding for different plakin family members. Both PRDs and linker domains 
are present in desmoplakin and envoplakin. However, only a linker domain is present at the C-
terminal tail of the periplakin protein. Desmoplakin has a preference of binding keratin over 
desmin/vimentin (Meng et al., 1997b). whereas desmin/vimentin is preferred over cytokeratins 
for envoplakin and periplakin (Kazerounian et al., 2002, Karashima and Watt, 2002). The 
structure of PRDs are only known from desmoplakin and it is presumed that subtle differences 
between PRDs of different plakin family members may give rise to these cytoskeletal 
preferences. In addition to this the linker domain which has been shown to be critical for binding 
cytoskeletal proteins (Karashima and Watt, 2002, Kazerounian et al., 2002) has not been 
structurally characterized. By structurally characterizing and comparing a variety of constructs 
from the C-terminal tails of desmoplakin, envoplakin and periplakin it was hoped it would explain 
cytoskeletal preferences and possible binding mechanisms.  
The final hypothesis presumed that by characterizing the structural implications of a number of 
different missense mutations thought to cause ARVC, it would help explain the ambiguity and 
complexity of the genotype-phenotype link. Prior to this study being conducted nothing was 
known of the biophysical impact of an ARVC mutation on any desmosomal protein. By gaining 
this information it was hoped it would ultimately aid cardiologists make more informed decisions 
when presented with mutation data from a patient thought to suffer from ARVC. 
1.9 Aims 
To address the above mentioned hypotheses the following aims were created: 




2) To purify plakin domains from desmoplakin, envoplakin and periplakin and assess their 
domain architecture by Circular Dichroism (CD), Analytical Ultracentrifugation (AUC), 
Nuclear Magnetic Resonance (NMR) and Small Angle X-ray Scattering (SAXS). 
3) To compare the binding of desmoplakin and envoplakin PRDs to the cytoskeletal protein 
vimentin and ascertain whether structural differences between PRDs lead to differential 
binding to vimentin. 
4) To crystallize the envoplakin PRD C and compare its structure to that of its homologue 
desmoplakin PRD C. 
5) To compare the structure of the linker domains of desmoplakin, envoplakin and 
periplakin and ascertain their overall fold using NMR and SAXS. 
6) To ascertain whether a variety of ARVC mutants caused biophysical differences in 
desmoplakin protein domains when compared to their wild type (WT) counterparts. 
Overall it was hoped that the information gained would give a clearer picture into the 








Chapter 2 - Materials and methods 
2.1 Molecular biology 
Three plakin proteins were investigated in this project. Constructs were designed using 
GenBank human cDNA sequences for desmoplakin (accession number: NM_004415), 
envoplakin (accession number: BC126103) and periplakin (accession number: BC114620) 
2.11 Construct Design  
Constructs were either provided kindly by Dr Martyn Chidgey or purchased from either 
ShineGene (Shanghai, China) or GenScript (New Jersey, USA). Depending on the predicted 
solubility of the construct, different vectors were used. For example, in low solubility constructs, 
the presence of glutathione-S-transferase (GST), a known solubility enhancing tag was present 
at the N-terminal of proteins when expressed from pGex6p-1 vectors. All constructs used are 
shown in tables 2.1-2.4. Some constructs in table 2.1 (flagged with an asterisk) were chemically 
synthesized so that cysteine residues were replaced by serine residues in the final protein 
product in order to enhance expression and purification. Constructs inserted into pET21b+ 
vectors contained an N terminal methionine residue and a C-terminal 6x His tag of LGHHHHHH.  
Constructs inserted into pET45b+ vectors contained N terminal MAHHHHHHVENLYFQG 
residues which include a Tobacco Etch Virus (TEV) protease site to facilitate proteolytic removal 
of the 6x His tag. Constructs inserted into pProEX HTc vectors contained a vector encoded N 
terminal 6x his tag, followed by a spacer, followed by a TEV protease site (see figure 2.12 for 
more details). Constructs were designed using information from the literature (Sonnenberg et al., 
2007, Karashima and Watt, 2002) and results from the Globprot server (Linding et al., 2003) and 









Sites (5’ and 3’) 
Tag 
Spectrin Repeat 3-4 
(SR34*) 
180-375 Yes pET21b+ NdeI and 
BamH1 
6x His 





Spectrin Repeat 5-6 
(SR56*) 
373-630 Yes pET21b+ NdeI and 
BamH1 
6x His 
Spectrin Repeat 5-6 
K470E (SR56-K470E*) 
373-630 Yes pET21b+ NdeI and 
BamH1 
6x His 
Desmoplakin SH3* 440-518 Yes pET21b+ NdeI and 
BamH1 
6x His 
Spectrin Repeat 7-8 
(SR78*) 
654-883 Yes pET45b+ PmlI and 
BamH1 
6x His 
Spectrin Repeat 7-8 
R808C (SR78-R808C*) 




terminal region  
(SR8-CT*) 































































   





Name Residues Codon 
Optimized? 
Vector Restriction 
Sites (5’ and 
3’) 
Tag 
Periplakin SH3 domain 
(Peri-SH3) 



















Table 2.2 Periplakin constructs 
Name Residues Codon 
Optimized? 
Vector Restriction Sites 
(5’ and 3’) 
Tag 












































EcoRI and XhoI 6x His 
Table 2.3 Envoplakin constructs 
Name Residues Codon 
Optimized? 
Vector Restriction 
Sites (5’ and 
3’) 
Tag 
Vimentin full length 1-466 No pET21a+ NdeI and XhoI None 
Table 2.4 Vimentin constructs 
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2.12 Vectors used 
 
 
Figure 2.11 pET21a-d 
pET21a+ and pET21b+ were used for vimentin full length and plakin domain subdomain 
constructs, respectively. Key features include a T7 promoter for expression in E.coli and 
ampicillin resistance. Since all constructs contained 5’ NdeI and 3’ XhoI sites no T7-tag was 
included in the expressed proteins. Vimentin in pET21a+ has no tag while constructs in 





Figure 2.12 - pProEX HTc 
The pProEX HTc vector was used primarily for C-terminal tail constructs (see Tables 2.1-2.3). 
Key features include a TRc promoter that can be induced using Isopropyl--D-Thio-Galactoside 
(IPTG), ampicillin resistance and a TEV protease recognition site that allows cleavage of the 6x 
His tag from the recombinant protein product. An artificial STOP codon is also encoded by the 






Figure 2.13 - pGex6p-1 
pGex6p1 was used for all GST fusion proteins. Key features include T7 promoter for expression 











Figure 2.14 - pET 45b+ 
pET45b+ was used for the constructs SR78 and SR8-CT only, with an added TEV protease site. 
Key features include a T7 promoter, ampicillin resistance and an N-terminal 6x His tag. An 




2.2 Protein expression 
2.21 Transformation into DH5α cells 
1 µl of plasmid DNA at 10-500 ng/µl was used to transform 20 µl of competent DH5α cells 
(Invitrogen). After a 30 min equilibration at 4 °C, a heat shock was applied at 42 °C for 30 sec. 
Super Optimal Broth – with catabolite repression (SOC) media (80 µl) (Invitrogen) was added 
and the cells were then grown at 37 °C, shaking at 220 rpm for 1 h. The transformed cells were 
then plated onto Luria Broth (LB) agar plates containing the appropriate antibiotic and grown 
overnight at 37 °C.  
2.22 Isolation of plasmid DNA and DNA sequencing 
A single colony was picked and used to inoculate a 10 ml LB culture containing the appropriate 
antibiotic and grown overnight at 37 °C and shaking at 220 rpm. Cells were harvested at 4000 g 
and plasmid DNA was extracted and purified using the QIAPREP Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions. DNA concentration was measured using a 
Nanodrop system (Thermo Scientific). Plasmid DNA was sequenced at the Functional Genomics 
Laboratory (University of Birmingham, UK) using 10 µl of plasmid DNA at a concentration of 10-
100 ng/µl and 25 ng of sequencing primer.  Once sequence verified, the construct was 
transformed into E.coli strain BL21 (DE3) (Novagen) as described in 2.21.  
2.23 Site Directed Mutagenesis 
Site directed mutagenesis reactions were conducted using the QuickChange Lightning site 
directed mutagenesis kit (Agilent Technologies) according to the manufacturer’s instructions. All 
PCR reactions were conducted on a Eppendorf Thermal Cycler (Eppendorf). Mutagenic primers 
were designed using the online primer design tool (www.agilent.com/genomics/qcpd) and 
synthesised by Invitrogen.  
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2.24 Small scale protein expression/solubility trials 
For constructs that needed optimization for expression and/or solubility, small scale expression 
trials were conducted. A 10-200 ml culture containing the appropriate antibiotic was inoculated 
with a single colony. The culture was incubated at 37 °C with shaking at 220rpm until an O.D of 
0.4-0.6 had been reached. Prior to induction cultures were incubated for 15-30 min at 18 °C, 20 
°C, 25 °C, 28 °C or 37 °C , depending on size of the culture. The culture was divided into two so 
that a non IPTG induced and IPTG induced fraction could be compared by sodium 
dodecylsulphate polyacrylamide gel electrophoresis (SDS-Page) analysis. IPTG was added to a 
final concentration of 1 mM. The cultures were left to grow for either 4 h or overnight. Samples 
(10µl) were taken for analysis by SDS-Page from the non-IPTG and IPTG induced cultures.     
2.25 Overnight growth of starter cultures and large scale expression in LB media 
Starter cultures were prepared by inoculating LB media (10 ml) with single bacterial colonies. 
Starter cultures were grown overnight at 37 °C (shaking at 220 rpm) and expanded by adding to 
LB media (10ml per l) with appropriate antibiotic selection. Cultures were incubated at 37 °C 
until an O.D of 0.4-0.6 had been reached. Flasks were left to equilibrate at their optimal 
expression temperature, which typically was 18 °C for 45-60 mins. Cells were then induced with 
IPTG at a final concentration of 1 mM. Cells were then grown either for a further 4 h or overnight 
except in the case of those expressing vimentin which were induced with IPTG (final 
concentration of 1 mM) and then grown at 37 °C for a further 3-5 hours to form inclusion bodies.  
2.26 Large scale expression of 15N labelled proteins for NMR analysis in minimal 
media 
Proteins selected for 15N (and those including 13C) labelling were grown in M9 minimal media 
(appendix A2). Proteins were expressed as described in 2.25 except the LB media was replaced 
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with M9 minimal media.  Nutrient mix (appendix A2) was added to the minimal media after filter 
sterilization (0.2 µm) and before inoculation with the starter culture. After induction with IPTG 
(final concentration 1 mM), cells were grown overnight.  
2.3 Protein Purification 
2.31 Harvesting cells  
E.coli cells were harvested by centrifugation at 4000 rcf for 20 min at 4 °C (Avanti J-20XP 
centrifuge with JLA 8.1 rotor). Cells were resuspended with either PBS or His-equilibration buffer 
(Appendix A2) and one complete protease inhibitor cocktail tablet (Roche Applied sciences). 
Cells were either stored at -80 °C or used immediately.  
2.32 Mechanical cell lysis and separation of insoluble fraction 
Typically, cell pellets (from cultures of 200ml or more) were mechanically homogenized and 
lysed using 3 passes through an Emulsiflex C-3 (Avestin, Canada). Throughout lysis the 
resuspended cell pellet was kept at 4 °C. For smaller volumes a sonicator was used (Soniprep 
150 from MSE). The homogenized cell pellet was then spun at 25000 rcf for 45-60 min (Avanti J-
25, JA25.50 rotor) at 4 °C. The soluble fraction was then decanted and filtered (0.2 μm filter).  
Since a wide variety of solubility tags were used for protein purification an overview of how each 
tag was purified is given below.  
2.33 Protein purification of GST-tagged proteins using GSTrap columns 
Bacterial lysates were loaded onto a 5 ml GSTrap HP column (GE Healthcare) pre-equilibrated 
with at least 5 column volumes of GSTrap equilibration buffer (appendix A2). The column was 
then washed with at least 5 column volumes of GSTrap wash buffer (appendix A2). Finally the 
protein was eluted using GSTrap elution buffer (appendix A2). Samples were taken at each 
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purification stage for analysis by SDS-Page. Eluted protein was transferred to SnakeSkin 
dialysis tubing (Thermo Scientific) and dialyzed in 2 l of either His equilibration buffer (if His-tag 
was present on the protein to be purified) or PBS together with 25 units of PreScission protease 
(GE Healthcare). Pre and post cleavage samples were taken for SDS-Page analysis. The 
purification was continued only if over 90% cleavage had been achieved.   
2.34 Protein purification of His-tagged proteins using HisTrap™ columns 
His tagged proteins were purified with HisTrap columns (GE Healthcare).  His-tagged proteins 
were loaded onto pre-equilibrated 5 ml HisTrap HP columns (GE Healthcare) with His 
equilibration buffer. These were washed with at least 5 column volumes of His wash buffer 
(appendix A2). Proteins were either eluted using a single step gradient or by a linear gradient 
using an Äkta prime system (Äkta prime Plus). If using a single step gradient proteins were 
eluted using 15-25 ml of HisTrap elution buffer in 1-2ml fractions. If using linear gradient 
purification, buffer A would be the His wash buffer while buffer B would be the His elution buffer 
eluted in 2ml fractions. Samples were analysed by SDS-Page to gauge purity. Fractions 
sufficiently pure were pooled. If further purification was required the pooled eluates were purified 
using size exclusion chromatography (see 2.36).  In some cases proteins tagged with both GST 
and His were purified using GSTrap columns (as above) and then further purified (post cleavage 
of GST) by Nickel chelation chromatography.  
2.35 Cleavage and removal of His-tag using Tobacco Etch Virus (TEV) protease 
Proteins expressed in the pET45b+ and pProEX HTc vectors contained a TEV protease 
recognition site that allows the His tag to be cleaved from the purified protein. Pooled HisTag 
eluates were transferred to SnakeSkin dialysis tubing (Thermo Scientific) and dialyzed in His 
equilibration buffer in the presence of 10-50 μl 5mg/ml TEV protease (kindly provided by either 
Mrs Pooja Sridhar or Mrs Sandya Rajesh, University of Birmingham) at 4 °C and left overnight. 
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Pre and post cleavage samples were taken for SDS-Page analysis. If >90% cleavage had 
occurred the sample was purified as stated in 2.33. Those fractions containing the desired 
protein were then pooled. 
2.36 Purification of proteins by size exclusion chromatography  
Proteins were purified by size exclusion chromatography using either Superdex 75 or Superdex 
200 column systems (GE Healthcare) depending on the molecular mass of the protein to be 
purified. Purification and analysis was implemented using the Äkta purifier FPLC system with 
Unicorn software. Depending on volume, proteins were either loaded onto 10/300 GL column or 
26/60 PG columns. A flow rate of 0.5 ml/min was used for the 10/300 GL column with 0.5 ml 
fraction sizes, while 2.5 ml/min was used for the 26/60 PG column with 4ml fraction sizes.   
Samples of fractions containing the highest peaks at 280 nm were analysed by SDS-Page and 
those with sufficient quantity and purity of the protein were pooled.  
2.37 Vimentin purification 
Large scale expression of vimentin was performed as described in section 2.25. Essentially a 
modified version of the Garboczi method (Garboczi et al., 1992) was utilized in which the final 0 
M urea buffer had been previously shown to contain folded vimentin (Quinlan et al., 1986). 
Vimentin was expressed in inclusion bodies which were retained in the insoluble fraction. Hence 
in the case of vimentin the soluble fraction was discarded and the insoluble fraction re-
suspended and washed with Triton wash buffer (appendix A2) and centrifuged at 13500 g for 15 
min. This was repeated 3 times. A final wash step was carried out using triton wash buffer 
without triton X-100. The final insoluble pellet was re-suspended in solubilisation buffer 
(appendix A2) and left on a rocker overnight at 4 °C. Once the pellet had solubilized, the sample 
was centrifuged at 15000 g for 30 min. Vimentin was retained in the soluble fraction, with the 
insoluble fraction discarded. Folded vimentin was obtained following the step wise removal of 
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urea in the solubilisation buffer by dialysis. The soluble fraction was  dialyzed in 10 mM Tris-HCl 
(pH 8), 5 mM DTT, 4 M urea overnight, then 10mM Tris-HCl pH 8, 5mM DTT, 2M urea overnight 
and finally 10mM Tris-HCl pH 7, 5mM DTT overnight at room temperature. In preparation for 
NMR titrations the sample was dialyzed in the same buffer as the labelled protein. 
2.4 Biochemical analysis of proteins 
2.41Sodium dodecylsulphate polyacrylamide gel electrophoresis gels  
Samples (1-15 μl) were added to an equal volume of 2x Laemelli buffer (Sigma-Aldrich) and 
loaded on to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-Page) 4-12% 
pre-cast bis-tris gels (Bio-Rad). Precision Plus molecular weight markers (Bio-Rad) (10 μl) were 
also loaded on to all gels. Gels were run at 180 V for 40min in 2-(N-morpholino)ethanesulfonic 
acid MES SDS running buffer (Bio-Rad). Gels were stained with Instant blue™ (BioRad) and left 
on a shaker for at least 1 h. Gels were washed thoroughly at least three times with water and an 
image taken for future reference.  
2.42 Concentrating proteins and calculation of concentration  
Proteins were concentrated using Amicon Ultra™ (Amicon) or Vivaspin (Vivaspin) concentrators 
using appropriate molecular weight cut offs. These were centrifuged at 4000 g at 4 °C using a 
centrifuge (Eppendorf Centrifuge 5810R). Final protein concentration was measured using a UV 
spectrophotometer (Shimadzu UV-1700 Pharmaspec) with an absorption set to 280nm. The 
optical density reading and ProtParam (used at http://web.expasy.org/protparam/) parameters 
for each individual protein were input into the following equation: 
Concentration (M) = (A280nm x dilution factor) / (extinction co-efficient (M




2.5 Biophysical analysis 
2.51 Analytical Ultracentrifugation (AUC) 
Analytical Ultracentrifugation experiments were carried out in collaboration with Mrs Rosemary 
Parslow at the Birmingham Biophysical Characterization facility (University of Birmingham). 
Proteins were supplied at three concentrations between 0.05-5 mg/ml in PBS. Samples were 
centrifuged at 25000 and 40000 rpm for 20h at 20 °C on a Beckman XL-1 analytical 
ultracentrifuge (Beckman Coulter) and detected at 280nm. Sedimentation profiles were analysed 
using the SEDFIT software (Brown and Schuck, 2006). 
2.52 Circular Dichroism 
Circular dichroism (CD) is a spectroscopic technique in which secondary structure can be 
ascertained. It uses circular polarized light which has a property of moving in a circular motion 
along a vector. The motion is both left and right handed and if absorbed equally, no difference is 
observed. However, if absorbed by optically active chiral molecules such as proteins, a 
difference in speed and extent of both the left and right handed motion causes a difference in 
the polarization of light that is recordable. As a result CD values are measured as a change in 
absorbance or more accurately:  
Δε ≡ εL- εR. 
Where Δε is the observed difference in the polarization of light, εL is the left handed component 
and εR is the right handed component.  
All proteins subjected to CD analysis were dialyzed into 20 mM sodium phosphate pH 7.2-7.5. A 
reduction in Cl
-
 ions is critical to maximizing signal to noise at lower wavelengths of ~180-
195nm. Proteins at a concentration of 0.1 mg/ml were transferred to a 1 mm cuvette with a 
capacity of ~300 µl. Measurements were conducted on a JASCO-J810 spectrometer, at 25 °C 
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with a spectrum collected between 240nm-180nm, the range in which peptide bonds absorb 
polarized light. Data were deconvoluted using the DICHROWEB server (Lobley et al., 2002) 
which is a database of CD spectra from proteins of known secondary structure. This gives an 
estimated percentage per secondary structure element.  
2.53 Thermal stability measured by Thermofluor™ 
Thermofluor™ is an assay used to measure protein thermal stability. It relies on a fluorescent 
dye (SYPRO Orange) which binds to hydrophobic residues in the core of the protein. An 
increase in fluorescent signal is observed when the protein begins to unfold as a result of 
temperature increase. For folded proteins a sigmoidal curve is often observed which often tails 
off. The “tailing off” is attributed to degradation of the dye at high temperatures according to the 
developers of the assay (Ericsson et al., 2006). Since disordered proteins do not have 
hydrophobic cores, this assay is less sensitive to measuring their thermal stability, however, can 
give a qualitative suggestion that they are unfolded. This however, is not definitive, given that 
some folded proteins may have hydrophobic patches on the surface which skews the fluorescent 
signal. The assay can also be used to identify optimal buffer conditions. Optimized buffer 
conditions can be observed by higher melting temperatures since this correlates with the thermal 
stability of the protein. Screening for optimized buffer conditions involved using a 96 well plate 
with each well containing a different buffer of varying buffer conditions developed by the 
Overduin lab.  
Fluorescent dye (2 µl of a 10-20x stock) was added to the protein (20-100 µM) (final volume 200 
µl). 2 µl was of the protein/dye mix was added to 18 µl of the buffer of interest. The sample was 
loaded into the wells of a 96 well Peqlab plate (Low profile reaction plate) and this was placed in 
an RT- Mx3005P PCR machine (Stratagene). The experiment was carried out at 25 °C -90 °C 
and fluorescence was filtered through custom interference excitation (492nm) and emission 
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(568nm) filters. The data was either plotted from raw data or normalized using Microsoft Excel 
and Tm values calculated using the XLFit 5 program (IDBS solutions) to fit the data to a 
Boltzmann model represented by the equation:  
               
   
    
             
  
   
Where C is the Tm; A is pretransitional and B is posttransitional intensities and D is a slope 
factor. A sigmoidal curve fit was applied which scales the data as suggested by previous 
protocols (Ericsson et al., 2006). 
2.54 Limited Proteolysis and N-terminal sequencing 
In an effort to identify protease resistant fragments (separated by flexible and exposed linkers) 
by limited proteolysis two alternative experiments were carried out. Proteins at 10 mg/ml were 
subjected to limited proteolysis using a variety of proteases from the Proti-Ace™ Kit (Hampton 
Research) according to the manufacturer’s instructions. Alternatively, proteins at 10 mg/ml were 
subjected to 10-100 ng (final concentration) of trypsin digestion. Trypsin typically cleaves at the 
carboxyl side of the amino acids lysine or arginine. Typically limited proteolysis reactions were 
carried out at 37 °C for 1 h or overnight, or at room temperature for 1 h-9 days. Samples were 
collected at different time points for SDS-Page analysis. Protease resistant fragments were 
excised from the SDS-Page gel and subjected to N-terminal sequencing by Alta Bioscience 
(University of Birmingham).   
64 
 
2.6 NMR experiments 
2.61 NMR Introduction 
NMR is a powerful technique in which a variety of parameters can be acquired, these include 
(but are not limited to): determination of the solution structure of a protein at atomic resolution, 
gauging overall fold, backbone assignment (the sequential assignment of a peak in the HSQC to 
a residue on the protein chain), side chain assignment and protein-protein interactions. It has an 
advantage over X-ray crystallography (discussed in 2.7) by lacking the rate limiting step of 
requiring proteins to crystallize. It also has the added advantage of being able to be performed in 
near-physiological solutions in which proteins are more likely to assume native conformations. 
Unlike X-ray crystallography NMR has a size limitation whereby proteins greater than 30 kDa are 
often too challenging for 3D structural determination due to significant line broadening and peak 
overlap. Although full NMR structural determination was not carried out on any protein, a brief 
overview of the theory will be given. 
2.62 NMR theory 
NMR uses the properties of 1H, 13C, and 15N to acquire information on proteins. All atomic nuclei 
possess two properties: one called spin and the other magnetism. Spin values are determined 
by the proton and neutron content of the nucleus. Only spin values that are integral or half 
integral are amenable for NMR as these are associated with a magnetic field and as such these 
types of nuclei are called spin active. 1H, 13C, 15N are all spin half nuclei. These nuclei have 
spins that can be in one of two orientations e.g. a lower energy state and a higher energy state. 
They can thus align with the magnetic field in one of the two orientations.  
Magnetism is a property in which nuclei with non zero spin (in this case 1H, 13C and 15N) also 
possess a magnetic moment. When the external magnetic field is applied from the spectrometer 
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the spin of each nuclei precess about the axis of the magnetic field. The nuclear spins then 
either align with or against the field. A key feature of NMR is that nuclei align slightly more with 
than against the field. If the nuclei aligned equally with and against the field, no signal would be 
observed. The frequency at which the spins precess is termed the Larmor frequency. The 
introduction of a radiofrequency (RF) pulse (a second oscillating magnetic field perpendicular to 
the static magnetic field) causes fluctuations to the magnetic field when the RF pulse is 
removed. This causes the spins to precess back to their original state, (called the ground state) 
in a process termed relaxation. An electrical signal is then generated as a result of relaxation in 
the metal coil surrounding the NMR tube which is recorded as the Free Induction Decay (FID). 
This is then processed by Fourier transform (a mathematical function that deconvolutes a signal 
made up of a multitude of different signals which is plot as a frequency spectrum) and is used to 
plot a 1-dimensional proton spectrum. The Fourier transform in effect converts a function of time 
to a function of frequency.  
The Larmor frequency for a given nucleus is proportional to the applied magnetic field. However, 
for nuclei within proteins surrounded by moving electrons, the situation is more complicated. For 
each nucleus the local magnetic field around the nucleus is altered caused by an opposing 
magnetic field produced by the surrounding electrons. This in turn reduces the external magnetic 
field the nucleus encounters and alters the Larmor frequency. This “shielding” effect is termed 
the chemical shift phenomenon. This alters the FID which is composed of a multitude of different 
frequencies, which when Fourier transformed reveals a spectrum of chemical shifts with each 
peak corresponding to an individual chemical environment. Since the Larmor frequency is 
proportional to the applied magnetic field the scale is described in parts per million (ppm). As a 
result this unit is also independent of the magnet size.  
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2.63 Preparation of the sample for NMR analysis  
Proteins of > 90 % purity as determined by SDS-PAGE analysis, and of a concentration of at 
least 100 µM were analyzed by NMR in the presence of 10 % D2O.  Samples were analysed 
using Agilent 600 MHz, 800 MHz or 900 MHz spectrometers (Biomolecular NMR facility, 
University of Birmingham). Each experiment used a triple-resonance cryogenic probe and z-axis 
pulsed-field gradients. Parallel to the data acquisition experiment another experiment was 
conducted in which the D2O signal was measured. This is the lock signal. Locking the D2O signal 
prevents “magnetic drift” which can lead to errors in the magnetic pulses of the NMR experiment. 
This corrects the magnet so that the signal returns to its original value. 
Firstly, the spectrometer is tuned and shimmed using automated gradient shimming on the z 
dimension. The transmitter offset was also optimized using automated methods. Since the 
molarity of water is at 55 M, in vast excess to the typical protein concentration, this can have an 
adverse effect on data acquisition and must therefore be suppressed. This can be conducted 
using the software package of the spectrometer automatically. The signal of the protein can now 
be acquired. The simplest of all experiments is a 90 ° pulse (as in 1D-NMR) and this needs 
optimization. The 90 ° pulse is the length of time (in µs) the RF pulse is switched on for to allow 
the magnetization of nuclei to rotate onto the y axis from the z axis. By the magnetization 
precessing back to the z axis from the xy plane it gives the maximum signal possible from the 
protein. In addition the in-built pulse programs within the Agilent software package must also be 
manually checked.  These include: length and power of the water suppression pulse, the 
recovery time and the phase correction pulse.  
Since one of the main aims of this project was to elucidate the structure of a novel domain, many 
constructs were gauged by 1-D and 2D-Heteronuclear single quantum coherence (HSQC) 
spectra, to assess overall fold (how these were assessed is discussed in section 2.65). Since 
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many domains were of sufficient quality for NMR assignment high impact constructs were taken 
further to 3D experiments which were carried out in collaboration with Dr Mark Jeeves. These 
included: SR78 and the envoplakin SH3 domain. 
2.64 1D NMR 
One-dimensional NMR can give limited information on the folded state of the protein. These 
experiments were often used to gauge the extent of folding of unlabelled proteins or as a test to 
ascertain fold before HSQC spectra of labelled proteins. These experiments consist of a simple 
90 ° pulse on proton followed by signal acquisition. Typically they were carried out on an Agilent 
600 MHz Direct Drive NMR spectrometer equipped with a HCN 5 mm cryogenic probe at 25 °C 
using standard 1D Biopack experiments (Agilent).   
2.65 2D-HSQC NMR 
Heteronuclear Single Quantum Coherence (HSQC) is a 2-D NMR method which correlates 
attached protons and 15N labelled amide groups, and was used primarily in this study to assess 
the foldedness of proteins. Typically a 2D NMR method records the NMR signal as a function of 
two time variables, t1 and t2. The resulting free induction decay is then fourier transformed twice 
which is a function of two frequency variables. It can thus be broken down into four stages. 
Firstly, the preparation stage where the sample is excited by one or more pulses. Secondly, the 
resulting magnetization of the first stage is allowed to evolve as the time period t1. The third 
stage, the mixing period contains further pulse(s). The fourth stage records the signal as a 
function of the second time variable t2. Once processed, the result is a 2D spectrum with a 
15N y 
axis and 1H x axis in ppm.  
HSQC spectra are predominantly used for backbone and secondary structure assignment and 
binding studies which in combination with 3D experiments can be used to assess the overall fold 
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of the protein. The HSQC gives a 2-dimensional spectrum with the first being proton and the 
second being a heteroatom, predominantly nitrogen (or carbon). Backbone amides are 
represented by a single peak observed in the spectrum (with the exception of prolines which due 
to their lack of protons directly attached to nitrogens do not show a signal) whilst for side chain 
NH2 groups (Asn and Gln) two peaks are observed at the same nitrogen frequency, 
corresponding to the two protons attached to a single nitrogen. In effect to ascertain whether all 
the expected peaks were observed the following equation was used: 
Peaks expected = [(Number of amino acids – prolines) + 2(Asn + Gln)] 
Qualitative assessment was also used in which as long as a good signal to noise ratio was 
observed, proteins were classified into four main groups:  
a) The “folded” globular proteins suitable for structure determination with >90% of peaks 
well dispersed between 7-10ppm, as was the case for the envoplakin PRD (see figure 
5.3). 
b) The “flexible and/or partially folded” proteins exhibiting <90% of expected peaks but with 
dispersion limited to the 8-8.5ppm region, as in the case of SR56 (see figure 3.72). 
c) The “unstructured / highly disordered” protein with >90% peaks visible, relatively good 
dispersion of peaks (particularly for small proteins) in the 15N dimension but poor 
dispersion in the 1H dimension (usually between 8-8.5 ppm), as in the case of the 
desmoplakin SH3 domain (see figure 3.71). 
d) The “unresolvable” protein where few peaks were observed and no interpretation of 
overall fold could be reliably inferred, owing to possible aggregation or intermediate 
timescale dynamics occurring, as in the case of SR8-CT (see figure 3.74).  
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2.66 NMR titrations 
In order to characterise protein-protein interactions, NMR titrations were conducted with one 
protein 15N labelled and the other unlabelled. Initially an 1H,15N-HSQC was taken of the labelled 
protein. These were compared and superimposed onto 1H,15N-HSQC spectra of 15N labelled 
protein in the presence of unlabelled protein ligand. Depending on stock concentrations of 
labelled and unlabelled proteins, NMR titrations were conducted in one of two ways. If stock 
concentrations were low, one NMR tube was used with the unlabelled protein added in gradual 
amounts, increasing the overall volume and lowering the labelled protein’s concentration. The 
resulting decrease in labelled protein’s concentration was artificially compensated during 
analysis by altering the threshold levels of the signal to noise ratio. Where stock concentrations 
were ample, two NMR tubes were used with one tube containing an excess of labelled protein 
and the other tube an excess of unlabelled protein. These were then analysed by 1H,15N-HSQC 
and taken as the start and end points of the titration. An equal volume was then taken from each 
tube and added to the other and analyzed by 2D-HSQC at different points until a saturation point 
was reached.     
2.67 Data processing and analysis 
Before analysis, FIDs were processed in NMRPipe (Delaglio et al., 1995) using a shifted sine 
bell apodization . This is a post-experimental processing step in order to optimize signal to noise 
ratios.  Superpositions of spectra collected with similar parameters were carried out using the 
program CCPN analysis (Vranken et al., 2005). 
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2.7 Small Angle X-Ray Scattering (SAXS) 
2.71 History and the use of SAXS 
SAXS was used to characterise the structures and dynamics of constructs in solution with 
conditions similar to those used for NMR. It is becoming an increasingly important and 
complementary tool for structural biologists across a wide spectrum of fields. It is a fundamental 
technique that allows for the study of proteins, nucleic acids and complexes in solution. It can 
give information on size, shape and flexibility amongst other things (Putnam et al., 2007). While 
SAXS has a low resolution of 1-2 nm it has an advantage over crystallography in terms of the 
physiological relevance and lack of the need for crystals, being in solution. It also has an 
advantage over NMR in terms of the almost limitless size of protein it can characterize. The 
technique is especially useful where proteins are refractory to structure elucidation by NMR or X-
ray crystallography as was the case with many proteins in this project.  
The technique was originally pioneered by Guinier in the late 1930s when working on metallic 
alloys (Guinier, 1939). The work was later refined in the 1950s for use on easily purified proteins 
such as haemoglobin (Guinier, 1955). Breakthroughs occurred in ab initio modeling by Dmitri 
Svergun and co-workers in the 1990s (Semenyuk and Svergun, 1991, Svergun et al., 1995). 
This, together with advances in instrumentation, the use of synchrotron radiation and high-
throughput automation have resulted in SAXS becoming accessible to the wider scientific 
community and not just restricted to structural biologists.    
Since SAXS was one of the main structural techniques for the experiments presented in this 
thesis a detailed scope of the theory and methods involved is given below. 
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2.72 SAXS theory 
X-rays are plane waves which have properties of amplitude and wavelength. As they pass 
through matter they interact with their atoms and secondary wavelets are generated which 
constructively or destructively interfere with one another in a coherent fashion. Diffraction 
patterns are thus created which if detected appropriately (i.e. by pixel detectors) are exploited by 
X-ray crystallography and similarly in SAXS. During the SAXS experiment a sample is exposed 
to a highly collimated X-ray from a very small distance. Because biomolecules scatter weakly 
and concentrations are relatively dilute the method often requires high intensity X-ray photon 
beams only available at synchrotron facilities. The resulting scattering pattern is collected at 
small angles (typically ≤ 3 Å) by a detector and the direct exposure of the beam is absorbed by a 
beamstop (figure 2.2). The scattering pattern is radially averaged to give a scattering profile 
which is calculated by the intensity (I) versus the scattering angle (q) (where q=4πsinθ/λ, 2θ is 










   
Figure 2.2 The experimental setup of SAXS  
A schematic diagram for the experimental setup of SAXS. Samples are exposed to X-rays which 











2.721 SAXS Data collection and reduction 
Protein measurements were collected from three runs on the EMBL X33 beamline of the storage 
ring DORIS III (Deutsches Elektronen Synchrotron, Hamburg, Germany). All measurements 
were conducted at room temperature using an automated SAXS sample changer. The data was 
recorded using a single photon counting pixel detector system (PILATUS 500 K) at a sample 
detector distance of 2675 mm covering the range of 0.06-6 nm using a wavelength of 1.5 Å. 
Proteins were measured between 0.5 and 10 mg /ml in 20mM sodium phosphate (pH 7.2) and 
100mM NaCl unless otherwise stated. Using the in-house automated processing software 
available, buffer scattering was automatically subtracted from the protein scattering. The 
software also indicated possible radiation damage to the sample; such samples were excluded 
from further analysis. The same software gave basic analysis of the protein sample which 
included auto-subtracted scattering curves to allow for manual checking of the data quality and 
parameters such as: Rg and Dmax (see 2.73). Both sets of information gave indications as to 
whether the sample should be re-run. Given that runs at synchrotron facilities are infrequent, it 
was important to maximize quality of data before the experiment had ended.  
2.73 Ascertaining data quality 
The correct interpretation and processing of SAXS data is the most critical bottleneck in data 
analysis. Mis-interpretation of the data can lead to incorrect processing and erroneous biological 
conclusions. There are numerous parameters that need to be checked prior to continuing on to 
data analysis. Using the program PRIMUS (Konarev et al., 2003) the main parameters were 
checked as described below and are based on checkpoints suggested at the European 
Molecular Biology Organization (EMBO) SAXS workshop (ESRF, Grenoble, May 2011) and 




a) Are inter-particle effects observed?  
This can be checked by firstly making sure the Guinier region is linear. If an upward trend 
is observed this suggests that at that particular concentration aggregation is occurring. If 
a downward trend is observed it suggests that repulsive interactions are occurring. If 
either event is observed at the very least the scattering at low angles should not be used 
in the merged data set, or the entire data set not used at all. 
b) Have alternate concentrations of the protein been merged efficiently? 
Acquisition of at least three different concentrations is encouraged at synchrotrons. One 
of the main benefits of this strategy is based upon the fact that differing concentrations 
can benefit the scattering graph. High concentrations give the benefit of increased signal 
to noise, especially at higher angles, although inter-particle effects are much more likely 
to be observed at lower angles. Low concentrations give the benefit of a decreased 
likelihood of inter-particle effects observed at lower angles and would therefore give a 
more accurate radius of gyration (Rg), although signal to noise is decreased at higher 
angles. Once scaled, the merged data sets of a combination of low concentration at low 
angles and high concentration at higher angles would be used for further data analysis. 
c) Have mutants / homologues been scaled and superimposed correctly? 
Due to a normalization process of the scattering patterns by the in house auto processing 
software, two similar proteins may superficially appear different. This can be verified by 
scaling the scattering patterns using PRIMUS. Superimposable scattering patterns 
suggest that no global changes have occurred owing to the low resolution of SAXS. 
Differences may be apparent at atomic resolution, however, would need to be verified by 
alternative structural methods.   
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In addition to the above mentioned checkpoints, further processing suggestions were taken from 
an excellent review which discusses guidelines on SAXS analysis and is increasingly becoming 
the gold standard for SAXS analysis interpretation (Jacques and Trewhella, 2010).   
2.74 SAXS Data analysis 
Once the data was judged to be of high quality, each merged data set was analysed using a 
suite of programs called “ATSAS” (Konarev et al., 2006). PRIMUS was used to scale, merge and 
evaluate Rg. The evaluation of the Rg was conducted manually using the Guinier approximation 
(Guinier, 1939) assuming that at small angles s < 1.3/Rg. The Rg was also automatically 
evaluated using the program GNOM which also provided the distance distribution function p(r) 
and the maximum particle dimension (Dmax). Typically the Rg value from GNOM was used for this 
thesis as it has an algorithm to automatically detect the region most representational of the Rg 
from the scattering curve (as long as it corroborated with the manual Rg value). Dmax was found 
using a method suggested by the S4SAS Workshop (Cardiff University, 2010) in which 3 x Rg 
was taken as the initial value and a larger value was input to gauge where the distribution 
function became negative. Furthermore, a variety of values corresponding approximately to 
where the distribution function became negative were tried until the slope did not have a y-axis 
value of 0 preceded by a sharp decline.    
2.75 Ab initio shape reconstruction and comparison 
The output files from GNOM were used as the input files for the ab inito reconstruction program 
DAMMIF (Franke and Svergun, 2009) which creates envelopes of the protein based on the 
SAXS scattering profile. Ten low resolution ab initio bead models were generated using its 
default parameters. The program works using a simulated annealing process to fit a curve, 
initially one of a theoretical spherical shape, to one more representational of the scattering 
curve. Spatial discrepancy was minimized in the 10 low resolution ab initio models by DAMSEL 
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which gives an normalized spatial discrepancy (NSD) value to each model with the lowest value 
given to the model most representational of all the models. The DAMSEL output values were 
input into DAMAVER (Volkov and Svergun, 2003) to give an overall averaged model and finally 
DAMFILT to filter non overlapping dummy residues. In some cases bead models were converted 
into a volumetric map using Situs 2.5 (Wriggers and Chacon, 2001). Models were visualized 
using either PYMOL (Schrodinger, 2010) or CHIMERA (Pettersen et al., 2004). 
2.76 Comparison of SAXS models to atomic resolution models 
Atomic resolution models were either taken from the Protein Data Bank (PDB), from structures 
solved in this project or by using the I-TASSER (Roy et al., 2010) or PHYRE (Kelley and 
Sternberg, 2009) model prediction servers. A number of methods were used to compare SAXS 
models to atomic resolution models. Firstly, CRYSOL (Svergun et al., 1995) was used to back-
calculate theoretical scattering curves and fitted to experimental scattering data from atomic 
resolution models. A χ2 value was given, with values between 0.8-1.2 deemed to be highly 
similar.  Secondly, SUPCOMB (Kozin and Svergun, 2001) was used to compare a SAXS model 
to an atomic resolution model. A NSD value (a unit-less value due to the units involved in the 
calculation cancelling out) was given with values under 1.5 deemed to be highly similar. Unlike 
Root Mean Squared Deviation (RMSD) values which require atomic resolution coordinates 
between two similar structures, NSD values calculated by SUPCOMB have the benefit of 
allowing comparisons between two models created by two differing structural techniques (i.e. an 
ab-initio envelope created by SAXS and a crystal structure). For visualization purposes some 
models required manual fitting.  
2.77 Flexibility assessment 
SAXS scattering curves from multi-domain proteins were subjected to flexibility assessment by 
the Ensemble Optimization Method (EOM) suite (Bernadó et al., 2007). This incorporates two 
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separate programs: RANdom CHain (RANCH) and Genetic Algorithm Judging Optimization of 
Ensembles (GAJOE) (Bernadó et al., 2007). EOM assumes that for a given SAXS scattering 
data set, multiple conformations of a flexible protein exist in solution giving an averaged final 
curve. It can be used to quantitatively characterize flexibility and analyze size distribution 
between a number of different conformers. EOM was conducted using either the ATSAS Online 
server (Petoukhov et al., 2007) or manually. If conducted manually RANCH was used to 
generate 10000 structures with chains between globular domains denoted as “random”. GAJOE 
was then used to create a subset of 50 conformers most representational of the SAXS scattering 
curve using default parameters. GAJOE then gives the fit to the SAXS scattering curve 
represented visually and by a mathematical χ2 value, of which 1 would be optimal. The ATSAS 
online server uses the same protocol (as the manually conducted EOM parameters) except the 
final subset was 20 conformers. The advantage of using ATSAS online is that it is 
computationally (processor speed and memory demands) less demanding yet retains the 
reliability of conducting it manually. It should be noted that fits that do not match the 
experimental SAXS scattering curve do not represent the protein in solution.  Further details can 
be found in the paper by Bernadó et al (Bernadó et al., 2007). The subset of models most 
representational of the SAXS scattering curve (called the selected ensemble) was taken for 
further analysis. An in-house program designed to gauge inter-domain distance distributions 
between two different amino acids from the random pool and selected ensemble was kindly 
created by Dr Pau Bernado (Code given in appendix C). Using this program, two geometric 
points (amino acids) were selected and the distance between them were calculated. A 
distribution graph comparing the two amino acid distances of each model were then created of 
the random pool and the selected ensemble. 
78 
 
2.8 X-ray crystallography 
2.81 Introduction 
X-ray crystallography is one of the oldest and most widely used techniques for determining the 
three-dimensional structure of macromolecules. The first stage in this process is to crystallise 
the protein of interest by reducing protein solubility and hence forcing the protein molecules in 
solution to interact with another in a specific and controlled manner. To aid in the crystallisation 
screening process of proteins, there are numerous commercial crystallisation screens available 
which manipulate the protein in different ways such that it promotes protein-protein interactions 
in solution. The purity of the protein solution is critical as the presence of contaminants can 
disrupt crystal formation or yield crystals that diffract X-rays weakly. Typically the “hanging-drop” 
vapour diffusion method is used to crystallise proteins in which a small drop of protein solution is 
mixed with crystallization condition in an enclosed chamber with a well of crystallization buffer. 
Due to differences in osmolarity between the drop and the well reagent, water diffuses out of the 
drop by vapour diffusion until equilibrium is achieved. During this process the protein 
concentration in the drop steadily increases reaching supersaturated levels from which 
nucleation and crystal formation may take place. Following several days of incubation, 
crystallization plates are viewed using a light microscope to identify initial conditions that have 
led to crystal formation. These preliminary hits are subsequently optimised in an attempt to grow 
diffraction-grade crystals. Once crystals of suitable size and morphology are grown they are 
flash-cooled in liquid N2 and subjected to X-ray diffraction experiments using a focused X-ray 
beam. The crystal upon exposure to an X-ray beam will diffract X-rays in various directions. 
These diffracted X-rays are recorded by an X-ray detector in the form of array of spots (or 
reflections) that are collectively referred to as a diffraction pattern. More specifically, it is the 
electrons that surround the protein atoms within the crystal that diffract X-rays. The crystal is 
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then rotated with respect to the X-ray beam to allow all possible diffracted X-rays to be recorded 
and permit a complete data set to be collected. The diffraction data is then processed which can 
lead to solving the three dimensional structure of the protein. This involves determining the 
amplitude, phase and frequency for each reflection (observed as a “dot”) on the diffraction 
pattern. The amplitude of each reflection can be calculated directly from the intensity. The 
frequency is simply the wavelength of the X-ray beam, and typically 1.54 Å for an in-house CuKα 
X-ray generator. The phase angles of each reflection cannot be determined experimentally 
(known as the ‘phase problem’) but can be acquired using homologous structures (molecular 
replacement) or soaking with heavy atoms (multiple isomorphous replacement and single 
wavelength anomalous dispersion). The combination of amplitudes and estimated phase 
information allows for an electron density map to be calculated which permits a molecular model 
to be built. The model is then improved in an iterative fashion in a process called refinement, 
whereby it is altered to fit the electron density map. The progress of refinement is continually 
monitored through a reduction in two statistics, the Rwork and Rfree.   
2.82 Crystallization screens  
A variety of commercially available sparse-matrix based screens from Hampton Research 
(Index), Emerald Biosystems (Wizard 1 and II) and Molecular Dimensions Ltd (PACT and 
JCSG+) were used for crystallisation screening trials.  Small-scale crystallisation screening trials 
were set up in 96 well plates (Iwaki) using a Mosquito nanolitre crystallization robot (TTP 
Labtech). Briefly, 100 nl of protein were mixed with 100 nl of crystallization buffer on a viewdrop2 
plate seal and equilibrated against 100 µl of crystallization buffer. A variety of protein 
concentrations were used in the initial crystallisation screening trials. Once a number of 
crystallization buffers had been identified as providing promising “hits”, these were optimized by 
altering conditions such as pH of the crystallization buffer, precipitant concentration and drop 
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volume. In addition, further optimisations involved adjusting the protein concentration as well as 
attempting sitting drop experiments.  Once these conditions had been optimized, large scale 
screens were set up using 24 well Linbro plates to grow diffraction-grade crystals. Larger size 
drops typically 1 µl of protein solution and 1 µl of crystallisation reagent were manually mixed on 
a cover slip which was inverted onto a greased chamber containing 1 ml of the crystallisation 
solution. The enclosed system allowed the hanging drop to equilibrate with the well solution until 
crystals were formed. All screening trials were incubated at 23 °C and examined for crystal 
growth at 3 days and then weekly thereafter using a light microscope (Leica).  
2.83 Data collection and processing 
Data collection and processing was conducted primarily by Dr Fiyaz Mohammed so only a brief 
overview will be given. Crystals deemed to be worthy of X-ray data collection were soaked in a 
number of solutions containing crystallization buffer and increasing concentrations of the 
cryoprotectant, ethylene glycol. Crystals were then flash cooled at 100 K in N2 (Oxford 
Cryosystems). X-ray data were collected using an in-house MicroMax 007HF rotating anode X-
ray generator (Rigaku) with a Saturn CCD detector (University of Birmingham Macromolecular 
X-ray facility). Diffraction data sets were integrated, scaled and merged using programs of the 
XDS suite (Kabsch, 2010). Molecular replacement was attempted using the PHENIX suite 
(Adams et al., 2010) with varying lengths of different models or homologues. 
2.84 Single Anomalous wavelength Dispersion (SAD) phasing with Iodine 
An alternative approach to molecular replacement utilizes a halide such as iodide, whereby initial 
phase information was determined through their anomalous scattering signal. An approach 
pioneered by Dauter et al (2000) . Large scale screens using optimized crystallization buffer in 
the presence of no greater than 1 M sodium or ammonium Iodide were attempted. Crystals 
already grown in native conditions were soaked in mother liquor (and cryoprotectant) 
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supplemented with varying concentrations of sodium iodide concentrations. Structure 
determination was conducted by Dr Scott White (University of Birmingham) using programs of 
the PHENIX suite (Adams et al., 2010) and will therefore not be discussed in detail.  The 
molecular model was refined with PHENIX interspersed with rounds of model building using 
COOT (Emsley et al., 2010). 
2.91 Data analysis, presentation and molecular docking modelling 
Proteins were visualized using either PYMOL (Schrodinger, 2010) or CHIMERA (Pettersen et 
al., 2004). Electrostatic surfaces were calculated using an online server for PDB2PQR at: 
http://kryptonite.nbcr.net/pdb2pqr/ and APBS using default parameters (Dolinsky et al., 2004). 
The program High Ambiguity Driven DOCKing (HADDOCK) was used to model potential 
complexes using default parameters (Dominguez et al., 2003). 
2.92 Vimentin co-sedimentation assays 
Vimentin co-sedimentation assays were used to ascertain whether protein constructs from the 
C-terminal tails could bind to vimentin in the polymerized state. Using previously published 
protocols (Choi et al., 2002) and manufacturer’s instructions (Cytoskeleton, Inc) desmoplakin 









Chapter 3 – Biophysical analysis of constructs from plakin domains  
Many members of the plakin family bind to both desmosomes and IFs. These include 
desmoplakin, periplakin, envoplakin and plectin. It is known that the N-terminal head domain is 
responsible for tethering the plakin protein to the desmosome while the C-terminal tail region 
binds to IFs (Choi et al., 2002, Bornslaeger et al., 2001, Kowalczyk et al., 1997, Meng et al., 
1997a, Stappenbeck et al., 1993). The desmoplakin N-terminal region is also mandatory for 
effective assembly of the desmosome in cooperation with plakoglobin and plakophilin 
(Bornslaeger et al., 2001). However, the binding regions on the desmoplakin N-terminal region 
have not been mapped more precisely. The N-terminal region of plakin proteins typically consist 
of a presumably unstructured extreme N-terminal region and a globular plakin domain.  
Previous studies revealed insights into the plakin domain architecture. In 1992 the plakin domain 
was proposed to consist of 5 α-helical regions termed NN, Z, Y, X, W, V (Virata, 1992). It was 
not until 2007 that a study on BPAG1 revealed that the plakin domain was actually part of the 
spectrin superfamily (Jefferson et al., 2007). Further studies then showed greater details for the 
proposed architecture of the entire plakin domain based on sequence homology (Sonnenberg et 
al., 2007). These studies suggested that each plakin domain typically consisted of 6 SRs and a 
SH3 domain. However, how the SRs organized in combination with the SH3 domain within the 
plakin domain architecture in solution was unclear. Ascertaining how the plakin domain SR 
modules orientate may clarify why certain regions are involved in assembly of the desmosome. 
Understanding how the SR modules orientate would corroborate ligand binding studies to other 
desmosomal proteins conducted by other members of the lab.  
During the preparation for this chapter, two independent groups solved the structures of the first 
4 spectrin repeats of desmoplakin (Choi and Weis, 2011) and a homologous region of plectin 
(Ortega et al., 2011) with both encompassing the SH3 domain. The structures reveal a series of 
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canonical SRs connected by rigid α-helical linkers and a non-canonical SH3 domain which has 
an intimate association with SR4. The interactions between the SH3 domain and SR4 are 
conserved between desmoplakin and plectin which consists predominantly of hydrophobic 
residues. Both sets of authors propose that this interaction works to rigidify the SR3-6 region of 
the globular plakin domain. The architecture of the more divergent C-terminal region of the 
plakin domain which was previously proposed to contain SR modules was unknown and was of 
interest to this study. In addition to this it was hoped that a solution based study using NMR and 
SAXS would give an indication of the dynamics of the SR modules and linking regions. It was 
hoped by acquiring such information it would help understand how the plakin domain’s 
architecture could be involved in desmosome assembly and/or binding to its known ligands. 
The aim of the work in the following chapter was therefore to elucidate the modular organization 
of the desmoplakin plakin domain by CD, AUC, thermal stability assays, NMR and SAXS. It was 
hoped that the structure of these modules could be elucidated either by NMR or X-ray 
crystallography. In order to elucidate the structural and functional units of desmoplakin’s plakin 
domain, a variety of constructs spanning this entire region were made. As stated in the methods  
sequence alignments , solubility prediction tools, and identification of regions predicted to be 
folded were used to aid construct design.  
3.1 Expression and purification of subdomains 
In order to structurally characterize the subdomains they were first purified to homogeneity. 
SR56 will be used as an example since each subdomain was purified the same way (with the 
exception of SR78 and SR8-CT which had an extra histag cleavage step). Since each of the 
subdomains was his-tagged they were purified by single step nickel ion chromatography using a 
Histrap column. Figure 3.1A depicts the purification of SR56 from lysis of the bacterial pellet to 
elution from the Histrap column. The protein was soluble as it can be seen in the soluble fraction 
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(size is ~30 kDa). It can also be seen in the wash fraction suggesting that not all the SR56 was 
able to bind to the column. However, once eluted from the column in 1 ml fractions it was the 
most abundant protein albeit with contaminants still remaining. To eliminate the remaining 
contaminants fractions with the most SR56 were pooled and concentrated for further purification 
by size exclusion chromatography using an S75 superdex column. Figure 3.1B shows the 
pooled fraction, concentrated pooled fraction and the elutions from the size exclusion column. 
The purity of the SR56 protein was estimated to be >95% and so was considered suitable for 
structural characterization.  Other desmoplakin subdomains were also purified to >95% 






Figure 3.11 Purification and SDS-PAGE analysis of SR56 
SDS-PAGE analysis of purification of SR56. A. Shows Lysate (Lys), Soluble lysate fraction (Sol), 
Insoluble lysate fraction (Ins), Histrap wash elution (Was) and 1ml Histrap elutions numbered 
from 1-21. B. Shows the pooled 1ml Histrap elutions (pool), this was then concentrated (Conc), 
and further purified by size exclusion chromatography with the resulting gel filtration elutions 








3.2 Expression trials of SR34 
Two different temperatures and induction times were attempted to optimise solubility of SR34 as 
initial trials suggested it was insoluble upon expression in E.coli. Initially his-tagged SR34 was 
grown for 4 h at 20 °C and 1H at 37 °C. SR34 was observed in the insoluble fraction at 
approximately 25 kDa (figure 3.2A). The construct was then optimized to contain a Small 
Ubiquitin-like MOdifier (SUMO) fusion solubility tag known to increase solubility of difficult to 
express proteins (Marblestone et al., 2006). Even with the addition of a SUMO fusion tag the 
protein could not be expressed in the soluble fraction (figure 3.2B). The lack of a soluble 
desmoplakin SR34 is in stark contrast to the homologue in BPAG1 that was expressed as a 
SUMO-fusion and eventually crystallized. Despite the inability to produce soluble SR34 protein, 












Figure 3.2 Expression trials of SR34 
SR34 was expressed as two constructs and two different temperatures to optimise solubility. A: 
Expression of the his-tagged construct reveals that SR34 remains in the insoluble fraction. (M: 
marker, Pre: Pre induction sample, Sol: Soluble fraction post lysis, Ins: Insoluble fraction post 
lysis). B: Expression of the SUMO fusion construct seen at approximately 45kDa in the insoluble 
fraction (M: marker, Pre: Pre induction sample, Sol: Soluble fraction post lysis, Ins: Insoluble 
fraction post lysis). Despite the expression with a his-tag and solubility enhancing SUMO tag, 













3.3 Circular dichroism of desmoplakin plakin domain subdomains 
The plakin domain of desmoplakin was predicted to be predominantly composed of α-helical 
subdomains. This was investigated using CD analysis of the subdomains of the desmoplakin 
plakin domain.  
SR56 was subjected to CD at room temperature within the range of 240 nm to 190 nm. As 
expected a predominantly α-helical structure was observed as shown by the minima at 222 nm 
and 208 nm (figure 3.3). Deconvolution using the DICHROWEB server (Whitmore and Wallace, 
2004) revealed estimated secondary structure of SR56 as: 73% α-helical, 10% β-sheet, 6% turn 
and 11% disorder. This is consistent with amino acid derived secondary structure predictions of: 
61% α-helical, 11% β-sheet, 4% turn and 24% disorder using SOPMA (Geourjon and Deléage, 
1995).  
The SH3 domain was not subjected to CD analysis as 2D-HSQC revealed a completely unfolded 
state (see 3.71). 
SR78 was subjected to CD at room temperature within the range of 240 nm to 190 nm. Once 
again as expected for a SR tandem, a predominantly α-helical structure was observed as shown 
by the minima at 222 nm and 208 nm (figure 3.3). Deconvolution using the DICHROWEB server 
revealed estimated secondary structure as: 88% α-helical, 0% β-sheet, 3% turn and 8% 
disorder. This is consistent with amino acid derived secondary structure predictions of: 88% α-
helical, 1% β-sheet, 0% turn and 11% disorder using SOPMA. Furthermore, unlike the CD 
spectrum of SR56, SR78 had a positive elliptical value more than double its negative minima 
values. This suggested that the α-helical content is greater in SR78 than that of SR56 (Personal 
communication: Dr Raul Pacheco-Gomez, University of Birmingham) and is reflected in the 
DICHROWEB predictions.  
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SR8-CT was subjected to CD at room temperature from 240 nm to 190 nm. A predominantly α-
helical structure was observed as shown by the minima at 222 nm and 208 nm (figure 3.3), 
however deconvolution using the DICHROWEB server revealed estimated secondary structure 
as: 39% α-helical, 16% β-sheet, 17% turn and 28% disorder. This is inconsistent with the 
secondary structure of a typical spectrin repeat tandem. It is also inconsistent with amino acid 
derived secondary structure predictions of: 86% α-helical, 0% β-sheet, 0% turn and 14% 
disorder using SOPMA. This therefore implies that SR8-CT has a structure anomalous to that 
predicted for it by sequence homology.  
The results indicated that of SR56, SR78 and SR8-CT, SR56 and SR78 are the most folded. 
SR8-CT revealed a distinct CD spectrum which suggested a need for further characterization to 
understand the anomalous result. Thermofluor thermal stability assays were then used to probe 








Figure 3.3 Circular dichroism analysis of each subdomain 
CD spectra of SR56 (red, squares), SR78 (purple, triangles), and SR8-CT (pink, circles) were 
collected at room temperature using a Jasco J-810 spectrometer and a protein concentration of 
0.1 mg/ml in 20 mM sodium phosphate (pH 7.2). The scanned wavelength range was 190-240 
nm. Spectra were analyzed by DICHROWEB to ascertain their secondary structure content. 
Spectra of SR56 and SR78 were indicative of α-helical proteins. SR8-CT reveals a structure of 
some α-helical content. See text for further details. Adapted with permission from Elsevier, (Al-
Jassar et al, 2011) under license number: 2862440887646. 
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 3.4 Thermofluor stability assays  
One of the main aims of the chapter was to elucidate the solution structure of the core structures 
of the desmoplakin plakin domain. Using a custom prepared 96 well plate of various buffer 
conditions and additives, it was hoped that an optimized condition could be found for structural 
studies. An optimized condition would be classed as a buffer and/or additive which gives a 
positive thermal shift of at least 2 °C (Personal communication: Professor Michael Overduin, 
based on unpublished findings from the Structural Genomics Consortium, Oxford). Previous 
studies reported this high-throughput method to successfully optimize crystallization of E.coli 
proteins (Ericsson et al., 2006). In addition to this our lab has used Thermofluor to find improved 
conditions for NMR structural determination (unpublished results: Overduin lab). Qualitatively, 
Thermofluor can also be used to ascertain whether the protein is folded, as typically a sigmoidal 
curve is observed. Unfortunately a significantly optimized condition was not found for any of the 
constructs used. Instead sigmoidal curves obtained in 20 mM sodium phosphate and 100 mM 
NaCl will be used to compare the thermal stabilities of all subdomains (figure 3.4). 
SR56 gave a typical sigmoidal curve expected of a folded protein, which also suggested that the 
spectrin repeats and SH3 domain acted as cooperatively folded units. In 20 mM sodium 
phosphate (pH 7.2), 100 mM NaCl a Tm of 50 °C was recorded.    
The SH3 domain did not give the sigmoidal denaturation curve expected for a stable domain in 
any buffer condition (data not shown). This is based on the premise that a hydrophobic core of 
the protein is present for which the dye can bind. This is discussed further in 3.71.   
SR78 gave a typical sigmoidal denaturation curve expected of a folded protein, which also 
suggested that both spectrin repeats 7 and 8 act cooperatively as folded units as shown by the 
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single transition. In 20 mM sodium phosphate (pH 7.2), 100 mM NaCl a Tm of 59 °C was 
recorded.   
The SR8-CT construct gave a sigmoidal curve expected of a folded protein, which also 
suggested that both spectrin repeats 8 and the CT region acted cooperatively as a folded unit. 
The optimal condition included 20 mM sodium phosphate (pH 7.2), 100 mM NaCl and yielded a 
Tm of 52 °C was recorded.    
The thermal stability results are in agreement with the CD data as all canonical spectrin repeat 
constructs yielded spectra indicating that they were folded. To gauge their oligomerization states 













Figure 3.4 Raw thermofluor thermal stability profiles of each subdomain 
Raw thermal stability profiles of SR56 (red, squares), SR78 (purple, triangles), and SR8-CT 
(pink, circles) were calculated using a Stratagene MX-3005 with temperatures ranging from 25 
°C to 90 °C. Proteins were in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl at a final 
concentration of 2 µM. The midpoint reflects the melting temperature (Tm) (see text). It shows 
that whereas SR56 and SR8-CT have similar Tm’s of 50 °C and 52 °C respectively, SR78 is 
more thermally stable and this is reflected by its higher Tm of 59 °C. Adapted with permission 





3.5 Analytical ultracentrifugation of SH3, SR56, SR78, SR8-CT 
Although the rod domain of the desmoplakin full length protein had been proposed to mediate 
homo-dimerization, the oligomeric states of the plakin domain and its subdomains were 
unknown. Particularly of interest was the fact that the N-terminal head domain (where the plakin 
domain is present) is shown as 2 lobes in close proximity by electron microscopy studies which 
implied a possible association (Green et al., 1990). AUC was used to investigate whether the 
subdomains of the desmoplakin plakin domain self associate.  
AUC analysis of the SH3 domain revealed a single species corresponding to a molecular weight 
of 8.0 kDa (figure 3.5). This compared favourably with the theoretical sequence based molecular 
weight of 9.8 kDa. This suggested that the desmoplakin SH3 domain remains monomeric in 
solution.  
AUC analysis of SR56 revealed a single species corresponding to a molecular weight of 31.1 
kDa (figure 3.5). This compared favourably with the theoretical molecular weight of 31.3 kDa. In 
common with the SH3 domain, it suggested that SR56 is monomeric in solution. 
AUC analysis of SR78 revealed a single species corresponding to a molecular weight of 25.8 
kDa (figure 3.5). This compared favourably with the theoretical molecular weight of 27.8 kDa. 
SR78, again like SR56 and the SH3 domain is therefore monomeric in solution.  
AUC analysis of SR8-CT domain revealed a single species corresponding to a molecular weight 
of 31.1 kDa (figure 3.5). This compared favourably with the theoretical molecular weight of 30.6 
kDa. This confirmed that SR8-CT is monomeric.   
The results confirm that all subdomain constructs investigated from the plakin domain are 
monomeric.  This is consistent with previous reports suggesting that dimerization of the 




Figure 3.5 Analytical Ultracentrifugation (AUC) profiles of each subdomain 
Each subdomain was subjected to AUC experiments at room temperature at a speed of 25000 
rpm for 20 h on a Beckman XL-1 analytical ultracentrifuge using an eight cell 50Ti rotor and 
detected at 280 nm. Samples were run at between 0.05 and 4 mg/ml in 20 mM sodium 
phosphate (pH 7.2) and 100 mM NaCl. The results were analysed by the program SEDFIT 
(Brown and Schuck, 2006) in which the continuous c(S) analysis method was used to calculate 
estimated molecular masses. The peaks were then standardised. SH3 (blue), SR56 (red), SR78 
(purple), and SR8-CT (pink) each reveal a monomeric profile. No other higher order species 
were observed. A residual buffer signal is observed at very low molecular weight. Adapted with 




3.6 Crystallization trials of the SH3 domain, SR56 and SR78  
One of the aims of the work herein was to obtain the structure of a desmoplakin plakin domain 
subdomain. The SH3 domain, SR56 and SR78 were subjected to crystallization trials using a 
variety of commercially available screens. Although a few preliminary hits were identified, these 
were subsequently identified as salt crystals and no further crystals were found. Further 
crystallization attempts were abandoned due to the lack of crystal formation. Instead, NMR was 
used an alternative strategy. X-ray crystallography is heavily reliant on the bottleneck of protein 
crystallization. However, NMR analysis in contrast can be conducted rapidly on small monomeric 
proteins in solution. The sizes of all the subdomains used in the experiments of this chapter 
were within the size limitations of NMR (<30 kDa).  
3.7 NMR analysis 
At the time the experiments for this chapter were undertaken the structure of the desmoplakin 
plakin domain was unknown. As previously described, structures of homologues of SR34 from 
plectin (Sonnenberg et al., 2007) and BPAG1 (Jefferson et al., 2007) are available. 2D-HSQC 
NMR analysis of 15N labelled SH3 domain, SR56, SR78 and SR8-CT were conducted to gauge 
whether these constructs were viable for NMR structure determination. Expression and 
purification was conducted in the same way as their WT counterparts and no significant 
differences were recorded in either yield or purity.  
3.71 2D-HSQC NMR analysis of the desmoplakin SH3 domain 
The SH3 domain was analysed by 2D-HSQC NMR. A total of 85% of the expected peaks were 
observed (figure 3.71). The NεH resonance of the single tryptophan 493 was resolved at 10.2 
ppm. The lack of dispersion of backbone amide resonances indicated a fully disordered protein. 
The lack of dispersion is indicated by the peaks residing predominantly within the range of 8-8.5 




Figure 3.71 2D-HSQC of the SH3 domain 
A 2D-HSQC spectrum was acquired for the SH3 domain. The protein was run at 25 °C on an 
Agilent 600 MHz spectrometer in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl at 100 
µM. Boxed is the sole trypophan 493 present in the SH3 domain construct. The spectrum is 
typical of an unfolded protein as shown by the lack of dispersion of peaks located between 7.8-




3.72 2D-HSQC NMR analysis of SR56 
The SR56 protein was analysed by 2D-HSQC NMR. Of the 185 peaks expected only 75 were 
observed (figure 3.72). The NεH resonances of tryptophan residues 493, 537 and 550 were 
viewed as two overlapping peaks at ~10.2 ppm. Although CD confirmed the presence of a 
secondary structure, a globular tertiary structure is unlikely to be resolvable by NMR. This is 
based firstly on the few observable peaks residing predominantly in the random coil region of the 
spectrum. (8-8.5 ppm) and secondly on the lack of sufficiently intense and dispersed NH peaks. 
An increase in temperature from 25 to 30 °C did not improve the quality of the spectrum (data 








Figure 3.72 2D-HSQC of SR56 
A 2D-HSQC spectrum was acquired for SR56. The protein was run at 25 °C on an Agilent 600 
MHz spectrometer in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl at 100 µM. Boxed 
are tryptophans 493, 537 and 550 present in the SR56 construct seen as 2 overlapping peaks. 
Secondary structure and CD predictions suggested that the spectrum would be indicative of a 
mixed α-helical and β-sheet protein with well dispersed peaks. However, the general lack of 
dispersion of peaks indicates that SR56 is predominantly flexible although some α-helical 
elements may be present as some dispersion of peaks occurs between 8 and 8.75 ppm. The 
spectrum thus indicates that although there may be some α-helical and β-sheet content (as 
suggested by secondary structure and CD predictions), there is unlikely to be an overall tertiary 




3.73 2D-HSQC NMR analysis of SR78 
The SR78 protein was analysed by 2D-HSQC NMR. At 25 °C approximately 40% of the 
expected peaks were observed (figure 3.73A). However, increasing the temperature to 30 °C 
increased this to 90% of the expected peaks observed (figure 3.73B). The spectrum is typical for 
predominantly α-helical proteins as observed by the spread from 7-9 ppm. Each of the NεH 
resonances of tryptophan residues 667, 867 and 879 were observable. This confirmed that the 
SR78 construct had a tertiary fold and is viable for further NMR structure determination. The 
requirement of an increased temperature at 30 °C is likely due to the prolate shape of the protein 
typical of SR tandems previously observed (Yan et al., 1993). Models of SR78 from the PHYRE 
server (Kelley and Sternberg, 2009) suggested an extended helical bundle fold, typical of SRs. 
Combined with the size of the protein (25kDa), at 25 °C it is highly likely that the protein tumbles 
in solution at a nonisotropic rate in a manner unfavourable for NMR determination. This leads to 
a faster relaxation time, which ultimately leads to a decreased signal to noise ratio. At 30 °C 
however, the tumbling is increased due to the increased energy in the system and therefore 
relaxation time is decreased, and finally increased signal to noise ratio. To date, the spectrum is 
the most dispersed recorded by NMR for a tandem spectrin repeat construct in the literature. 







Figure 3.73 2D-HSQC of SR78 
2D-HSQC spectra were acquired for SR78. The protein was run at two different temperatures 
(25 °C and 30 °C) on an Agilent 800 MHz spectrometer in 20 mM sodium phosphate (pH 7.2) 
and 100 mM NaCl at 100 µM.  A) A comparison of SR78 2D-HSQC at two different temperatures 
superimposed (blue, 30 °C, red 25 °C). Boxed are tryptophans 667, 867 and 879 present in the 
SR78 construct. The spectrum indicates that SR78 is predominantly α-helical with a tertiary fold 




3.74 2D-HSQC NMR analysis of the SR8-CT 
The SR8-CT protein was analysed by 2D-HSQC NMR. Very few of the expected number of 
peaks were observed (figure 3.74). The NεH resonances of tryptophans 867, 879 and 901 also 
overlap as one superimposed peak at 10.2 ppm. Although CD confirmed the presence of some 
secondary structure, a globular structure observable by NMR was unlikely to exist. This 
suggested that SR8-CT contains flexible elements, which in turn make the folded elements 
unresolvable on a NMR spectrum. Like SR56 an increase in temperature from 25 to 30 °C did 






Figure 3.74 2D-HSQC of SR8-CT 
A 2D-HSQC spectrum was acquired for SR8-CT. The protein was run at 25 °C on an Agilent 600 
MHz spectrometer in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl at 100 µM. Boxed 
are tryptophans 867, 879 and 901 present in the SR8-CT construct. The spectrum indicates that 
S8-CT was predominantly flexible or unfolded due to the few peaks observable. Adapted with 





3.75 2D-HSQC NMR analysis of the envoplakin SH3 domain 
It was hoped that since the desmoplakin SH3 domain in isolation was disordered that other 
plakin SH3 domains may harbour more favourable folding properties for structural determination. 
The envoplakin and periplakin SH3 domains were thus investigated. 
The envoplakin SH3 domain was analysed by 2D-HSQC NMR. Overall the spectrum yielded a 
typical dispersion indicative of a folded predominantly β-sheet containing protein (figure 3.75). 
This is based on the dispersion being spread between 7.5 and 10.2 ppm. The NεH resonances 
of tryptophans 424 and 448 were observed as 3 peaks between 10.0 and 10.2 ppm. The 
presence of an extra peak may reflect a chemical shift of a backbone residue that is particularly 
downshielded. An alternative explanation may be that the envoplakin SH3 domain may have a 
tryptophan that is dynamic. The observation of a folded plakin SH3 domain was a surprising 
result given the high sequence homology to the desmoplakin SH3 domain which itself was 
shown to be disordered (figure 3.71). As the NMR spectrum indicated that the envoplakin SH3 











3.75 2D-HSQC of the envoplakin SH3 domain 
A 2D-HSQC spectrum was acquired for the envoplakin SH3 domain. The protein was run at 25 
°C on an Agilent 600 MHz spectrometer in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl 
at 200 µM. Boxed are tryptophans 424 and 448 present in the envoplakin SH3 domain construct.  
Three peaks are present because of the possibility of the protein being observed in 2 possible 
conformations. The spectrum indicated that the envoplakin SH3 domain is a folded, 







3.76 2D-HSQC of the periplakin SH3 domain 
The periplakin SH3 domain was analysed by 2D-HSQC NMR spectroscopy.Very few peaks 
were observed for the periplakin SH3 domain (figure 3.76). The NεH resonances of its 
tryptophans were not observed in the spectrum. Overall the spectrum yielded dispersion 
indicative of a disordered or aggregated protein. This is based on the dispersion being spread 
narrowly between 7.7 and 8.5 ppm. The lack of peaks and the narrow spread of those present 
suggested the protein was either disordered, highly dynamic or self associating.  
Overall, the 2D-HSQC NMR data showed that each plakin SH3 domain exhibited differential 
conformations in isolation. Again, given the high sequence similarity between each plakin SH3 













3.76 2D-HSQC of the periplakin SH3 domain  
A 2D-HSQC spectrum was acquired for the periplakin SH3 domain. The protein was run at 25 
°C on an Agilent 600 MHz spectrometer in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl 
at 300 µM. No NεH resonances were observed in the usual position at the bottom left corner of 
the HSQC spectrum. The spectrum indicated that the periplakin SH3 domain was predominantly 
disordered and/or oligomerizes as shown by the lack of dispersion, the lack of tryptophan NεH 








3.77 Feasibility of assigning SR78 and the envoplakin SH3 domain 
To assign the backbone of any protein by NMR a variety of 3D spectra are acquired from 
samples that are 13C and 15N labelled. It is only economically feasible to conduct further 3D NMR 
experiments if the HSQC suggested that the protein is folded since 13C labelling of the protein is 
expensive. Both SR78 and the envoplakin SH3 domain were therefore good candidates to take 
for further structural elucidation based on their resolved HSQC spectra (figures 3.73 and 3.75 
respectively). The “gatekeeper” to 3D NMR spectra is the HNCO which acquires the i-1 of each 
hydrogen bound to a 15N labelled amide. It is the most sensitive of all 3D spectra and therefore 
determines whether further 3D spectra acquisition is worthwhile. As each HNCO experiment was 
conducted by Dr Mark Jeeves (University of Birmingham) only a brief overview will be given.  
3.78 HNCO of SR78 and the envoplakin SH3 domain 
A HNCO of 13C and 15N labelled SR78 was conducted on an Agilent 800 MHz spectrometer at 
30 °C at 500 µM in 20mM sodium phosphate (pH 7.2) and 100mM NaCl. Unfortunately, very few 
peaks were observed in the HNCO suggesting that NMR assignment was going to be 
challenging (data not shown).  Therefore, it appeared that although the protein was folded, there 
may be other factors preventing collection of data via the HNCO experiment. Since the HNCO is 
the “gatekeeper” to conducting further NMR experiments, this route was not continued. Previous 
NMR studies have solely investigated single SRs (1 SR) as opposed those in tandem (2 SRs) 
which are more physiologically relevant (Park et al., 2003, Pascual et al., 1997). Therefore the 
failure to acquire 3D NMR data for the SR78 construct may reflect a problem faced by other 
researchers studying non globular prolate structures in solution.  
An HNCO of the 13C and 15N labelled envoplakin SH3 domain was conducted on an Agilent 600 
MHz spectrometer at 25 °C at 700µM in 20mM sodium phosphate (pH 7.2) and 100mM NaCl. 
Unfortunately, very few peaks were observed in the HNCO suggesting that further NMR 
109 
 
structural determination was again going to be challenging (data not shown).  Therefore, in 
common with SR78 it appears that although the protein is folded there may be other factors 
preventing the HNCO and therefore other 3D NMR experiments from being acquired. One 
possible explanation may involve the observation of an extra peak in the range usually expected 
for the NεH resonances of tryptophans. It implies that if the extra peak is that of a NεH resonance 
from a tryptophan then one of the tryptophans is being observed in 2 orientations. If true, it 
implies that the envoplakin SH3 domain could be dynamic and exists in two alternating 
conformations.  
Given that none of the subdomain constructs were suitable candidates for atomic structural 
determination by NMR or X-ray crystallography an alternative approach was required to 
ascertain further structural properties.   
3.8 SAXS of the desmoplakin plakin domain subdomains 
Although SAXS is a low resolution technique, it allows for basic structural properties, foldedness 
and similarity to atomic resolution models to be probed. One of the main benefits of SAXS is that 
it is a relatively low risk technique often used for proteins refractory to conventional structural 
elucidation experiments such as NMR or X-ray crystallography.   
The SR56, SR78 and SR8-CT constructs were subjected to SAXS analysis at the DESY X33 
beamline (EMBL, Hamburg). A key element of SAXS structural determination is the importance 
of monodispersity. Since each subdomain was shown to be monomeric in solution by AUC this 
suggested they were amenable for structural characterization by SAXS. Prior to exposure to the 
beamline, each sample was dialyzed in 20mM sodium phosphate (pH 7.2), 100mM NaCl and a 
variety of concentrations ranging from 1-7 mg/ml were used. Each protein was analyzed in the 
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same fashion as one another and SR78 will be used as a guide to show how SAXS analysis was 
conducted.  
3.81 SAXS analysis of SR78 
A buffer subtracted SAXS scattering curve was acquired for SR78 using previously published 
methods (figure 3.81A). SR78 was then checked for interparticle effects. As shown in figure 
3.81B the Guinier region was linear. The guinier region is usually/nearly always at lower angles 
as long as S<1.3 for globular proteins. The Rg value can then be taken manually via linear 
regression which was calculated to be 4.2 nm. Another parameter to calculate was the Dmax. 
This was conducted using the program GNOM (Semenyuk and Svergun, 1991) and a P(r) 
distribution graph created as shown in figure 3.81C. The Dmax was calculated to be 13 nm. An 
automated value for the Rg was also calculated by GNOM which was 4.3 nm - in good 
agreement with the manually obtained Rg value. Ten ab-initio DAMMIF (Franke and Svergun, 
2009) models were created and then manually superimposed on one another. As shown in 
appendix D little heterogeneity is shown between the models suggesting that the protein is a 
rigid structure (Personal communication: Dr Katsuaki Inoue, Diamond light source, Oxford, 
September 2009). Of the 10 models, the program DAMSEL selects the one most 
representational of all 10 and the program DAMAVER (Volkov and Svergun, 2003) creates an 
average based on these statistics. Finally DAMFILT is used to filter any extraneous regions not 
aligned with the average model. Since DAMMIF’s output is bead orientated, it must be stated 
that each bead does not depict an individual amino acid and is representational of space 
instead. Although non essential, for easier visual inspection the bead model was then converted 
to a volumetric map by the program SITUS (Wriggers and Chacon, 2001). Since the atomic-
resolution structure of SR78 was unobtainable, its sequence was fed into the PHYRE server. 
This yielded a model 14% identical to the crystal structure of erythroid spectrin SR8 and SR9 
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(Protein Data Bank ID: 1S35). Although 14% is a relatively low figure, this is regarded as an 
acceptable percentage by those in the spectrin repeat field (Mirza et al., 2010). The model was 
input into the envelope automatically using SUPCOMB (Kozin and Svergun, 2001) and a 
normalized spatial discrepancy value of 0.456 was obtained (figure 3.81D). This indicated that 
both SR7 and SR8 exist as canonical SRs with three-helix-bundles arranged in a linear 
extended rod. This also validated the results of the 2D-NMR HSQC of SR78 which suggested 
that the construct was likely to be extended and contain an α-helical structure. The program 
CRYSOL (Svergun et al., 1995) was then used to create a theoretical SAXS scattering profile for 
the SR78 model which when superimposed onto the experimental SAXS scattering profile gave 
a good fit (appendix D). Although not perfect, it suggested some discrepancies between the 
atomic model and the envelope. This may be due to flexible termini which would skew the result 
created by uncertainty as to where SR7 and/or SR8 begin and end respectively. This is 
understandable given the low identity between the sequence and the template. Nonetheless, 
given that the atomic model fits well into the envelope it is highly likely the orientation of the core 







Figure 3.81 SAXS analysis of SR78 
SR78 was analyzed at 1, 2 and 5 mg /ml in 20 mM sodium phosphate (pH 7.2) and 100 mM 
NaCl. The SAXS scattering curves were scaled and merged to create a final SAXS scattering 
curve in accordance with published methods. A: Buffer subtracted SAXS scattering curve with a 
DAMMIF fit. B: Guinier analysis showing that the fit is good indicating a reliable Rg value of 4.2 
nm (visualized in PRIMUS). C: P(r) distribution curve indicating the Dmax (13 nm). D: Final 
averaged and filtered envelope with a model inserted automatically (see text). Adapted from Al-






3.82 SAXS analysis of SR56 
As with SR78, no inter-particle effects were observed so SAXS analysis was undertaken. GNOM 
revealed a Rg value of 3.9 nm and a Dmax of 12.5 nm. A total of 10 ab-initio models were created 
by the program DAMMIF and superimposed manually to gauge flexibility. As shown in appendix 
E the 10 superimposed models revealed a degree of heterogeneity. This is in keeping with the 
suggestion that SR56 contains flexible elements based on the 2D-NMR HSQC in figure 3.82. A 
final averaged and filtered envelope revealed a bent-rod shape containing two dissimilar lobes. 
Given that how and if the protein was correctly folded was unknown, an estimation of the model 
orientation is given in figure 3.82B using a small hinge between SR5 and SR6 (as postulated by 
Choi and Weis, 2011). A theoretical SAXS scattering profile of the crystal structure derived for 
the region encompassing SR56 by Choi and Weis (2011) was superimposed onto the 
experimental SAXS scattering curve using CRYSOL (appendix E). This gave a poor fit and 







Figure 3.82 SAXS analysis of SR56 
SR56 was analyzed at 1, 2 and 6 mg /ml in 20 mM sodium phosphate (pH 7.2) and 100 mM 
NaCl. The SAXS scattering curves were scaled and merged to create a final SAXS scattering 
curve in accordance with published methods. A: Buffer subtracted SAXS scattering curve with a 
DAMMIF fit. B: Final averaged and filtered envelope with crystal structure derived atomic data 
(pdb code: 3R6N) manually inserted (see text). Adapted from Al-Jassar et al. (2011) with 







3.83 SAXS analysis of SR8-CT 
No interparticle effects were observed for SR8-CT so this construct was progressed for further 
SAXS analysis. GNOM revealed a Rg value of 4.3 nm and a Dmax of 12.5 nm. Ten ab-initio 
models were created by the program DAMMIF and superimposed. In common with SR56 the 10 
superimposed models of SR8-CT revealed a degree of heterogeneity (appendix F). This is in 
keeping with the CD data which showed a relatively higher level of disorder compared to SR56 
and SR78 and the NMR data which revealed no discernible peaks. Together this suggested that 
like SR56 there was a degree of flexibility within the SR8-CT construct. This is more evident with 
the final averaged and filtered envelope which revealed a shape highly dissimilar to that of a 
canonical spectrin repeat shown in figure 3.83B. A tandem spectrin repeat model predicted by 
the PHYRE server (calculated from the 1S35 template) could not be inserted by either 
automated or manual fitting (data not shown). A SR8 model was inserted manually leaving the 
remainder of the envelope to the flexible CT element (figure 3.83B). A theoretical SAXS 
scattering profile of the model was superimposed onto the experimental SAXS scattering profile 
and a reasonable fit was observed (appendix F). The reasonable fit like that observed for a 
SR78 model suggests that the protein in solution may behave somewhat like a canonical 
spectrin repeat but has elements that do not. Combine this data with the 10 superimposed 
DAMMIF models and CD and NMR data and it is likely that SR8-CT is at best spectrin repeat 
like. It is possible that the CT region may still harbour a spectrin repeat-like domain but the data 





Figure 3.83 SAXS analysis of SR8-CT 
SR8-CT was analyzed at 2, 5, and 8 mg /ml in 20 mM sodium phosphate (pH 7.2) and 100 mM 
NaCl. The SAXS scattering curves were scaled and merged to create a final SAXS scattering 
curve in accordance with published methods. A: Buffer subtracted SAXS scattering curve with a 
DAMMIF fit. B: Final averaged and filtered envelope with a model for SR8 manually inserted 















3.9 Chapter 3 conclusions 
Overall it appears that the modular organization of the desmoplakin plakin domain is complex. 
SR78 appears to be the most independently stable and well defined of all 4 subdomain 
constructs analyzed. SR8-CT appears to be the most anomalous of all soluble subdomains, 
possibly requiring the adjacent rod domain to acquire its fold. In light of the recent publications 
on the N-terminal regions of the desmoplakin (Choi and Weis, 2011) and plectin (Ortega et al., 
2011) plakin domains it is also likely SR56 requires SR4 to acquire its stable fold.  
The SR domains of desmoplakin’s plakin domain were investigated to gauge their modular 
organization in solution. Each SR was analyzed separately, with SR34 and SR8-CT behaving 
anomalously and SR56 and SR78 folding independently. The SR34 construct appeared to 
require the neighbouring SR5/SH3 element for stability and therefore did not form an 
independent structural unit shown by its insolubility. This was confirmed by two studies on 
desmoplakin and plectin on the same region in which both suggested that SR4 had an intimate 
association with the SH3 domain (Choi and Weis, 2011, Ortega et al., 2011). The SH3 domain of 
desmoplakin was shown by 2D-HSQC to be unfolded despite being soluble. This was also likely 
to be the case for the periplakin SH3 domain. In contrast however, the envoplakin SH3 domain 
appeared to be independently folded and a well dispersed 2D-HSQC indicated a protein with 
high -sheet content. It is unusual to observe an SH3 domain incapable of independent folding 
since they are often folded (Kaneko et al., 2008, Musacchio et al., 1992, Musacchio et al., 1994). 
It is also interesting to observe the variation of folding capabilities of the SH3 domains from 
different plakin proteins. The reason why the envoplakin SH3 domain remained independently 
folded whereas the others were not remains uncertain but may be due to the subtle differences 
in the sequences between the plakin SH3 sequences and their respective interfaces with SR4. 
The uniqueness of the independent fold of the envoplakin SH3 fold is supported by alteration of 
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its key contacts with SR4. In particular tryptophan 424 in envoplakin’s RT loop is bulkier than the 
typical tyrosine at this position (which is known to be crucial for stability of the SH3 fold).  In 
particular its Ala-Cys sequence just prior to β-strand 5 which replaces the Val-Gly found here in 
desmoplakin that was shown to engage SR4 (Choi and Weis, 2011).  The desmoplakin SR4 
residues glutamic acid 290, tryptophan 360 and isoleucine 364 that provide critical contacts with 
its SH3 are substituted in envoplakin by Gln, asparagine and leucine residues respectively, and 
hence the electrostatic and hydrophobic interdomain contacts could again be compromised 
(alignment shown in appendix B). These subtle alterations may make envoplakin distinct from 
other plakin SH3 domains in that it is able to adopt an independent fold without the need of a 
bound SR4. Since the envoplakin SH3 domain is independently folded it is possible that plakin 
SH3 domains may have differential abilities to bind other as yet unknown ligands. However, 
given that the primary function of a SH3 domain is ligand binding, the presence of an 
independent fold (in contrast to those observed for desmoplakin and periplakin and presumably 
for plectin) suggests the envoplakin SH3 domain may be more available for ligand binding.  
Unfortunately, this hypothesis cannot be validated until a ligand can be found for the envoplakin 
SH3 domain. Both studies that investigated the crystal structure of plectin and desmoplakin 
suggested that the SH3 domain is solely required for “rigidifying” the SR3-6 element (Choi and 
Weis, 2011, Ortega et al., 2011). While it is still possible that the SR4-SH3 interface may be a 
crystal artefact this is unlikely since both report the same residues involved in the interface. 
However, it is possible that this may represent a “snapshot” of the true dynamics between the 
SR4-SH3 interface that is favoured in crystallization conditions. Further solution based analysis 
such as NMR could clarify this question.  
A construct encompassing SR5, the SH3 domain and SR6 (SR56) behaved anomalously. The 
crystal structure of the desmoplakin plakin domain encompassing this region suggested a rigid 
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rod like structure. However, the SAXS envelope of this construct revealed two lobes at different 
angles (figure 3.82). Subsequently the SR56 crystal structure did not fit the data and when fit to 
the envelope required manual fitting of SR6 at an obtuse angle. This suggests that a flexible 
hinge may exist between SR5 and SR6 where in the crystal structure a more favourable rigid rod 
is adopted. Indeed the authors of the paper implied a hinge may exist between SR5 and SR6 in 
addition to the possibility that SR6 may only be “spectrin repeat like” (Choi and Weis, 2011). In 
combination with the NMR data, the lack of a fully dispersed 2D-HSQC spectrum also reflects 
the possibility of internal dynamics only when the SR4 element is not included in the construct.  
The presence of SR7 was identified contrary to previous reports (in tandem with SR8) 
(Sonnenberg et al., 2007). It forms an independently folded and stable structure as well as being 
the most thermally stable of each soluble SR construct analyzed.  This was identified as having 
a canonical SR fold by SAXS which also fit a sequence derived model with a NSD value of 0.46 
(figure 3.81D). This clarifies the legitimacy of SR7 since it had previously been questioned 
(Sonnenberg et al., 2007). It appears that SR7 and SR8 therefore cooperate as a tandem 
structured unit as often observed in other SR constructs (Broderick and Winder, 2005, Grum et 
al., 1999, Legardinier et al., 2009, Yan et al., 1993, Ylänne et al., 2001). The 2D-HSQC of the 
SR78 construct was, as far as I am aware, the most dispersed ever recorded for a SR tandem in 
the literature. However, the lack of intense peaks in the HNCO spectra of SR78 and the 
relatively high Dmax observed for the construct suggested a tumbling nature refractory for NMR 
analysis.  
The SR8 and the CT region tandem, behaved particularly anomalously. In combination with the 
NMR and CD data it suggested that the CT region destabilizes the tandem. It is therefore likely 
that the CT region is disordered or at best partially folded. Furthermore its tendency to 
precipitate compared to the other SR tandems corroborated this argument since disordered 
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regions often expose hydrophobic patches which promote nonspecific protein to protein 
interactions. This may reflect its rather specialized role at the C-terminal end of the plakin 
domain adjoining the rod domain. 
Altogether dissection of the desmoplakin plakin domain reveals a variety of specialized units 
which originates in their inter-dependant nature. This included the rigid SR36 region, a thermally 
stable SR78 and an anomalous CT region. This leaves a region of unknown significance 


















Chapter 4 - Plakin domains are unexpectedly non-linear and flexible 
The N-terminal head region of plakin proteins are important for tethering to the desmosome 
(Bornslaeger et al., 2001). They are typically comprised of a presumed unstructured N-terminal 
region and a globular plakin domain. The importance of this region is highlighted by its 
importance in binding to multiple desmosomal partners (Bornslaeger et al., 2001, Kami et al., 
2009). In light of this modular organization discussed in chapter 3, it was felt that a structural 
perspective on full length plakin domain constructs of desmoplakin, envoplakin and periplakin 
may give further insights into how the SRs collectively orientate in solution. It was anticipated 
that gauging the overall orientation of a plakin domain would shed light into how its structure 
translates into function (e.g. binding ligands). Desmoplakin is incorporated into desmosomes 
and is essential for desmosome function whereas envoplakin and periplakin act as accessory 
proteins and are not essential for desmosome function. Therefore by gauging their plakin 
domain structures it would allow assessment for why this is the case.   
Plakin proteins are members of the spectrin superfamily, which includes spectrin and dystrophin, 
by virtue of their plakin domains which consist of a variable number of spectrin repeats. Proteins 
such as spectrin and dystrophin typically consist of many spectrin repeats (>10) (Broderick and 
Winder, 2005). Chains of up to four serial spectrin repeats from a number of different proteins 
have been shown to have a linear organisation by X-ray crystallography (Ortega et al., 2011, 
Ylänne et al., 2001, Choi and Weis, 2011).  It was therefore assumed that serial chains of SRs 
are linear elements with limited propensity for flexibility. The relevance of this is that functionally; 
SRs are known to withstand mechanical stress which has been characterized extensively (Law 
et al., 2003). However, serial chains of SR proteins (≥2) had not been investigated by NMR or 
SAXS and their orientation in solution remains unknown.  It is unclear how the orientation of a 
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serial chain of SRs in solution correlates with their ability to withstand mechanical stress. One 
possible explanation is that flexibility exists within and between SRs.  
Grum et al proposed a mechanism in which non α-helical linkers within SRs allow limited 
flexibility (Grum et al., 1999). However, as shown in the protein dystrophin there are regions 
between SRs that are thought to be linkers or “hinges” (Koenig and Kunkel, 1990). The 
contribution of these “hinges” to the overall orientation of a serial chain of SRs in solution 
remains unknown. The presence of a “hinge” or linker was suggested to exist in the region 
separating SR6 and SR7 in the desmoplakin plakin domain as described in chapter 3. It is 
possible that these “hinges” may provide some form of flexibility to the serial chain of SRs. SAXS 
is one of the few experimental techniques that can provide information on the presence of 
flexibility in proteins and was therefore employed in the following chapter to explore flexibility in 
plakin domains.  The plakin domains from desmoplakin, envoplakin and periplakin were purified 
and analyzed using a battery of biophysical techniques, including CD, AUC, limited proteolysis 
and SAXS in order to determine the structure of the plakin domains in solution and ascertain 






4.1 Purification of plakin domains 
All plakin domain constructs used contained a cleavable N-terminal GST tag and a C-terminal 6x 
HisTag and were purified in the same way. Purification of the desmoplakin plakin domain is 
described in detail as an example.  Bacterial cells expressing GST fused desmoplakin plakin 
domain were grown in culture, harvested and lysed.  The GST fused protein was not visible in 
the cell lysate or in the soluble fraction following centrifugation (figure 4.1).  Nevertheless the 
soluble fraction was loaded on to a GSTrap column.  Following elution with GST a peak of 125 
kDa was observed in the GST elution fraction (figure 4.1). This band is the GST-desmoplakin 
plakin domain fusion protein. Overnight cleavage by PreScission protease resulted in two bands, 
one at 100 kDa and one at 25 kDa. The 100 kDa band is the desmoplakin plakin domain while 
the 25 kDa band is free GST. GST was removed from the solution using an additional single 
step his trap purification. The his trap elution is observed in the “Elu2” fraction in figure 4.1. The 
purity of the final desmoplakin plakin domain product was estimated to be > 90 % and was 
deemed suitable for further biophysical analysis.  Final purity of the plakin domains of envoplakin 
and periplakin were similar (i.e. >90 %) (data not shown). 









Figure 4.1 SDS-PAGE analysis of purification of the desmoplakin plakin domain.  
A. Shows: molecular weight marker (M), Lysate (Lys), Soluble lysate fraction (Sol), GSTrap 
wash elution (Wsh), single step glutathione elution (Elu) and cleavage of the eluted protein by 
PreScission protease (overnight at 4 °C) (Clv). B. Single step his trap purification step, final 
elution is shown (Elu2). The SDS-PAGE gels reveal that the desmoplakin plakin domain is 









4.2 Circular dichroism of the plakin domains from desmoplakin, envoplakin and 
periplakin 
The desmoplakin plakin domain was analysed by CD to gauge its secondary structure. It was 
anticipated that the secondary structure would be predominantly α-helical based on sequence 
based secondary structure predictions and previous reports (Sonnenberg et al., 2007). The 
spectrum was recorded at wavelengths between 240 nm and 190 nm. The CD spectrum shows 
minima at 208 and 222 nm indicative of predominantly α-helical structure. The data was fitted 
using DICHROWEB (Whitmore and Wallace, 2004) and a predicted secondary structure of 67% 
α-helices, 8% β-sheet, 12% turn and 13% disorder obtained. This is consistent with an amino 
acid derived secondary structure prediction using SOPMA (Geourjon and Deléage, 1995) of 
75% α-helices, 5% β-sheet, 2% turn and 18% disorder.   
The envoplakin and periplakin plakin domains were also analysed by CD to gauge their 
secondary structure in the same way as the desmoplakin plakin domain. For envoplakin, a 
secondary structure content of 67% α-helices, 9% β-sheet, 10% turn and 14% disorder was 
predicted by DICHROWEB. This is consistent with an amino acid derived secondary structure 
prediction using SOPMA of 74% α-helices, 4% β-sheet, 1% turn and 21% disorder.  For 
periplakin, a secondary structure content of 62% α-helices, 4% β-sheet, 11% turn and 23% 
disorder was predicted by DICHROWEB. This is consistent with an amino acid derived 
secondary structure prediction using SOPMA of 81% α-helices, 2% β-sheet, 1% turn and 16% 






Figure 4.2 Circular dichroism analysis of the plakin domains of desmoplakin, 
envoplakin and periplakin 
Circular dichroism spectra of desmoplakin (blue), envoplakin (red) and periplakin (gold) were 
collected at room temperature using a Jasco J-810 spectrometer and a protein concentration of 
0.1 mg/ml in 20 mM sodium phosphate (pH 7.2). The scanned wavelength range was 190-240 
nm. Spectra were analyzed using DICHROWEB to ascertain their secondary structure content. 





4.31 Limited proteolysis of the desmoplakin plakin domain 
The purified desmoplakin plakin domain protein was subjected to limited proteolysis in order to 
identify protease resistant fragments since they are more amenable for structural determination. 
Limited proteolysis can be also be used to facilitate in future construct design in addition to 
qualitatively gauging the location of solvent exposed loops or hinges that are more accessible to 
proteases. Three predominant bands were observed by SDS-page analysis following limited 
proteolytic digestion with trypsin (figure 4.3). Bands at approximately 26 kDa, 53 kDa and 85 
kDa were seen. The band at 27 kDa was subjected to further analysis as a candidate for 
structural determination by NMR due to its relatively small size (in chapter 3). N-terminal 
sequencing (Alta Bioscience, University of Birmingham) of the first 6 amino acids revealed a 
sequence of 654VIETNR659 which is preceded by a lysine in the desmoplakin sequence. This 
resides in the C-terminal of the desmoplakin plakin domain. Given that plakin domains are made 
up of serial chains of SRs it suggested the presence of a tandem pair of SRs. Since SRs are 
often found as tandem 25 kDa species, this corroborates Sonnenberg et al’s (2007) prediction of 
the presence of a SR8 but also a potential SR7, which was not predicted. This was shown to be 
a tandem SR named SR78 in chapter 3. 
The presence of a 53 kDa band (figure 4.3) corroborated Weis et al’s findings in which they also 
found a protease resistant fragment of the same size that turned out to be SR3-6 and was 
subsequently crystallized (Choi and Weis, 2011). Finally this leaves the region separating the 
two protease resistant fragments which was cleaved by trypsin, indicating a potentially solvent 
exposed loop. This coordinates to residues P627-K653, the relevance of which is discussed later 





Figure 4.31 Limited proteolysis of the desmoplakin plakin domain 
The desmoplakin plakin domain (10 mg/ml) was subjected to limited proteolysis at 37 °C by 100 
ng of trypsin (a 1:1000 protease to protein ratio) at various times points (indicated). Three bands 
were observed, one at approximately 85 kDa (dashed arrow), one at approximately 55 kDa 










4.32 Limited proteolysis of the envoplakin and periplakin plakin domains 
Based on the limited proteolysis of the desmoplakin plakin domain and the high homology 
between all plakin domains, it was assumed that other plakin domain homologues adopt a 
similar organization. The envoplakin plakin domain was subjected to limited proteolysis with 
trypsin (0.001 mg/ml) for 60 mins and sampled at different time points. This yielded 3 prominant 
bands : one at ~48 kDa, one at ~85 kDa and one at 27 kDa. This yielded a similar limited 
proteolysis profile to that of desmoplakin. N-terminal sequencing of the ~48 kDa band revealed a 
sequence of GPLGS (Alta Bioscience).  These amino acids are vector derived and located at the 
extreme N-terminal end of the envoplakin plakin domain construct.  The data suggest that in 
common with the desmoplakin plakin domain the envoplakin plakin domain also has a 
rigid/protease resistant SR3-6 region. 
Limited digestion of the periplakin plakin domain was also conducted in a similar manner to that 
of envoplakin. This yielded a limited proteolysis profile dissimilar to those observed for 
desmoplakin and periplakin in which only a single ~48 kDa band was seen. N-terminal 
sequencing of this band revealed a sequence of 131EVDP134 (Alta Bioscience) corresponding to 
the first 4 residues of the periplakin plakin domain. Hence the protease resistant fragment is 
likely to be SR3-6. Interestingly, it also appears that at least qualitatively, the SR3-6 fragment of 
periplakin is the most resistant of all plakin domain SR3-6 protease resistant fragments. This can 
be observed by the fact that the band is the most prominent of all 3 plakin domains analyzed by 







Figure 4.32 Limited proteolysis of the envoplakin and periplakin plakin domains 
The envoplakin and periplakin plakin domains (10 mg/ml) were subjected to limited proteolysis at 
37 °C by 0.001 mg/ml of trypsin. Left: in envoplakin three bands were observed, one at 
approximately 85 kDa, one at approximately 48 kDa (arrowhead) and one at approximately 27 
kDa. Right: a different limited proteolysis profile was observed for the periplakin plakin domain in 
which only a single prominent band was observed at ~48 kDa (arrowhead). Experiment 







4.33 Identification of a potential solvent exposed loop/hinge in the plakin domains 
of desmoplakin, envoplakin and periplakin 
A solvent exposed loop/hinge appeared to present in all plakin domains as ascertained by the 
limited proteolysis results. To more accurately address the position of the solvent exposed 
loop/hinge the plakin domains of desmoplakin, envoplakin and periplakin were aligned using 
CLUSTALW (Thompson et al., 1994) (figure 4.33). It revealed the presence of a sequence 
separating the protease resistant fragments of the SR3-6 region and the (desmoplakin) SR78 
fragment from in all 3 plakin domains. This coordinates to the region immediately after the SR6 
region which was suggested to be a solvent exposed loop/hinge by the limited proteolysis data 
shown in 4.31 and 4.32. Interestingly, the sequence present in desmoplakin appeared to be 
longer. Unfortunately, time did not allow for the modular organization of envoplakin and 
periplakin to be assessed. However, that said, this region was taken for further analysis by 












Figure 4.3 Identification of a hinge region in the plakin domains of desmoplakin, 
envoplakin and periplakin 
The plakin domain sequences of envoplakin, periplakin and desmoplakin were aligned using 
CLUSTALW (Thompson et al., 1994). It revealed that a sequence separating SR6 and SR7 was 
present in each of the plakin domains which coordinated to the solvent exposed loop/hinge. Of 
interest was the fact that the desmoplakin solvent exposed loop/hinge was longer than those 












4.4 Analytical ultracentrifugation of the desmoplakin, envoplakin and periplakin 
plakin domains 
The oligomeric state of the desmoplakin plakin domain was gauged by analytical 
ultracentrifugation. A single peak of which approximated to 89.8 kDa (as calculated by SEDFIT) 
(Brown and Schuck, 2006) was observed (figure 4.4). This indicates that the desmoplakin plakin 
domain is monomeric in solution and corroborates previous work suggesting the homo-
oligomerization of desmoplakin is facilitated by the adjacent rod domain (Green et al., 1990).  
The oligomeric state of the envoplakin and periplakin plakin domains was also ascertained by 
AUC. For envoplakin and periplakin single peaks which approximated to 89.5 kDa and 84.1 kDa 
respectively were observed (figure 4.4). The data indicate that both the envoplakin and 







Figure 4.4 Analytical Ultracentrifugation (AUC) profiles of each subdomain  
Each plakin domain was subjected to AUC at room temperature at a speed of 40000 rpm for 20 
h on a Beckman XL-1 analytical ultracentrifuge using an eight cell 50Ti rotor and detected at 280 
nm. Samples were run at between 0.05 and 4 mg/ml in 20 mM sodium phosphate (pH 7.2) and 
100 mM NaCl. The results were analysed by the program SEDFIT (Brown and Schuck, 2006)in 
which the continuous c(S) analysis method was used to calculate estimated molecular masses. 
Desmoplakin (blue), envoplakin (red) and periplakin (gold) each reveal a single peak. Molecular 
masses of 89.8, 89.5 and 84.1 kDa were estimated for desmoplakin, envoplakin and periplakin 





4.5 SAXS analysis of the desmoplakin plakin domain 
4.51 Acquiring biophysical data of the desmoplakin plakin domain by SAXS 
Purified desmoplakin plakin domain protein was analysed by SAXS to determine its structure in 
solution (figure 4.51A). The Guinier region indicated lack of aggregation as indicated by a linear 
regression (figure 4.51B). This implies that the protein is of sufficient quality to continue with 
SAXS analysis. GNOM analysis revealed an Rg value of 9.4 nm. GNOM was also used to gauge 
the Dmax and using the P(r) function it was calculated as 33.5 nm (figure 4.51C). Using ab-initio 
modelling based on the program DAMMIF 10 bead models were created and superimposed 
manually in an attempt to ascertain the convergence of the models (figure 4.51D). When the 
models were superimposed manually a large amount of heterogeneity was observed which 
implied the model may require some extra modelling (discussed further in 4.52). However, a final 
ab-initio envelope was acquired using DAMAVER and DAMFILT which revealed an “L” shape 
with the longer arm being 24.0 nm and the shorter arm being 17.9nm long. This is in stark 







Figure 4.51 SAXS analysis of the desmoplakin plakin domain  
The desmoplakin plakin domain was analyzed at 0.5, 1, 2 and 4 mg /ml in 20 mM sodium 
phosphate (pH 7.2) and 100 mM NaCl. The SAXS scattering curves were scaled and merged to 
create a final SAXS scattering curve in accordance with published methods. A: Buffer subtracted 
SAXS scattering curve with a DAMMIF fit (blue). B: Guinier analysis showing that the fit is good 
indicating a reliable Rg value (visualized in PRIMUS). C: P(r) distribution curve indicating the 
Dmax to be 33.5 nm. D: Superimposition of the 10 output files of DAMMIF highlighting the 
heterogeneity of each pdb file. Adapted with permission from Elsevier from Al-Jassar et al. 




4.52 Gauging non-linearity of the desmoplakin plakin domain 
Unexpectedly, the ab-initio envelope of the desmoplakin plakin domain was revealed to be non-
linear.  Hence linear models of the entire plakin domain were created by I-TASSER (Roy et al., 
2010) and BUNCH. If the SAXS scattering data was truly representational of a non-linear 
structure, one would expect to observe a poor fit of a linear model to the SAXS scattering curve. 
Using the program CRYSOL linear models from the two independent modelling programs were 
superimposed to the SAXS scattering curve (figure 4.52A). This gave a poor fit for both 
modelling programs suggesting a full length plakin domain cannot be linear in solution. When the 
known structured regions of the desmoplakin plakin domain (SR3-6 and SR78) were manually 
input into the ab-initio envelope only one orientation appeared likely (figure 4.52B). This left a 
region separating the SR6 and SR7 and the likely flexible CT region. This corroborates the 
limited proteolysis data which suggests that the plakin domain is comprised of two structured 
regions separated by a solvent exposed loop or hinge. Since a bend is observed between SR6 
and SR7 it implies there may be some flexibility between the two regions. This leaves an 
unoccupied (and non-cylindrical) region proceeding SR8. An anomalous construct 
encompassing SR8-CT was shown to be flexible or partially folded in chapter 3. Therefore it is 
highly likely that given the non-cylindrical shape of this region observed in the envelope, the CT 







Figure 4.52 Non-linearity of the desmoplakin plakin domain 
A: Buffer subtracted SAXS scattering curve for the desmoplakin plakin domain (black), DAMMIF 
fit (cyan) and CRYSOL created back-calculated theoretical curves using a linear BUNCH model 
(gold) and a linear I-TASSER model (green). B: A final averaged and filtered ab-initio envelope 
shown in two orthogonal views viewed by CHIMERA. The recently derived crystal structure of 
SR3-6 (Choi and Weis, 2011) was inserted manually (SR3: green, SR4: blue, SR5+SH3: red, 
SR6: gold). A gap is left intentionally for a likely hinge region. The model created for SR78 was 
also placed manually (SR7: purple, SR8: magenta). The likely flexible CT region is left 
unoccupied. Collectively, it suggests that the desmoplakin plakin domain is non-linear and 
contains loop/hinge regions between SR6 and SR7 and proceeding SR8. Adapted with 








4.53 Assessing flexibility of the desmoplakin plakin domain by SAXS 
Given the non-linearity of the desmoplakin plakin domain, the presence of a solvent exposed 
loop/hinge between SR6 and SR7 and the anomalous behaviour of the CT region, it was thought 
that the desmoplakin plakin domain contained flexible elements. Using the program EOM, two 
models based on anticipated flexible regions were calculated to investigate whether specific 
regions of the plakin domain contributed to the proposed flexibility. As stated in the methods the 
EOM suite is based on two algorithms. The first program (RANCH) created 10000 randomly 
orientated models based on the structured and unstructured regions input. The second (GAJOE) 
then used these models to select an ensemble of random models that fits the SAXS scattering 
data named “the selected ensemble”.  
Since the crystal structure of desmoplakin SR3-6 and a similar homologous region in plectin 
were shown to be rigid and linear (Choi and Weis, 2011; Ortega et al, 2011) this region was 
marked as structured in both theoretical models. On one model the solvent exposed and likely 
hinge at amino acid region P627-K653 was designated as a rigid and linear α-helix predicted 
from the I-TASSER model (named Plakin Domain Rigid or PDR model), while the second model 
had the same region assigned as flexible (named plakin domain flexible or PDF model). This is 
based on the limited proteolysis data in which SR3-6 and SR78 were both protease resistant 
with remaining regions as likely solvent exposed and/or flexible. In both models the CT region 
was assigned as flexible based on previous biophysical analysis of this region (discussed in the 
chapter 3).  
Χ2 values of 3.1 and 0.8 were calculated for PDR and PDF models respectively (figure 4.53). Χ2 
values indicate how valid the proposed model is representational of the protein in solution. Given 
that a χ2 value close to 1 represents a fit of a selected ensemble matching closely to the actual 
behaviour of the protein in solution (as long as the curve fits the experimental data perfectly); a 
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difference is observed between the PDR and PDF models (figure 4.53). The higher value for the 
PDR model implied that it is less representational of the protein in solution than that of the PDF 
model. The PDR model also gave a poorer fit to the SAXS scattering curve compared to the 
PDF model. In contrast, the PDF model which additionally contained a flexible hinge region at 
position P627-K653 is significantly contributing to the flexibility observed for the desmoplaklin 
plakin domain. It must be noted that given the low resolution of SAXS the exact stretch of amino 
acids that are responsible for the flexibility cannot be identified. This also has implications on the 
DAMMIF generated ab-initio envelope which implied a static model. Since the SAXS scattering 
data is an average of all orientations in solution, DAMMIF in turn creates an averaged 
representation of the protein. While the DAMMIF model is not incorrect, the ensemble of models 
generated by the inclusion of flexibility within the plakin domain is more valid and is discussed 
further in 4.7. To investigate whether the flexibility is an inherent feature of all plakin domains, 





Figure 4.53 Assessing flexibility of the desmoplakin plakin domain using the Ensemble 
Optimization Method (EOM).  
Two models differing in their flexible regions were created to gauge the possible presence of a 
flexible hinge within each of the plakin domains using EOM (see methods for further details). (A) 
Buffer subtracted SAXS scattering curve of desmoplakin (black) including EOM fits for a flexible 






4.61 SAXS analysis of the envoplakin and periplakin plakin domains 
The envoplakin plakin domain was analyzed by SAXS. The Guinier region indicated lack of 
aggregation with a manually estimated Rg value of 8.2 nm. GNOM analysis revealed an Rg value 
of 7.7 nm corroborating the manually acquired Guinier Rg value. A Dmax value of of 23.1 nm was 
obtained by GNOM.  
Similarly the periplakin plakin domain was analyzed by SAXS. The scattering curve indicated 
lack of aggregation with a manually estimated Rg of 8.9 nm. GNOM analysis revealed a similar 
Rg value of 9.3 nm and a Dmax value of 35.0 nm 
Since envoplakin and periplakin are homologous to desmoplakin it was assumed that they also 
do not adopt rigid structures and therefore was not be investigated by DAMMIF for an averaged 
model. Using the program CRYSOL, a theoretical SAXS scattering curve for a linear model 
created by I-TASSER was superimposed to the experimental SAXS scattering curve of the 
envoplakin plakin domain. In common with the desmoplakin plakin domain it revealed a poor fit 
confirming the non-linearity of the envoplakin plakin domain (figure 4.61A). Linear models were 
also created of the periplakin plakin domain by I-TASSER. CRYSOL was used to superimpose a 
theoretical SAXS scattering curve on the experimental SAXS scattering data.  Again a poor fit 








Figure 4.61 The envoplakin and periplakin plakin domains adopt non-linear 
conformations in solution.   
A: the envoplakin plakin domain (black) was analyzed at 1, 2 and 5 mg /ml in 20 mM sodium 
phosphate (pH 7.2) and 100 mM NaCl. A theoretical SAXS scattering curve (red) was 
superimposed on to the experimental data for a linear model created by I-TASSER (below 
graph). B: the periplakin plakin domain (black) was analyzed at 2, 4 and 10 mg /ml in 20 mM 
sodium phosphate (pH 7.2) and 100 mM NaCl. A theoretical SAXS scattering curve (red) was 
superimposed on to the experimental data for a linear model created by I-TASSER (below 
graph). The SAXS scattering curves were scaled and merged to create a final SAXS scattering 
curve in accordance with previously published methods. The poor correlation between the 
experimental data and the I-TASSER linear models suggest that plakin domains are non-linear 










4.62 Gauging flexibility of the plakin domains of periplakin and envoplakin 
Knowledge of flexible/disordered regions within multidomain proteins for EOM analysis is highly 
advantageous.  Unlike the desmoplakin plakin domain which had subdomains spanning the 
entire region subjected to biophysical analysis in chapter 3, only limited information was 
available on the modular architecture for periplakin and envoplakin. This included alignment data 
present in the literature (Sonnenberg et al, 2007) and in section 4.33, limited proteolysis data 
(figure 4.32) and models created by I-TASSER which collectively suggested a SR3-6 protease 
resistant rigid domain, a sovent exposed loop connected to a SR78-CT region (although SR78 of 
periplakin was shown to be protease sensitive in 4.32). SAXS data for the envoplakin and 
periplakin plakin domains were subjected to EOM analysis to gauge flexibility.  Hence, a strategy 
similar to that used to investigate the possibility of a hinge in desmoplakin was applied to 
envoplakin and periplakin. In the flexible models both SR3-6 and SR78 were set as “rigid” while 
the solvent exposed loop/hinge and CT region were set as flexible in the EOM program. The 
rigid models contained only a flexible CT region with the solvent exposed loop/hinge set as a 
rigid linear α-helix based on I-TASSER predictions. Based on the previously described sequence 
alignment in 4.33, the exposed loop/hinge was judged as being V545-P558 in envoplakin while 
in periplakin this was I525-A538. In addition to the CT region proceeding SR8 of envoplakin and 
periplakin the solvent exposed loop/hinge was set as flexible regions in the program GAJOE 
while the remaining regions were set as rigid. Using GAJOE the χ2 values of envoplakin and 
periplakin were also obtained for each of the rigid and flexible models and are given in figures 
4.62 and 4.63 respectively. Like desmoplakin, the insertion of a flexible hinge between SR6 and 
SR7 significantly lowers the χ2 value in both envoplakin and periplakin, arguing for the existence 
of a flexible hinge. Again due to the low resolution of SAXS, the exact amino acid stretch that is 




Figure 4.62 Assesing flexibility of the envoplakin plakin domain using the Ensemble 
Optimization Method (EOM).  
Flexible and rigid models were created to gauge the possible presence of a flexible hinge within 
each of the plakin domains using EOM (see methods for further details). (A) Buffer subtracted 
SAXS scattering curve of envoplakin (black) including EOM fits for a flexible (red) and rigid 
(yellow) models. (B) χ2 values for the rigid and flexible models. The χ2 values indicate that the 





Figure 4.63 Assesing flexibility of the periplakin plakin domain using the Ensemble 
Optimization Method (EOM).  
Flexible and rigid models were created to gauge the possible presence of a flexible hinge within 
each of the plakin domains using EOM (see methods for further details). (A) Buffer subtracted 
SAXS scattering curve of periplakin including EOM fits for a flexible (red) and rigid (yellow) 
model. (B) χ2 values are given for both the rigid and flexible models. The χ2 values indicate that 





4.7 Assessment of the flexible models created by EOM for the plakin domains 
The “selected ensemble” of 50 models that GAJOE selects to fit to the data can be visualized. In 
the following sections the 50 models selected for desmoplakin, envoplakin and periplakin were 
both qualitatively (visually), and quantitatively analyzed.   
4.71 Qualitative assessment of the selected ensemble from desmoplakin, 
envoplakin and periplakin 
A visual inspection was conducted using the selected ensemble of 50 models selected by 
GAJOE from the pool of the original 10000 random models created by RANCH. A representation 
of each of the plakin domain selected ensembles is shown (figure 4.71). For ease of inspection 
the SR3-6 region was superimposed for each model with the remaining SR78 and CT free in 
solution. It is important to note that the 50 models do not necessarily reflect the only orientations 
the protein is able to adopt (Personal communication: Dr Pau Bernadó, Barcelona, 2011). With 
that said, qualitative comparisons to the pool and general orientations can be examined. In all 
three selected ensembles the existence of a subset of linearized models was not observable. 
The hinge in desmoplakin more so than envoplakin and periplakin appears to create a “U-bend” 
in which SR78 almost becomes anti-parallel with the SR36 rigid entity. Envoplakin, more so than 
periplakin and desmoplakin, appears to contain a SR78 domain orientating around SR36 in a 
“helicopter” propeller fashion. Envoplakin’s CT region also appears to point in the direction of 






Figure 4.71 Molecular representation of the selected ensemble.   
The 50 models selected by the program GAJOE most representative of their respective SAXS 
scattering curves were superimposed. In each case SR3-6 (red) was fixed in position and SR7-8 
(purple) and the CT region (green) were allowed to rotate freely about the hinge (gold). A: 
envoplakin B: periplakin C: desmoplakin. 
149 
 
4.72 Size distribution graphs of all plakin domains 
Distribution graphs based on outputs of GAJOE include Rg and Dmax size distribution graphs of 
the 10000 randomly created models and the final 50 selected ensemble most representative of 
the SAXS scattering curve are given in figure 4.72. As one would expect, a randomly generated 
pool of models for each plakin domain gives a broad Gaussian distribution (figure 4.72). The 
selected ensemble for each plakin domain gave an average and maximum Rg lower than that of 
the random pool of models (figure 4.72). The same was true for the Dmax (figure 4.73).  
An overview of the rigidity and flexibility of the plakin domains based on the distribution graphs 
can be ascertained. If the protein was entirely disordered, the selected ensemble would 
superimpose over the distribution of randomly generated models. Since the plakin domain 
selected ensembles did not superimpose on the random pool, this can be discounted. 
Conversely if the protein was entirely rigid a very narrow and sharp peak would be observed 
solely for the selected ensemble distribution. Although qualitatively the selected ensemble peaks 
were sharper than the random pools, it is unlikely the proteins are entirely rigid given the 
diversity of the 50 selected models shown in figure 4.71. This would be consistent with the idea 
that plakin domains contain two rigid linear domains separated by a flexible hinge. Interestingly 
for all plakin domains the selected ensemble distribution of Rg values appears to be broader 
than that of the Dmax values. This would suggest for a motion in which a central domain (taken as 
the centre of origin) is fixed and another domain orientates around it relatively freely. This 
appears to be the case upon closer inspection of the 50 selected ensembles for each plakin 






Figure 4.72 Radius of gyration (Rg) distributions between the pool and selected ensemble 
of each plakin domain. 
The program GAJOE was used to calculate Rg for each model from the random and selected 
pools and a distribution was created. Comparisons between the starting 10000 conformations, 
the random pool (blue) and selected ensemble (red) Rg values are given for each plakin domain. 
A: desmoplakin, B: envoplakin, C: periplakin D: Table of maximum and average Rg values of 




Figure 4.73 Maximum particle distance (Dmax) distributions between the pool and selected 
ensemble of each plakin domain. 
The program GAJOE was used to calculate Dmax for each model from the random and selected 
pools and a distribution was created. Comparisons between the starting 10000 conformations, 
the pool (blue) and selected ensemble (red) Dmax values are given for each plakin domain. A: 
Desmoplakin, B: Envoplakin, C: periplakin D: Table of maximum and average Dmax values of 










4.8 Quantitative analysis of inter-domain distribution distances between two 
amino acids  
To mathematically determine the distance distributions between two amino acids on the protein 
chain from each model from the random and selected pools of each plakin domain, a custom 
built program kindly created by Dr Pau Bernado was used (code can be seen in appendix 
C).The program calculates the distance between two geometrical positions (in this case, amino 
acids) at different regions of the protein and calculate their distance apart in angstroms. The 
program creates a distribution of the distances from all 10000 randomly generated models and 
compares it to the 50 models from the selected ensemble most representational of the 
experimental SAXS data by GAJOE.  
Using the first and last amino acids of each plakin domain, inter-domain distribution graphs were 
created (figure 4.8). A few general trends are observable between the plakin domain graphs. 
Firstly that the selected ensemble is negatively skewed in each plakin domain meaning that the 
end amino acid of each plakin domain is likely to be closer to the beginning amino acid of the 
protein when compared to a random pool of 10000 structures. Secondly periplakin and 
envoplakin have similar inter-domain distribution graphs for their selected ensembles suggesting 
that the inter-domain distributions of the beginning to end amino acids are similar. Thirdly and 
most interestingly, the desmoplakin inter-domain distribution between the beginning and end 
amino acids is significantly more negatively skewed than compared to periplakin and envoplakin. 
This suggests that the end amino acid is much more likely to occupy a region closer to the 
beginning amino acid when compared to the desmoplakin pool and the selected ensembles of 






Figure 4.8 Inter-domain distance distribution graphs between the first and last 
amino acid of each plakin domain. 
Distance distributions from each of the 10000 models and the 50 selected ensemble were 
calculated for the first and last amino acids only using a program written by Dr Pau Bernado for 
this project (appendix C). Distributions from the random pool are shown as blue while 
distributions from the selected ensemble are shown as red. (A) Comparisons between the pool 
and selected ensemble distance distribution between envoplakin’s first (P144) and last (S891) 
amino acids. (B) Comparisons between the pool and selected ensemble distance distribution 
between periplakin’s first (E131) and last (P871) amino acids. (C) Comparisons between the 
pool and selected ensemble distance distribution between desmoplakin’s first (W180) and last 
(K1022) amino acids.  
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4.9 Chapter 4 conclusions 
 
The experiments presented within this chapter describe the biophysical properties of entire 
plakin domains from desmoplakin, envoplakin and periplakin in solution. They reveal that plakin 
domains are predominantly α-helical as predicted from sequence alignment, and that plakin 
domains are monomeric, suggesting that dimerization is facilitated by their respective rod 
domains as previously described (Green et al., 1990, Ruhrberg et al., 1997). Furthermore, this is 
the first time that a serial chain of 6 spectrin repeats has been investigated in solution by SAXS 
analysis.   
When linear models were created for each of the plakin domains investigated, none fit the SAXS 
scattering curves of the proteins in solution. Thus, it appeared that each of the three plakin 
domains investigated was non-linear. This was in stark contrast to previously published crystal 
and NMR studies which have all shown that chains of up to 4 spectrin repeats are linear (Choi 
and Weis, 2011, Ortega et al., 2011, Ylänne et al., 2001). While the findings described herein do 
not invalidate in any way previously published findings, what they do indicate is that there may 
be a crystallization bias towards rigid and linear SRs. This is because proteins with flexible 
regions are unlikely to be crystallized. When the potential dynamics caused by the likely hinge 
regions of desmoplakin, envoplakin and periplakin were investigated by SAXS using the suite of 
programs from EOM, differences were revealed between the three plakin domains. For example 
the C-terminal region of the desmoplakin plakin domain is much more likely to lie anti parallel 
with its N-terminal region. Envoplakin’s C-terminal region of its plakin domain is likely to orientate 
in a “helicopter” fashion. Finally, periplakin’s orientation appeared to be much more random than 
that of desmoplakin and envoplakin. Interestingly, subsets of linear models within the selected 
ensemble were either very limited or non-existent suggesting that in isolation plakin domains 
cannot form linear rods further corroborating the idea that plakin domains are non-linear.  
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Initially, the desmoplakin plakin domain was investigated as it was the primary target for 
structural elucidation given desmoplakin’s critical role in the desmosome and cardiomyopathy 
related disease. The desmoplakin plakin domain was subjected to limited proteolysis to identify 
protease resistant fragments. It revealed the presence of two predominant bands (figure 4.31), 
one which was N-terminal sequenced and was subsequently identified as SR78. The other 52 
kDa band (previously identified by Choi and Weis, 2011) was revealed to be SR3-6. These 
protease resistant domains were separated by an exposed proteolytically accessible loop region, 
the hinge sequence (figure 4.33). Given the presence of a loop between the two domains it is 
interesting to note that this is the first time a protein with a serial chain of spectrin repeats has 
indicated such a possibility by the use of limited proteolysis. Serial chains of SRs are often 
observed with small (3-5 amino acids) -helical linkers between tandem spectrin repeats (Law et 
al., 2003). Atomic force microscopy showed that the protein dystrophin has a rod domain 
consisting of a serial chain of SRs interrupted by two hinge regions (Bhasin et al., 2005). To 
further ascertain the structural organization of the desmoplakin plakin domain SAXS was 
conducted.  
The SAXS envelope of the desmoplakin plakin domain was the first of its kind, encompassing a 
serial chain of multiple SRs. It revealed a two-lobed structure, one 24.0 nm and the other 17.9 
nm consisting of the SR3-6 and SR78-CT regions respectively. The lobe appeared to have an 
elbow as seen by the kink between the two lobes. The kink between the SR3-6 and SR78-CT 
domains suggests either a potential hinge or flexibility whereby the SR3-6 domain acts as a rigid 
entity and SR78 (being the most thermally stable) acts as a structural unit. This corroborates the 
previous limited proteolysis data which implied a loop region between SR3-6 and SR78. It 
therefore suggests that proteins harbouring serial chains of spectrin repeats may not in fact be 
static rods as originally thought. Whether this was a desmoplakin plakin domain specific 
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phenomenon was also investigated by exploring the plakin domains of envoplakin and 
periplakin. 
Limited proteolysis results also revealed a 48 kDa protease resistant fragment for each of the 
envoplakin and periplakin plakin domains (figure 4.32). When N-terminal sequencing of these 
fragments was conducted it revealed a homologous region similar to that found by Choi and 
Weis (2011) from desmoplakin which corresponds to SR3-6. This suggested that the SR3-6 
fragment in each of the plakin domains studied in this thesis was a rigid entity resistant to 
proteolysis. Based on the crystal structure of desmoplakin SR3-6 it is highly likely that SR3-6 of 
envoplakin and periplakin are also linear which was corroborated by models created by the I-
TASSER server. Interestingly, no SR78 or similar protease resistant fragment was observed for 
periplakin. This therefore suggests that SR78 of desmoplakin is more proteolytically resistant 
than that of periplakin and may have a specialized role. That said, a similarly sized protease 
resistant fragment of 25 kDa was observed for envoplakin but was not N-terminal sequenced 
(figure 4.32).  
Using the SAXS data for envoplakin and periplakin the non-linearity observed in desmoplakin 
was also investigated in envoplakin and periplakin. Linear models of the entire periplakin and 
envoplakin plakin domains were created using the I-TASSER server. Theoretical SAXS 
scattering patterns for each linear model were superimposed onto the experimentally derived 
patterns using the program CRYSOL. Both revealed a very poor fit confirming they were not 
linear. This suggests that like desmoplakin, the plakin domains of periplakin and envoplakin 
adopt a non-linear conformation.   
Alignment data of envoplakin, periplakin and desmoplakin suggested the presence of a hinge 
located between SR6 and SR7 (figure 4.33). No structural motif was suggested between SR6 
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and SR8 in a previous alignment in desmoplakin (Sonnenberg et al, 2007), which failed to take 
into account the recently characterized SR7 in chapter 3. This still leaves a region of 27 amino 
acids (P627-K653). A stretch of amino acids aligned with this region in envoplakin (V545-P558) 
and periplakin (I525-A538) was also observed. To investigate the possibility of a flexible hinge 
within the plakin domains of envoplakin, periplakin and desmoplakin, the above mentioned 
regions were designated as flexible and analyzed by the program EOM. Two models were 
created for each plakin domain which both contained a CT region designated as flexible. The 2 
models differed at the region between SR6 and SR7. One contained a linearized and rigid α-
helical hinge (rigid model) while the other contained a flexible hinge (flexible model). Using the 
program RANCH a pool of 10000 randomly generated models were created for each model. 
Using the program GAJOE a selected ensemble of 50 models from the 10000 randomly 
generated pool that were most representational of the SAXS scattering curve, were fitted. For all 
3 plakin domains the rigid model fit the data reasonably well, while the flexible model gave an 
excellent fit. This is especially the case at higher angles which gives the most significant effect 
on shape determination. Although 2 values are not applicable to data that do not fit excellently, 
there is a significant drop in the flexible model 2 value suggesting that the added flexibility in the 
hinge is more representational of the SAXS scattering curve than the rigid model. This 
suggested that a flexible linker or hinge is present in all 3 plakin domains, but given the low 
resolution of SAXS, the precise location cannot be obtained. However, based on the alignment 
data it is likely to reside between SR6 and SR7.  
When Rg and Dmax values were compared between the selected ensemble and the random pool 
of each plakin domain, a trend is observed. Each plakin domain has a selected ensemble 
average Rg and Dmax value lower than that of the pool (figures 4.72 and 4.73). The selected 
ensemble peaks are also narrower and sharper when compared to the pool. Together this 
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suggests the added flexibility is allowing the protein to compact, with a very low propensity to 
linearize in isolation. That said, the ensemble of proteins selected for desmoplakin and 
envoplakin in particular do not form entirely random ensembles.  Furthermore, virtually no linear 
models were selected in the ensemble of any plakin domains. Closer inspection of all Rg, Dmax 
and selected ensembles data also suggests relative differences in the degrees of flexibility.  
Envoplakin appears to contain the least flexible hinge element as shown by the relatively low 
number of different orientations assumed for the SR7 to CT region and the sharp Rg and Dmax 
values, compared to that of desmoplakin and periplakin. Desmoplakin’s hinge appears to create 
a “u-bend” in the SR7 to CT region which can almost become anti-parallel with SR3-6 (figure 
4.71). The CT region of desmoplakin also appears to reside more closely to the beginning of the 
protein when compared to envoplakin and periplakin. Periplakin appears to adopt the most 
random orientations between all three plakin domains shown by the large heterogeneity in the 
selected ensemble (figure 4.71).  
Inter-domain distribution graphs were then created for the start and end amino acids of each 
plakin domain (figure 4.8). Both envoplakin and periplakin shared similar profiles indicating that 
the distances between the beginning and end amino acids of each protein were similar. 
Desmoplakin however, adopted a broader and more negatively skewed selected ensemble 
when compared to both the selected ensembles of envoplakin and periplakin and that of the 
desmoplakin pool. This suggested that the end residue of desmoplakin is much more likely to 
reside nearer to the beginning residue when compared to envoplakin and periplakin and these 
findings were further corroborated by qualitative visual assessment of the superimposed 50 
selected ensemble models.     
159 
 
Overall it appears that as well as identifying a flexible hinge, each plakin domain has varying 
degrees of flexibility and behaviour in solution. How this translates to function is less clear, 
although is likely to relate to the ability of SRs to withstand mechanical stress. Each plakin 
protein is expressed in tissues subjected to high mechanical stress (e.g. heart and skin). 
Spectrin repeats are well known to resist mechanical stress as shown by a variety of atomic 
force microscopy studies although plakin domains have to yet been shown to directly resist 
mechanical stress. It can however, be inferred that a component of the desmosome is likely to 
resist mechanical stress based on their presence in tissues experiencing mechanical stress such 
as the epidermis and heart. The likely (and probably only) candidate for this is the plakin domain 
given the presence of serial SRs. How these newly identified flexible hinges could relate to 
biological function is based on previous studies conducted on the hinges found in the serial SR 
containing rod domain of dystrophin. As far as I am aware the only direct experimental evidence 
for the function of flexible hinges in serial spectrin repeat domains comes from two papers based 
on dystrophin’s H2 and H3 hinges in their serial SR chain containing rod domain (Banks et al., 
2010, Bhasin et al., 2005). It was originally proposed by sequence based modelling that 
dystrophin had four hinges, with two in the serial SR rod domain (Koenig and Kunkel, 1990). 
Patients with deletions of H3 in dystrophin suffer from Becker Muscular Dystrophy (BMD) 
suggesting that H3 is likely to have an important functional role (Bhasin et al., 2005). Since 
desmoplakin’s hinge has ~40% homology to H3 of dystrophin (data not shown) it is likely to 
share a similar functional role. H2 and H3 of dystrophin contain proline residues suggested to be 
critical to their function. No such proline residues exist in the proposed hinges of any of the 
plakin domains. However, H3 and the proposed desmoplakin hinge both contain threonines 
which align well and it is possible that these residues are important for desmoplakin. The 
relatively high abundance of threonines in the desmoplakin hinge (40%) implies the possible 
presence of secondary structure elements such as threonines can be incorporated into both 
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structured and disordered stretches of sequences. Banks et al (2010) proposed that the 
enhanced flexibility of H3 lead to an improvement of artificial mini-dystrophins to alleviate 
dysfunction caused by BMD. It is likely therefore that the hinge present in the plakin domains is 
also critical to the function of the plakin domain. Bhasin et al (2005) proposed that H3 of 
dystrophin as well as acting as a mechanical separator between SRs, is also likely to limit 
extensible unfolding. This is also likely to be the case in plakin domains, although since plakin 
domains have not been directly tested to withstand mechanical stress this would require further 
exploration.   
No ligands are yet known for the envoplakin and periplakin plakin domains – although ligands 
are known for the periplakin N-terminal unstructured region (Boczonadi et al., 2007, Groot et al., 
2004). As a result it would be difficult to speculate on the biological significance of the flexibility 
of the periplakin and envoplakin plakin domains. The desmoplakin N-terminal head region is 
known to bind to the intrinsically disordered desmoglein specific cytoplasmic region (DSCR) 
(Kami et al, 2009), plakophilin1 and plakoglobin (Bornslaeger et al., 2001, Kowalczyk et al., 
1997) although their specific binding regions have not been localized (with the exception of 
PKP1 which is likely to be localized to SR34 (Al-Jassar et al., 2011)). Why the desmoplakin 
SR78-CT region folds back anti-parallel to SR3-6 in relation to its involvement in these 
interactions is unclear. It may reflect an orientation favourable for binding any of the above 
mentioned ligands. Given the flexibility of the desmoplakin plakin domain it is possible that upon 
induction of mechanical stress an alternative orientation may present a more preferable 
conformation of one ligand over the other. Indeed, ligand binding upon conformational change 
caused by mechanical stress has recently been shown in a protein with a similar role to 
desmoplakin (del Rio et al., 2009). Although this has not been directly shown in SRs the up and 
coming field of “intracellular mechanotransduction” has identified a number of candidate proteins 
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and complexes with such qualities including cell-cell junctions (Gomez et al., 2011, Chen, 2008). 
In combination with the thermal stability assays of the desmoplakin plakin domain subdomains, it 
suggests that there may be further subdivisions of functional properties within a plakin domain 
related to mechanical stress. SR78, being the most thermally stable of all constructs may act as 
the predominant “shock-absorber” in the desmoplakin plakin domain given that thermal stability 
correlates well with SRs ability to withstand mechanical stress (Law et al., 2003). The SH3 
domain would rigidify SR3-6 (Choi and Weis, 2011) and SR34 shown to bind to PKP1 may act 
as the “mechanotransducer” allowing ligand binding in the unstressed state (Al-Jassar et al., 
2011) while releasing PKP1 in the stressed state. This may also occur in the other ligands 
especially plakoglobin. Evidence for this possibility also comes from the fact that (in addition to 
desmosomally located catenin family members) there are nuclear and cytosolic stores of these 
catenin family members (Garcia-Gras et al., 2006, Palka and Green, 1997, Zhurinsky et al., 
2000, Mertens et al., 2001) and it is unknown how/why the location of these proteins is so 
varied. Therefore the non-linear and flexibility of plakin domains described in this chapter may 
reflect a function related to mechanotransduction which has an implication towards altered gene 










Chapter 5 – Biophysical analysis of the envoplakin and desmoplakin 
plakin repeat domains 
The plakin family proteins typically serve as cytolinkers that tether the intermediate filament (IF) 
cytoskeleton to the desmosome, with a crucial role of developing and maintaining tissue integrity 
(Garrod and Chidgey, 2008, Sonnenberg and Liem, 2007b). Their N-terminal head domains 
serve to bind to the desmosome, while their C-terminal tails bind to the IF proteins vimentin, 
desmin and keratin (Bornslaeger et al., 2001, Fontao et al., 2003, Kazerounian et al., 2002, 
Kouklis et al., 1994, Stappenbeck et al., 1993). Disruption of the desmoplakin-IFs linkages in 
desmosomes leads to skin and/or heart disease (Awad et al., 2008, Russell et al., 2004). 
This chapter focuses on the C-terminal tail and more specifically the PRDs, although the C-
terminal linker domains are also discussed in greater detail in chapter 6. In general plakin family 
members have one highly homologous “linker domain” and variable numbers of PRDs. The 
functional significance of the different number of PRDs in these plakin proteins is unknown, 
although their PRD sequences share high sequence similarity. It has been previously shown that 
binding occurs across multiple elements of the plakin c-terminal tails with IFs (Fontao et al., 
2003, Kazerounian et al., 2002, Meng et al., 1997b, Nikolic et al., 1996, Stappenbeck et al., 
1993, Steinböck et al., 2000). More specifically there appears to be a complex interplay between 
the PRDs, the linker domain and the extreme C-terminal tail. Furthermore, desmoplakin has a 
serine residue 23 amino acids from its carboxyl terminus (S2849) that plays a critical role in 
regulating cytoskeletal binding (Stappenbeck et al., 1994). Phosphorylation of S2849 decreases 
binding affinity to keratin 9-fold and desmin/vimentin 2-fold. While desmoplakin binding to 
desmin or vimentin is predominantly dependent on its PRD region, its binding propensity for 
keratin is dependent on both the PRDs and the extreme C-terminal tail (Meng et al., 1997b, 
Stappenbeck et al., 1993, Lapouge et al., 2006). It has been suggested that desmoplakin has 
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preference for binding keratin (K8/K18 hetrodimer) over desmin or vimentin. Plectin in contrast, 
has a higher affinity for desmin and vimentin compared to cytokeratins 5/14 (Steinböck et al., 
2000). Thus desmoplakin and plectin appear to have distinct binding preferences for cytoskeletal 
proteins. The same also applies to envoplakin and periplakin in which desmin/vimentin is 
preferred over cytokeratins (DiColandrea et al., 2000, Karashima and Watt, 2002, Kazerounian 
et al., 2002). How this is achieved at the molecular level is unclear, and a more thorough 
understanding of the structural determinants present in the C-terminal tails of plakin family 
members may offer potential explanations.      
The crystal structures of the PRDs B and C of desmoplakin were determined in 2002 and 
revealed a novel 38 amino acid motif repeated 4.5 times consisting of a β-hairpin linked to anti-
parallel α-helices (Choi et al, 2002). Prior to their structure determination, PRDs were thought to 
possess an extended structure similar to that of the ankyrin repeat motif (Li et al., 2006).  
However, pilot structural studies revealed that the PRDs were unexpectedly compact due to 
multiple hydrophobic contacts between and within the PR motifs of PRDs. Further analysis of the 
PRD structure revealed a long positively charged groove on the surface area encompassed 
between the two halves of the PRD formed by PR1-2 and PR3-4. This was proposed as a 
putative binding site for the cytoskeletal protein vimentin. Interestingly, since vimentin also 
possesses multiple highly negatively charged patches, binding to the desmoplakin PRDs was 
proposed to occur via electrostatic interactions (Choi et al, 2002). Due to sequence homology it 
is presumed that PRDs of other plakin family members utilize similar mechanisms to bind to 
cytoskeletal proteins. Interestingly, two opposing theories suggest how the desmoplakin and 
plectin C-terminal tails form globular structures which allow interactions with cytoskeletal 
proteins. Firstly, the “beads on a string” theory based on studies of the desmoplakin C-terminal 
tail by Weis and colleagues suggests that each PRD is a separate unit capable of binding 
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vimentin individually (Choi et al, 2002). Secondly, a “compacted cylindrical” theory by Wiche and 
colleagues, based on studies of the plectin C-terminal tail,  suggests an intricate interplay is 
required between each PRD where disulphide bonds are critical for inter-PRD binding (Janda et 
al., 2001). The “beads on a string” theory is based on the fact that PRDs B and C of 
desmoplakin independently fold (Choi et al, 2002). Conversely the compacted cylindrical theory 
of plectin is based on electron microscopy studies of the C-terminal tail of plectin which revealed 
a single globule 9 nm in diameter (Foisner and Wiche, 1987). While there is some evidence to 
support both theories there is currently no conclusive answer. This raises questions about what 
molecular mechanisms are involved in cytoskeletal binding and what governs cytoskeletal 
preferences. It was hoped that a structural approach would help answer these questions since 
the only X-ray crystallographic information available to date is on desmoplakin PRDs. A PhD 
thesis by Radavan Spurny reported an inability to crystallize plectin PRDs 4 and 5 (homologous 
to PRD B of desmoplakin), which may have been compromised by inclusion of flexible His tags 
and partial linker domains (Spurny, 2008). Hence there is still a need to characterise PRD-ligand 
and linker structures and interactions in order to address the opposing hypotheses of 
desmoplakin and plectin C-terminal tail assembly mechanisms. Overall, several questions 
remain unanswered including:  
a) What key structural features are conserved and divergent between different PRDs? 
b) Is the molecular surface and groove implicated in vimentin binding conserved between 
different PRDs and how does this contribute to specific binding of cytoskeletal ligands? 
c) What is the behaviour of the PRDs in solution? 
Less attention has been given to the interactions of cytoskeletal proteins with the plakin family 
members envoplakin and periplakin. This study aimed to determine why envoplakin possesses 
only a single PRD, whereas desmoplakin has 3, plectin has 6 and periplakin has none (see 
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figure 1.3). It was intended that by characterizing the structure of the envoplakin PRD the project 
would shed light on the mechanisms involved in cytoskeletal binding and whether certain 
specific PRDs were functionally unique. By understanding these mechanisms it would give a 
clearer picture as to how the desmosome and IF system are linked. Therefore it would allow for 
a better understanding of the molecular details of the mechanisms could lead to the cardio-
cutaneous diseases of the desmosome. 
This chapter will therefore discuss the biophysical properties of the envoplakin and desmoplakin 
PRDs and their binding propensity to vimentin. 
5.1 Construct design, expression and purification of the envoplakin PRD  
5.11 Construct design 
The extreme C-terminal tail of the envoplakin sequence is known to harbour the envoplakin 
PRD. This sequence was aligned with the homologous solved structure of the desmoplakin PRD 
C domain (PDB code: 1LM5). As observed in Figure 5.1 the PRD C of desmoplakin and 
envoplakin share 45% sequence identity and 65% sequence homology. Based on this alignment 
3 envoplakin PRD constructs were created; a long, medium and small construct. The long 
construct (F1812-R2030) was based on the exact sequence of the construct used to crystallize 
the desmoplakin PRD C (Choi et al, 2002). The medium construct (D1822-A2014) removed 
sequences at the N and C termini thought to be least homologous to the desmoplakin PRD C 
and therefore not critical to the core PRD structure. The small construct was based on the 
premise that the extra residues located in the medium construct at the N and C termini did not 
contribute to the PR motifs. The small construct therefore represented the smallest of all 





Figure 5.11 Construct design of the envoplakin PRD  
The desmoplakin PRD C sequence which was used to crystallize the construct (1LM5) (Choi et 
al, 2002) was aligned against that of the full human envoplakin sequence. The alignment was 
intended to determine similarities/divergence between the two sequences. This alignment was 
also used to aid in the design of three envoplakin PRD constructs for structural studies. The final 











5.12 Expression and purification of envoplakin PRD constructs  
Each of the three envoplakin PRD constructs were subjected to standard cleavable his-tagged 
purification methods. The construct that provided the highest yields of protein and purity were 
selected for subsequent large-scale production of envoplakin PRD for downstream biophysical 
analyses.  
Firstly, the envoplakin PRD small construct (incorporating residues 1829 to 2000; 22kDa, 
including a vector derived cleavable his-tag) was investigated. Purification beyond Ni2+-NTA 
chromatography was not possible owing to the fact that multiple species were observed 
following analysis by SDS-PAGE (Figure 5.21A). In fact a variety of protein species were 
present, one at the correct molecular weight for the small construct and multiple others at slightly 
lower molecular weights of equal quantity, suggesting non-specific cleavage or spontaneous 
degradation. In an attempt to remove the majority of contaminants, it might have been possible 
to subject the Ni-NTA eluted samples to additional purification steps such as size exclusion or 
ion exchange chromatography. However, this was deemed impractical as use of such 
conventional purification steps would most likely adversely affect the final protein yield and 
prevent subsequent biophysical analysis. Hence, the short construct was considered unsuitable 
for structural studies and was not utilised further.  
Secondly, the envoplakin long construct was investigated (incorporating residues 1812 to 2030; 
27 kDa including a vector derived cleavable his tag) for its ability to produce high levels of pure 
and stable protein. However, SDS-PAGE analysis of the long construct following purification with 
Ni-NTA and size exclusion chromatography revealed that the protein was either degrading 
spontaneously or cleaved by a non-specific protease post elution from the size exclusion column 
(Figure 5.21B). Interestingly, the degraded or smaller fragment appeared to be similar in size to 
the medium construct, suggesting that the termini of the protein were susceptible to cleavage. 
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As a result, it was decided that the envoplakin long construct was not viable for further 
biophysical analysis.  
Lastly, the envoplakin PRD medium construct was investigated (incorporating residues 1822 to 
2014; 24 kDa including a vector derived cleavable his tag). SDS-PAGE analysis following Ni2+-
NTA purification revealed a high quantity of relatively pure protein (Figure 5.22A). This suggests 
that the medium construct is more stable than the small construct. The protein was incubated 
with TEV protease to cleave off the his-tag and loaded onto the Ni2+-NTA column. The cleaved 
His-tag and TEV protease were bound to the Ni2+ column allowing the protein to be collected in 
the flow through and wash steps. Finally, the protein was subjected to size exclusion 
chromatography on a S75 column (Figure 5.22B). The protein eluted at 12.6 ml, and its purity 
was gauged as ~95% by SDS-PAGE analysis (Figure 5.22C). This construct was regarded as 
most suitable for biophysical analysis. Therefore the envoplakin medium construct was the 
optimal construct for further biophysical analysis and from hereon will be referred to as the 
envoplakin PRD.  As a control, similar strategies were employed to purify desmoplakin PRD C 










Figure 5.12 Purification of the short and long envoplakin PRD constructs 
A: single-step His-trap purification of the small envoplakin PRD construct. Elu: Elution, M: 
marker. An arrowhead indicates the position of the envoplakin small construct (with the his tag 
retained) at ~22 kDa. B: Post size exclusion purification of the long envoplakin PRD. Pre: 
envoplakin long construct (post his cleavage) prior to size exclusion purification, A9-B6: fractions 
eluted from the S75 size exclusion column, M: marker. The arrowhead indicates the envoplakin 
long construct at approximately 27 kDa. The data shows that the envoplakin short and long 








Figure 5.13 Purification of the medium envoplakin PRD construct 
A: His-trap purification of the medium envoplakin PRD construct (pre his cleavage eluted in 1ml 
fractions). M; marker, E7-E13; elution fraction number. B: A S75 size exclusion profile of the 
medium envoplakin PRD construct (post his tag cleavage; ~24 kDa) eluted in 20 mM HEPES 
(pH 7.5) and 50 mM NaCl at 12.6 ml. C:  SDS-PAGE analysis of envoplakin PRD fractions 
following purification by size exclusion chromatography. M: marker, Pre: pre gel filtration sample, 
B10-B7: fractions eluted from the S75 size exclusion column, Arrowheads indicate the position 
at which the envoplakin medium construct migrates. The final envoplakin medium construct was 
pure and deemed suitable for further biophysical analysis.  
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5.2 AUC of the envoplakin and desmoplakin C PRD 
Although both known crystal structures of the PRDs of desmoplakin B and C crystallized as 
dimers (Choi et al, 2002), it was unclear whether the dimer represented a physiologically 
relevant species. Indeed, to date a comprehensive analysis of the oligomeric state of any PRD in 
solution is undefined and such studies may provide insights into the molecular function of PRDs. 
Intriguingly, the desmoplakin PRD B was observed as a dimer in solutions up to 100 mM NaCl 
by size exclusion chromatography (Choi et al, 2002).  However at salt concentrations above 100 
mM a monomeric species was observed (Choi et al, 2002). This suggested the possibility that 
under physiologically relevant conditions, PRDs may exist as dimers in solution.  To address this 
issue the envoplakin PRD (his-tag cleaved) and desmoplakin PRD C (his-tag retained) were 
subjected to sedimentation velocity AUC to assess their oligomeric state in solution. Analysis by 
SEDFIT (Brown and Schuck, 2006) demonstrated a single species at 18.1 kDa for the 
envoplakin PRD and a single species at 21.3 kDa for desmoplakin PRD C. This is in good 
agreement of the sequence derived molecular weight determinations of 22.0 kDa and 26.0 kDa 
for envoplakin and desmoplakin PRDs, respectively and clearly demonstrates each protein is 










Figure 5.2 Analysis of the envoplakin and desmoplakin PRD C by AUC 
The envoplakin PRD (his-tag cleaved) and desmoplakin PRD C (his-tag retained) were 
subjected to AUC analysis to gauge their oligomeric states in solution. The AUC experiments 
were carried out in 20 mM Hepes (pH 7.5) and 100 mM NaCl at 0.1 mg/ml using a Beckman XL-
1 at 20000 rpm at 20 °C. Sedimentation coefficient profiles were converted to estimated 
molecular weights.  Envoplakin and desmoplakin PRDs reveal single peaks at 18.1 kDa (blue) 
and 21.3 kDa (red), respectively. Although the values observed deviate slightly from the 
sequence derived molecular weights of envoplakin (22 kDa) and desmoplakin (26 kD) PRDs, 







5.3 Thermofluor thermal stability assay of the envoplakin PRD 
The envoplakin PRD was subjected to thermofluor thermal stability assay to identify an optimal 
buffer condition that provided the highest thermal stability. This method also allows qualitative 
assessment of the foldedness of the protein as folded proteins typically give rise to sigmoidal 
curves. Unfortunately, no sigmoidal curves were observed for the envoplakin PRD in any of the 
conditions tested which included various buffers at different pHs, salts and additives. There are 
three possible explanations for the lack of a sigmoidal curve during the thermofluor thermal 
stability assay.  Firstly, the envoplakin PRD may not possess a stable hydrophobic core and 
therefore no tertiary fold is present to unfold. Secondly, the PRD may include a hydrophobic 
patch on its surface which is spuriously binding the fluorescent dye. Finally, the protein sample 
may have a tendency to precipitate or aggregate in solution. Since the protein exhibits high 
sequence homology to a crystallized homologue, it is unlikely that the protein is unfolded. 
Moreover, based on the observation that the envoplakin PRD is very stable at high 
concentrations for several weeks at 4 °C, suggests that it is unlikely to precipitate or aggregate 
at the low concentrations used. Hence, the most likely scenario is that a surface exposed 
hydrophobic patch is sufficiently exposed, permitting the dye to bind envoplakin and giving rise 
to an anomalous signal.  
5.4 2D-HSQC NMR analysis of the envoplakin PRD 
Although the protein was expected to be folded the thermofluor results suggested that it could be 
unfolded.  A more rigorous way of testing foldedness would be to use 2D-HSQC NMR analysis 
of 15N labelled envoplakin PRD, as the peak dispersion represent a much more sensitive and 
detailed indicator of foldedness.  Hence a 15N labelled version of the envoplakin PRD was 
expressed and purified in the same manner as its unlabelled counterpart. No significant 
differences were observed in final purity or yield. As shown in Figure 5.3 a very well dispersed 
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HSQC is observed with a spread between 7-10 ppm which indicates its well folded nature. The 
data clearly show that the protein is folded and has a stable tertiary structure. If the protein was 
unfolded a spectrum similar to that observed for the desmoplakin SH3 domain (figure 3.71) 
would have been expected. Given the spread of the peaks, the spectrum is indicative of a mixed 
α-helical β-sheet containing protein, consistent with the secondary structural predictions of the 
envoplakin PRD. Collectively, this information is contrary to the results obtained from the 
thermofluor thermal stability assay which suggested it may be unfolded or aggregated. This 
highlights the power of NMR spectroscopy using HSQCs and the limitations of thermofluor in 
terms of gauging foldedness. Given the stability, yield and high dispersion of the protein by NMR 
a choice between either NMR assignment or X-ray crystallography was needed for further 
structural elucidation at atomic resolution. A realistic time-frame for full NMR assignment of the 
envoplakin PRD was estimated to be 1 year (Personal communication: Dr Mark Jeeves, 2011), 
which was unfortunately beyond the time constraints of this PhD study given the other ongoing 
experiments. Based on the tight time constraints, it was decided that although there was a 
higher element of risk, due in part to the inherent challenges of protein crystallization, the X-ray 
crystallography route was to be initiated first, with NMR spectra being used predominantly to 









Figure 5.3 2D HSQC of the envoplakin PRD 
15N labelled envoplakin PRD was subjected to 2D HSQC analysis by NMR. This was conducted 
on an Agilent 600 MHz spectrometer at 298 K in 20mM Hepes (pH 7.2) and 100 mM NaCl. The 
data was processed using NMRPIPE and visualised (Delaglio et al., 1995). The HSQC spectrum 







5.5 Structural studies of the envoplakin PRD using X-ray Crystallography 
The determination of the high resolution three dimensional structure of the sole envoplakin PRD 
was important in an attempt to address some of the key questions posed in the introduction of 
this chapter. These questions included whether the structure of the envoplakin PRD was similar 
to those already crystallized from desmoplakin and if the putative vimentin binding groove was 
retained. Purified envoplakin PRD was tested at a variety of concentrations in 20 mM Hepes (pH 
7.5) and 50 mM NaCl in various crystallization screening buffers in order to crystallize the protein 
for eventual X-ray data collection and structure determination.  
5.51 Crystallization of the envoplakin PRD using sparse matrix commercial 
screens 
The initial crystallization hits were obtained with the hanging drop vapour diffusion method using 
the Mosquito nano-litre crystallisation robot. It was evident that the sparse matrix based 
commercial crystal screens yielded a large number of initial crystallisation leads for the 
envoplakin PRD (Table 5.1). Interestingly, the precipitant PEG 3350 was a common reagent in 
many of the preliminary crystallisation hits identified for envoplakin PRD. The most promising 
crystal hit was grown in with the Index condition (42) 0.1 M Bis Tris (pH 5.5), 25% PEG 3350 at 
6.6 mg/ml (figure 5.41A).  No crystals were observed in the negative control drops (in the 
absence of protein) equilibrated against index condition 42 (figure 5.41B). This suggested that 
the initial crystallisation hits were protein rather than salt derived and therefore worthy of further 






Crystallization screen Protein concentrations (mg/ml) Hits 
Index 6.6 and 5.0 5 
JCSG+ 11.0 and 8.5  3 
PACT 11.0 and 6.0 13 
 
Table 5.1 Preliminary crystallization screen hits 
A general overview of the number of envoplakin PRD crystal hits observed from each 
crystallization commercial screen.  A variety of protein concentrations were used to ascertain 
optimal protein concentrations. Crystals were grown at 298 K and appeared after 3 days. 
 
 
5.52 Optimization of initial crystallization hits 
The condition that yielded the preliminary hit was subjected to a variety of modifications to 
generate diffraction grade crystals. This is because the dimensions of the original crystals were 
too small and of too poor a morphology for high resolution X-ray data collection. The 
optimization strategy consisted of varying several factors. Initially, altering the concentrations of 
the constituent precipitant (PEG 3350 25%-10%) were trialled in order to reduce the number of 
nucleation sites. Although reducing the PEG 3350 concentrations from 25% to 23% yielded 
slightly larger sized crystals, they were still deemed unsuitable for X-ray diffraction experiments 
(Figure 5.41C).  Additional optimization trials for the envoplakin PRD consisted of varying the pH 
of the crystallization buffer (pH 4-9) and further reducing the PEG 3350 concentration (from 
23%-18%). This yielded single but larger crystals in each drop and were grown in the presence 
of 0.1 M Bis Tris (pH 6.5) and 20 % PEG 3350 with a protein concentration of 6.6 mg/ml (figure 
5.41D). 
Finally, large scale trials were performed during which the protein to crystallization buffer ratio 
was adjusted (0.5 µl-3.5 µl) as well as attempting the sitting drop method. Indeed, the most 
favourable crystallization condition was identified when utilising a 2:1 ratio of protein to 
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crystallisation buffer with the sitting drop method. The final optimised condition that reproducibly 
provided diffraction quality envoplakin PRD crystals consisted of 0.1M Bis Tris (pH 6.5), 20% 

















Figure 5.41 Preliminary and optimized hit for the envoplakin PRD 
A: initial crystal hit obtained from the Index screen condition 42 (0.1 M Bis-Tris pH 5.5, 25% PEG 
3350) at 6.6 mg/ml. B: Negative control with buffer alone (in the absence of protein) highlights no 
crystal formation suggesting that the crystals are derived from protein and not salt C: Optimized 
crystals grown in 0.1 M Bis Tris (pH 5.5) and 23% PEG 3350 at 6.6 mg/ml. Crystals were 
deemed to be 65 x 55 µm. D: Final optimized condition yielding a single relatively large crystal 
consisted of 0.1M Bis Tris (pH 6.5), 20% PEG 3350, at 6.6 mg/ml. Crystal was deemed to be 







Figure 5.42 Crystals of the envoplakin PRD grown on a large scale 
Crystals were grown using the sitting drop vapour diffusion method at a volume ratio of 2:1 (µl) 
protein to buffer in 0.1M Bis Tris (pH 6.5), 20% PEG 3350 at 6.6 mg/ml and appeared after 3 







5.53 Data collection and processing 
Crystals were soaked in the reservoir crystallisation buffer supplemented with increasing 
concentrations of ethylene glycol (at 5, 10, 15 and 18%) as a cryoprotectant in preparation for X-
ray data collection. These crystals were then flash cooled at 100 K under a nitrogen gas stream 
(Oxford Cryosystems). X-ray data was collected to 1.6 Å resolution (Figure 5.43) by Dr Fiyaz 
Mohammed on an in-house MicroMax 007HF rotating anode X-ray generator (Rigaku) using a 
Saturn CCD detector (Macromolecular X-ray facility, University of Birmingham). The envoplakin 
PRD crystallises in the orthorhombic space group P212121 with unit cell parameters (a = 42.4 Å, 
b= 68.8 Å, c = 112 Å, α = 90=β = γ = 90 °). Envoplakin PRD diffraction data were integrated, 
scaled and merged using programs of the XDS suite (Kabsch, 2010). The relevant data 
processing statistics are listed in Table 5.2.  
Resolution Range (Å) 20-1.6 
Total Reflections 540914 (19433) 
Unique reflections 78068 (94130 
Completeness (%) 92.9 (97.2) 
Rsym (%) 5.8 (38.5) 
I/σ(I) 27.9 (2.1) 
Multiplicity 6.9 (2.1) 
 
Table 5.2 Data processing statistics for the envoplakin PRD 
X-ray data processing statistics of the envoplakin PRD crystal. Numbers in parentheses 






Figure 5.43 Diffraction pattern for the envoplakin PRD crystal 
A 0.5° oscillation image of the envoplakin PRD crystal collected at 100 K using the University of 
Birmingham Macromolecular X-ray diffraction facility. The crystal diffracted X-rays to a resolution 








5.54 Structure determination using Molecular Replacement  
Assuming the envoplakin PRD crystal contains two molecules per asymmetric unit, a solvent 
content of 32% was calculated, which is similar to that of the desmoplakin PRDs (Choi et al, 
2002). Using the program PHENIX (Adams et al., 2010), a variety of search models were used 
to calculate initial phase information by automated molecular replacement. Models included full 
length desmoplakin PRD B (PDB ID code; 1LM7), desmoplakin PRD C (PDB ID code: 1LM5) 
and a sequence derived model of the envoplakin PRD calculated by I-TASSER (Roy et al., 
2010). Surprisingly, despite a very high sequence identity between the desmoplakin and 
envoplakin PRDs (45%), no rotation function peaks were observed. Therefore, the search 
models were improved by truncating the termini as well as deleting the internal flexible loops. 
Unfortunately, none of these truncated models provided any rotation function solutions, 
suggesting that molecular replacement could not be used to acquire initial phase information.  
5.55 Single wavelength anomalous dispersion (SAD)  
Due to the failure of molecular replacement to obtain initial phase information, an alternative 
method was required to calculate phases and hence determine the structure of the envoplakin 
PRD. One approach was to use multi-wavelength anomalous dispersion (MAD), in which 
selenium substitutes for methionine. However, this required expressing the protein in an E.coli 
methionine auxotroph strain, purifying and crystallising the protein and collecting X-ray data 
through the use of a tuneable X-ray source e.g. synchrotron radiation. Due to time constraints 
the MAD approach was not feasible. Therefore, an alternative strategy was to attempt ‘in house’ 
X-ray data collection on envoplakin crystals pre-soaked or co-crystallised in high concentrations 
of sodium iodide and determine the initial phase information using SAD (Dauter et al., 2000). 
This strategy  works on the premise that iodide ions bind to positively charged residues on the 
protein and are located easily due to their large anomalous signal at Cu Kα radiation 
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(wavelength = 1.5418 Å). In addition, the SAD method has the extra benefit of being relatively 
inexpensive, rapid and less toxic compared to other techniques such as MAD and multiple 
isomorphous replacement.  
Using the previously described crystallization condition, attempts were undertaken to co-
crystallise envoplakin PRD with sodium iodide. Unfortunately, despite constantly striving to 
optimise the concentration of sodium iodide added to the crystallisation buffer, none of these 
conditions generated envoplakin PRD crystals. Therefore, an alternative approach was 
employed which involved soaking existing envoplakin PRD crystals in mother liquor 
supplemented with various concentrations of sodium iodide (0.1-1 M) and cryoprotectant. Initial 
soak attempts with higher concentrations of sodium iodide (0.6 M) led to the envoplakin crystals 
dissolving (2/2 crystals). Therefore, the soaking steps were repeated at lower iodide ion 
concentrations. Through trial and error the maximum sodium iodide concentration was optimized 
to 0.45 M allowing a number of crystals to be soaked for up to 45 minutes where 3/5 were 
soaked successfully and vitrified for subsequent data collection. The optimised soaking 
procedure for generating iodine derivatised envoplakin PRD crystals are listed in Table 5.3 
Soak (#) Derivative Cryoprotectant Time (m) 
1 Sodium iodide (0.20 M) Ethylene glycol (5%) 10 
2 Sodium iodide (0.30 M) Ethylene glycol (10%) 15 
3 Sodium iodide (0.40 M) Ethylene glycol (15%) 30 
4 Sodium iodide (0.45 M) Ethylene glycol (18%) 45 
 
Table 5.3 Soaking procedure used to generate iodine derivatised crystal of 
envoplakin PRD.   
 
To maximize uptake of sodium iodide into the crystal, the optimal soaking procedure is given. 
Mother liquor of 0.1 M Bis tris (pH 6.5) and 20 % PEG 3350 was supplemented with increasing 




X-ray data collection for the envoplakin derivatised crystal was performed as described 
previously for the native crystal in section 5.53. X-ray data was collected to 2.3 Å resolution 
(figure 5.44). The derivatised envoplakin crystal was isomorphous to the native crystal belonging 
to the orthorhombic space group P212121 with unit cell parameters (a = 42.3 Å, b= 68.5 Å, c = 
113.7 Å, α = 90 =β = γ = 90 °). This suggested that soaking of the heavy atom iodide had little 
effect on the internal crystal packing and hence space group.   
 
Resolution Limit (Å) 20-2.3 
Total Reflections 743113 (129679) 
Unique reflections 31129 (5527) 
Completeness (%) 99.8 (99.9) 
Rsym (%) 10.6 (37.9) 
I/σI 32 (10.9) 
Multiplicity 23.9 (23.5) 
SigAno 1.7 (1) 
 
Table 5.4 Data processing statistics for the iodine derivatised crystal of 
envoplakin PRD.  
 







Figure 5.44 Diffraction pattern for the iodine derivatised crystal of envoplakin 
PRD.   
A 0.5° oscillation image of the envoplakin derivatised crystals collected at 100 K using the 
University of Birmingham X-ray facility. The crystal diffracted X-rays to a resolution of 2.3 Å. The 
native envopakin crystal was pre-soaked in 0.45 M sodium iodide and 18% ethylene glycol for 





5.56 Structure determination of the envoplakin PRD 
Since the phase information could not be acquired by molecular replacement techniques, SAD 
phasing using iodide ions was used. To acquire the phase information, firstly the iodide ions 
must be located. Since these steps were carried out by Dr Scott White (University of 
Birmingham) only a very brief description will be given. As mentioned earlier, data sets were 
collected in house using a Rigaku 007-HF X-ray generator and a Saturn CCD detector. Data 
were reduced with XDS (Kabsch, 2010) and iodide sites were located using PHENIX (Adams et 
al., 2010). The anomalous substructure was refined and extended, and phases were estimated 
using PHASER (McCoy et al., 2007) followed by density improvement in RESOLVE. Initial 
models were built using automated building in AUTOBUILD (Terwilliger et al., 2007), followed by 
model extension/rebuilding in PHENIX. The final model was produced after several iterative 
rounds of manual re-building in COOT (Emsley et al., 2010) and refinement in PHENIX. An 
example of the quality of electron density is shown in figure 5.45.  Final refinement statistics are 
listed in Table 5.5. The stereochemical quality of the protein structure was verified using the 
program PROCHECK (Laskowski, 1993) and demonstrates that the bond lengths and angles 
are acceptable (Table 5.5). Furthermore, all non-glycine residues are found in the allowed 
regions of the Ramachandran plot (figure 5.46). The final model encompasses two molecules in 
the asymmetric unit; residues 1822-2014 in molecule A (and 2 vector derived amino acids at the 








Resolution (Å) 19.9-1.6 
Total reflections used 41953 
Free value test 





Protein residues 383 
Water molecules 405 
RMS deviations 
Bond lengths (Å) 




Most favoured (%) 
Additionally allowed (%) 




Average B factors (Å2) 
Main chain (A) 
Side chain (A) 
Overall (A) 
Main chain (B) 










Table 5.5 Final refinement and stereochemical statistics for the envoplakin PRD 
aRcryst (F) = Σh||Fobs(h)| - |Fcalc(h)||/Σh|Fobs(h)| and |Fcalc(h)| are the observed and calculated 
structure factor amplitudes for the h, k, l reflection. bRfree is calculated over reflections in a test 










Figure 5.45 Electron density for the envoplakin PRD Molecule A.  
2Fo-Fc electron density map contoured at 1σ (blue mesh) is shown for molecule A. A: Electron 
density at the extreme N-terminal end. B: The same view as A except with the protein chain 
model built in using COOT (Emsley et al., 2010). Highlighted are residues D1822 and D1823 at 
the N-terminal end of the envoplakin PRD and a vector derived serine. Spheres with crosshairs 





Figure 5.46 A Ramachandran plot of the envoplakin PRD structure 
The Phi and Psi dihedral angles for the peptide bond of each residue in the envoplakin PRD 
structure are depicted as squares. Regions of the Ramachandran plot include the most favoured 
(red), additionally allowed (yellow), generously allowed (cream) and disallowed (white). Since 
glycine residues (depicted as triangles) exhibit additional flexibility and freedom they can occupy 






5.6 Crystal structure of the envoplakin PRD 
5.61 Overall structure of the envoplakin PRD 
The overall structure of the envoplakin PRD is largely similar to previously determined PRD 
structures (Choi et al, 2002), forming a globular structure with the same topology and fold (figure 
5.51).   The envoplakin PRD is characterised by a 38 amino acid motif (plakin repeat (PR)) that 
is repeated 4.5 times. Primary sequence alignments of the envoplakin PRs 1-5 reveals high 
degrees of conservation, as documented for desmoplakin PRDs B and C (Choi et al, 2002). The 
structural PR is comprised of an 11 amino acid beta hairpin (encompassing strands S1 and S2) 
followed by a pair of anti-parallel helices (designated H1 and H2),  typically  8 and 12 residues 
long, respectively (although subtle variations are evident). The secondary structure elements of 
the envoplakin PRD for molecules A and B are listed in table 5.6.  
PR1 PR2 PR3 PR4 PR5 
1829-1832 S1 1868-1870 S1 1906-1908 S1 1944-1954 L
+
 1982-1984 S1 
1833-1836 L 1871-1874 L 1909-1911 L 1955-1962 H1 1985-1987 L 
1837-1839 S2 1875-1877 S2 1912-1915 S2 1963-1964 L 1988-1991 S2 
1840-1848 H1 1878-1886 H1 1916-1924 H1 1965-1974 H2 1992-2000 H1 
1849-1850 L 1887-1892 L* 1925-1926 L 1974-1978 3/10 helix 
 1851-1866 H2 1893-1905 H2 1927-1942 H2 1979-1981 L 
 1867 L 
 
1943 L 
   
Table 5.6 Secondary structure elements of the envoplakin PRD 
Secondary structure elements from the 38 amino acid motif of each PR were determined using 
the structure of the envoplakin PRD. S1: strand 1, S2: strand 2, H1: helix 1, H2: Helix 2, L: loop. 
* indicates a longer loop than usually observed between H1 and H2 of PR2 suggesting  that H2 
is unusually shorter than a typical H2. + indicates that the S1+loop+S2 arrangement (β-hairpin 
forming regions) is replaced with a random coil in PR4. Furthermore, another novel feature of 





Figure 5.51 Crystal structure of the envoplakin PRD Molecule A  
The final refined crystal structure of the envoplakin PRD visualised by PYMOL. The PR motifs 
are colour coded as follows: PR1: red, PR2: green, PR3: dark blue, PR4: yellow, PR5: magenta. 
S1: stand 1, S2: strand 2, H1: helix 1, H2: helix 2, 3/10: 3/10 helix only observed in PR4. The N 








5.62 Assessing the possibility of envoplakin PRD dimerization – an academic 
exercise 
Since two molecules are found in the asymmetric unit (figure 5.52A), the structure raised the 
possibility that the crystal dimer may represent a physiologically relevant form of the envoplakin 
PRD.  Indeed, previous desmoplakin PRD structures, also determined by X-ray crystallography, 
demonstrated dimeric species within the asymmetric unit (Choi et al, 2002). However in the 
earlier cystallographic study from Weis’ group, the physiological relevance of the distinct crystal 
dimer was not discussed, suggesting that the lattice contact may be an artefact of the crystal 
packing rather than representing an interaction surface. Nevertheless, the envoplakin PRD 
dimer was subjected to a series of structural analyses to clarify whether this was a bona fide 
functional subunit-subunit interface or a non-specific interaction.  
Firstly, the number and size of inter-chain contacts, usually measured by the buried surface area 
were calculated, to discriminate between homodimeric and monomeric proteins in the crystalline 
state. For the envoplakin PRD dimer interface, a buried surface area of 589.2 Å2 was calculated 
using PISA (Krissinel and Henrick, 2007), a relatively less extensive contact area relative to the 
PRD C (673.8 Å2) of desmoplakin. These surface areas are considerably below values that are 
considered physiologically relevant (Krissinel and Henrick, 2007). Upon closer inspection, the 
envoplakin dimer interface is predominantly stabilised by a series of polar interactions that are 







Molecule A Location Molecule B Location Distance 
K1847N PR1 (H1) S1824OG (*) 3.08 
N1837OD1 PR1 (L) E1975OE1 PR4 (H2) 3.14 
N1837ND2 PR1 (L) K1994NZ PR5 (H1) 3.05 
K1842NZ PR1 (H1) G1998O PR5 (H1) 3.07 
D1870OD1 PR2 (S1) R1999NH1 PR5 (H1) 3.17 
D1870OD2 PR2 (S1) R1999NH2 PR5 (H1) 2.89 
K1842NZ PR1 (H1) C2000O PR5 (H1) 2.95 
     Table 5.7 Envoplakin PRD residues involved in stabilising the dimer interface.  
The side chain atom that is involved in forming molecular contacts is shown in superscript. The 
majority of the residues that contribute to the dimer interface are located in PR1 and PR2 in 
molecule A and PR5 in molecule B. * denotes that S1824 is not associated with the PR motif. 
 
If dimerization is important for the function of PRD molecules, one might expect that interface 
residues have evolved to optimize this interaction and these residues are conserved among 
PRD family members during evolution. Analysis of the desmoplakin PRD C dimer interface 
revealed that the majority of the residues were located in PR2 and PR3 of molecule A and PR4 
of molecule B. In contrast, the envoplakin PRD dimer is stabilised by residues from the PRs 1 
and 2 in molecule A and PR5 of molecule B (table 5.7). Given that the dimerization interface is 
not conserved between envoplakin and desmoplakin C PRDs it is unlikely that the dimer 
interface is physiologically relevant.  
To assess this further the geometric parameter, shape complementarity (Sc), was determined to 
quantify the “goodness of fit” between the two envoplakin PRD surfaces. Large values of Sc 
usually indicate a close and good shape complementarity between surfaces (Lawrence and 
Colman, 1993). Sc values of 0.67 and 0.72 were calculated for the envoplakin and desmoplakin 
PRD C dimers, which was consistent with typical Sc values (0.65-0.80) determined for protein-
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protein interfaces in oligomeric proteins. However, despite the relatively large Sc values, the 
biophysical data obtained for the envoplakin PRD and desmoplakin PRD C does not support the 
notion that the envoplakin PRD forms a physiologically relevant dimer. The data include a sharp 
peak eluting in the monomeric range from size exclusion chromatography (figure 5.13B), the 
AUC data which indicated a monomeric species (figure 5.2) as does analysis of SAXS results 
(discussed further in 5.7).  
Superimposition of molecules A and B of the envoplakin PRD revealed that they are structurally 
similar as reflected by the Root Means Square Deviation (RMSD) of 1.04 Å (Figure 5.52B). The 
small differences observed between the two envoplakin molecules particularly in PR4, the C-
terminus and the β-hairpin in PR3 were attributed to crystal packing effects. However, since 
those regions are divergent in the two asymmetric units (indicated in figure 5.52B) they may also 
be due to genuine flexibility or multiple conformers. Since the two envoplakin PRD molecules are 
almost identical (based on the RMSD value), molecule B (herein referred to as envoplakin PRD) 








Figure 5.52 Crystal structure of the envoplakin PRD dimer  
A) The crystal structure of the envoplakin PRD contains two molecules in the asymmetric unit 
(molecule A and molecule B). The PR motifs are colour coded as follows: PR1: red, PR2: green, 
PR3: dark blue, PR4: yellow, PR5: magenta. S1: stand 1, S2: strand 2, H1: helix 1, H2: helix 2, 
3/10: 3/10 helix only observed in PR4.The crystal dimer interface is stabilised by residues 
protruding from PRs 1 and 2 in molecule A and PR5 of molecule B. B) Superimposition of 
envoplakin PRD molecule B (red) onto molecule A (blue). Black arrows indicate two of the 
regions (one in the β-hairpin of PR4 and the other at the end of H2 in PR4 – discussed further in 
5.63) that are structurally divergent. 
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5.63 Comparison of the envoplakin PRD to PRD C of desmoplakin 
Superimposition of envoplakin PRD to desmoplakin PRD C reveals some degree of 
heterogeneity (Figure 5.53A). When either molecule A or B were superimposed to the individual 
molecules of desmoplakin PRD C, RMSD values were calculated to be 1.68 and 1.95 Å for 
molecules A and B, respectively. This is not surprising given the high level of sequence similarity 
between the two proteins of 65% homology.   
When the PR motifs from envoplakin and desmoplakin are superimposed on top of one another 
it reveals a striking similarity in orientation between all 5 PR motifs (figure 5.53B). These are also 
reflected in the RMSD values calculated for PRs1, PRs2, PRs3 and PRs4 (data not shown) 
between the PR motifs of envoplakin and desmoplakin. This implies envoplakin PR motifs adopt 
conformations similar to their desmoplakin PRD C counterparts. The hydrophobic core 
interactions that stabilise the PRs in desmoplakin PRD C are generally conserved in envoplakin. 
The residues involved in intra and interdomain interactions can be seen between the helices of 
H1 and H2 of envoplakin with the numerical positions within each PR motif conserved similarly 
to those seen for desmoplakin PRD (figures 5.54 and 5.55) Hydrophobic interactions between 
the extreme C and N terminals (absent in the envoplakin PRD small construct) and PR1 are also 
observed (figure 5.56), similar to observations in PRD C of desmoplakin, suggesting these 
interactions between these regions are required for folding or structural stability. Indeed, this 
may reflect why the envoplakin PRD small construct was insoluble/unstable.  
Close inspection of the superimposition does reveal some differences between the PRDs of 
envoplakin and desmoplakin. Firstly, the majority of the differences are restricted to the flexible 
loops within each PR motif (figure 5.53A). These differences may provide a molecular rationale 
for the lack of success in determining initial phases with molecular replacement. Secondly, the 
PR2 motif is unique in that it exhibits a distinctive “kink” in the envoplakin PRD which is also 
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observed in PR2 of desmoplakin PRD C (figure 5.53B).  Interestingly, the kink appears to be 
created by two different mechanisms in each PRD. In desmoplakin PRD C, a proline at position 
2690 contributes to the kink at the beginning of H2, whereas the corresponding residue in 
envoplakin PRD consists of Asn 1898. Nevertheless, the envoplakin PRD contains a shorter H2 
element due to a longer loop region proceeding H1, which typically separates the two anti-
parallel α-helices (table 5.6). This may allow for greater flexibility in the backbone to adopt this 
conserved “kinked” conformation in envoplakin. Despite the differing mechanisms for generating 
the kink, the precise molecular role of the kink is undefined. Thirdly, in the envoplakin PRD PR4 
contains a 310 helix (an α-helix created by 3 residues per turn rather than 3.6) at the end of H2 – 
which itself is shortened. In the corresponding region in the desmoplakin PRDs B and C no such 
helix is observed and instead H2 is a canonical length. Its presence on the surface may present 
a functionally relevant binding position divergent from desmoplakin.  
Finally, in PR4 the typical β-hairpin is replaced with a random coil whereas in desmoplakin PRD 
C the same region contains a canonical β-hairpin. In envoplakin this region contains subtle shifts 
in the backbone that places S1 and S2 sufficiently apart to prevent normal hydrogen bonding 
interactions. Therefore a canonical beta hairpin is not observed. Ambiguity in the electron 
density is also not observed, and is well define further in both asymmetric molecules arguing that 
the random coil formation is real. Closer inspection of the random coil region reveals that 
although a negatively charged residue is observed at position 4 (D1946) of the motif, a positively 
charged residue usually present at position 19 is absent and is instead replaced by a serine 
(S1961). Since an electrostatic interaction is typically observed between position 4 and 19 to “fix” 
the β-hairpin into place, this may explain why in envoplakin PR4 this region is replaced with a 
random coil. As shown in figure 5.52B both asymmetric units PR4 random coil region is 
divergent, arguing that the region is also flexible. This may have a functional role since 
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interestingly; a residue conserved in the putative vimentin binding groove is located in this loop 
region (R1952) and is discussed further in 5.85.   
Overall, while the fold, conformation and secondary structure elements are similar between the 
envoplakin PRD and desmoplakin PRD C, there are some subtle differences that may have as 





Figure 5.53 Structural comparison of the PRD C of envoplakin and desmoplakin  
A: The crystal structures of envoplakin PRD molecule B (red) and desmoplakin PRD C (yellow) 
were superimposed using PYMOL. Two orthogonal views are shown with their NH2 and COOH 
termini highlighted. B: Superimposition of the PR motifs using CHIMERA. Left: envoplakin PR 
motifs, right: desmoplakin PR motifs. PR1: red, PR2: green, PR3: blue, PR4: yellow, PR5: 
magenta. The similarities in the overall fold shown in A and the PR motif orientations in B show 








Figure 5.54 Intradomain interactions in PR1 of the envoplakin PRD 
The two main categories of typical intradomain interactions between PR motifs are highlighted 
using PR1 from the envoplakin PRD. The first type of interaction is observed between position 4 
from S1 of the PR motif (in this case D1832) and position 19 from H1 (in this case K1847). This 
involves an electrostatic interaction which ensures that the β-hairpin is “fixed” in solution. The 
second interaction involves multiple hydrophobic contacts from H1, the loop separating the two 
anti parallel helices and H2. Five hydrophobic residues are involved in PR1 which in effect 
creates a mini hydrophobic core between the two helices ensuring that the two anti parallel 









Figure 5.55 Interdomain interactions between PR1 and PR2 of the envoplakin PRD 
The main type of interdomain interaction is highlighted in which multiple hydrophobic contacts 
are required to stabilize the fold of the protein using two different PRs. In this case a 
hydrophobic residue (L1859) from H2 of PR1 (red) interacts with multiple hydrophobic residues 








Figure 5.56 Interdomain interactions between PR1 and the extreme C-terminal 
strand  
An interdomain interaction is observed between the extreme C-terminal of the protein (cyan), 
PR1 and the extreme N-terminal (both red). The extreme C-terminal orientates in a way in which 
it becomes parallel with S1 of PR1 and is stabilized utilizing an interaction of three hydrophobic 
residues (yellow) including I1827 (from the extreme N-terminal), I1830 (from S1 of PR1) and 
L2011 (from the extreme C-terminal). Although this was also observed in the desmoplakin PRDs 
B and C, the novel fact that deletion of both extremes of the N-terminal and C-terminal (that do 
not contribute to a PR motif) caused insolubility upon expression of the envoplakin PRD small 
construct implies that this region may act as an essential element to ensure complete and stable 






5.7 SAXS analysis of the envoplakin PRD 
The structures of the desmoplakin PRDs B and C are unusually compact given the presence of 
repeat motif structures. Envoplakin PRD is also similarly compact based on the RMSD values 
when compared to desmoplakin PRDs B and C. Crystallization artifacts can occur whereby a 
non-physiologically relevant conformation is favoured for structural determination. To exclude 
crystallisation artefacts, solution state biophysical techniques such as SAXS can be used.  
The envoplakin PRD was analyzed by SAXS to corroborate the envoplakin PRD crystal 
structure. Firstly, the Rg and Dmax values for the envoplakin PRD were calculated as 1.9 and 5.6 
nm respectively using GNOM. Using CRYSOL theoretical SAXS scattering curves for the 
monomeric and dimeric crystal structures of the envoplakin PRD was superimposed onto the 
experimentally acquired data. The theoretical curve for the monomeric crystal structure gave 
excellent agreement with the experimental data (Figure 5.61) Furthermore a χ2 value of 1.1 was 
recorded which highlights the high level of corroboration between the theoretical and 
experimentally derived data sets. In contrast the theoretical curve of the dimeric crystal structure 
gave a poor fit with a χ2 value of 4.9. This suggests that in solution the protein is monomeric 
solution. To further corroborate the findings of CRYSOL an ab-initio envelope model was 
created utilizing the SAXS scattering curve and the program DAMMIF. The crystal structure of 
the envoplakin PRD was then automatically superimposed on to the bead model using 
SUPCOMB (figure 5.62). A NSD value of 1.375 was recorded which indicated a good fit. 
Interestingly a non-overlapping section of the bead model is also revealed. This most likely 
represents the small flexible vector derived sequence located at the N-terminal end of the 
protein. Collectively, this suggests that the monomeric crystal structure of the envoplakin PRD is 
representative of its orientation in solution and therefore molecular and functional insights 





Figure 5.61 SAXS analysis of the envoplakin PRD 
An experimental SAXS scattering curve for the envoplakin PRD was acquired and buffer 
subtracted (black).Protein was run at room temperature in 20 mM Hepes (pH 7.5) and 100 mM 
NaCl. Concentrations of 2, 4 and 8 mg /ml were used and scaled and merged accordingly to 
previously described methods. A theoretical SAXS scattering curve was created from the 
monomeric envoplakin PRD structure (red) and superimposed onto the experimental scattering 
curve using CRYSOL. A theoretical SAXS scattering curve was also generated for the dimeric 
envoplakin PRD structure (yellow) and superimposed onto the experimental scattering curve. A 
high level of similarity is observed between the theoretical monomeric PRD and experimental 
curves (χ2 = 1.1).  The dimeric PRD did not fit as well (χ2 = 4.9). This confirms that a monomeric 







Figure 5.62 Superimposition of a monomeric envoplakin PRD into a SAXS ab-initio 
envelope 
An ab-initio model was created using previously described methods and was superimposed on 
to the monomeric crystal derived structure of the envoplakin PRD by SUBCOMB and visualized 
by PYMOL. The crystal structure fits well in the SAXS derived ab-initio envelope (NSD = 1.375), 









5.8 Binding of the envoplakin PRD to the cytoskeletal protein vimentin 
5.81 Expression and purification of vimentin 
Expression and purification of full length vimentin was conducted for ligand titration experiments. 
The protein was expressed in E. coli where it typically forms insoluble inclusion bodies. 
Previously published purification protocols for vimentin were attempted but failed (Quinlan et al., 
1986). Therefore a previously documented in vitro dilution refolding method for immunoglobulin 
domain containing proteins (Garboczi et al., 1992) was used to renature vimentin. However, this 
protocol failed to produce soluble vimentin in sufficient levels for titration experiments.  To 
circumvent this problem, an optimized version of the Garboczi protocol was used. Following lysis 
of the bacteria vimentin is located in the insoluble fraction (figure 5.71).   It remains in the 
remaining insoluble fractions during the wash steps. Upon solubilisation with 6 M urea it was 
finally purified to ~85% purity in a final buffer of 20mM Tris-HCl pH 7, as demonstrated by the 
predominant band migrating at ~53 kDa (Figure 5.71). Since the biophysical properties of 
vimentin have previously been well characterized by a variety of techniques (Herrmann and 
Aebi, 2004, Herrmann et al., 1996), it was instead examined as a potential ligand for the 
envoplakin PRD in NMR titrations (discussed further in 5.82. Due to time constraints the 
refolding of vimentin was not tested however, it was assumed that vimentin had refolded based 
on previously described methods (Quinlan et al., 1986). In addition to recombinant “in-house” 
purified vimentin, a commercially available source (Cytoskeleton, Inc) was used in co-








Figure 5.71 Renaturation of full length vimentin using an optimized Garboczi 
method.  
Lys: bacterial lysate, Sol: bacterial soluble fraction, Ins: bacterial insoluble fraction, WSx: wash 
step soluble fraction, WPx: wash step insoluble fraction, M: marker, 6M Urea: solubilised 
vimentin in 6M urea. The arrows indicate the position at which vimentin migrates (~53 kDa), and 
this is in good agreement with its sequence derived molecular weight. The contaminant 
observed at approximately 30 kDa has been removed upon solubilisation of vimentin with 6M 
urea. Urea was then removed in a stepwise fashion until it had been completely removed. 
Vimentin protein was estimated to be 85% pure and was used for NMR titration studies with the 






5.82 Titration of unlabelled vimentin to 15N labelled envoplakin PRD 
Vimentin is known to bind to a variety of plakin family C-terminal domains including the linker 
domain of periplakin and the PRDs of desmoplakin (Kazerounian et al., 2002, Meng et al., 
1997b, Stappenbeck and Green, 1992). A previous study suggested that the envoplakin PRD 
fails to bind vimentin in vivo (DiColandrea et al., 2000), but since it exhibits high homology to the 
desmoplakin PRD C, verifying this with NMR titration experiments was of considerable interest. 
If binding was observed, it was hoped that future backbone assignments could be used to 
identify residues critical for vimentin binding. Notably, vimentin has not previously been 
examined by NMR, possibly due to its large size and elongated shape presenting technical 
challenges. This is especially true for vimentin as it displays a propensity to oligomerize under 
certain conditions. To keep the experiment straightforward and prevent or limit oligomerization, 
the NMR experiment was conducted in the absence of NaCl and therefore vimentin was in an 
“unpolymerized” state. In this state, vimentin is typically observed as a mixture of dimeric and 
tetrameric oligomers (Quinlan et al., 1986). 
To investigate the possibility of vimentin binding to the envoplakin PRD, unlabelled vimentin was 
titrated against 15N labelled envoplakin PRD.  Strikingly, the titration experiments unequivocally 
demonstrated vimentin binding to the envoplakin PRD (Figure 5.72). For example, at a 10:1 ratio 
(envoplakin to vimentin), approximately 40% of the peaks broaden out. At a higher ratio of 2:1 
(envoplakin to vimentin), the majority of the envoplakin PRD peaks have broadened out. This 
suggests that at a ratio of 2:1 (envoplakin to vimentin), the interaction between the envoplakin 
PRD and vimentin has reached a saturation point. Unfortunately, given the high number of 
peaks broadening out at low vimentin concentrations, it is unlikely that the identification of 
specific residues critical to vimentin binding can be identified. The significant level of peak 
broadening raises two additional possibilities. Firstly, that the entire protein surface of the 
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envoplakin PRD is required for binding to vimentin. Secondly, the significant broadening is 
merely a reflection of the relatively large molecular weight of the vimentin-PRD complex being 
larger than the 35 kDa limit for NMR. The latter scenario represents a more likely explanation 
since the envoplakin PRD-vimentin complex would tumble in a manner that is unfavourable for 
NMR analysis. Unfortunately, the foldedness and function of vimentin was not tested during 
experiments in this chapter. However, the foldedness and function was validated in the following 














Figure 5.72 Vimentin titration to 15N labelled envoplakin PRD 
15N labelled envoplakin PRD was subjected to 2D HSQC analysis in a titration series with 
unlabelled recombinant vimentin. This was conducted on an Agilent 600 MHz spectrometer at 
298 K in 20mM Tris (pH 7). A variety of different sample points were collected: firstly envoplakin 
PRD alone and then a variety of different concentrations of vimentin were added while the 
volume was kept constant. A: overall HSQC with ratios between the envoplakin PRD and 
vimentin highlighted in their respective colours in the top left corner. B: Boxed section of the 
HSQC so that closer inspection reveals the extent to which peaks begin to broaden out. Peaks 
begin to broaden out when envoplakin PRD is in 10 fold excess and saturation occurs at two fold 
excess. This can be observed more clearly in B as many of the peaks in red (apo) do not contain 








5.83 Analysis of binding polymerized vimentin to desmoplakin PRD C and the 
envoplakin PRD using co-sedimentation pull down assays 
Previously the envoplakin PRD was shown to interact with non-polymerized vimentin using NMR 
spectroscopy (section 5.82). As polymerized vimentin is the main physiologically relevant 
species in the cell, an interaction between vimentin and the envoplakin PRD was investigated. 
Co-sedimentation pull down assays were used to test the interaction between the envoplakin 
PRD and polymerized vimentin since they are the gold standard for probing interactions of 
soluble proteins to polymerized cytoskeletal IFs (Bishr Omary and Coulombe, 2004). A previous 
study using this method on the desmoplakin C-terminal tail showed that all three desmoplakin 
PRDs were capable of independently binding to vimentin (Choi et al, 2002).. 
As expected, polymerized vimentin was observed solely in the pellet (figure 5.73). When 
incubated with desmoplakin PRD C it is able to pull down a fraction of the desmoplakin PRD C 
although the majority of the desmoplakin PRD C remains in the supernatant. Similarly when 
vimentin is incubated with the envoplakin PRD, the latter is pulled down into the pellet with the 
majority of the PRD remaining in the supernatant (figure 5.73). This suggests that both 
desmoplakin and envoplakin PRDs bind to vimentin in the polymerized state with similar affinity.  
These observations, together with the vimentin tritration experiments, suggest that the 








Figure 5.73 Analysis of binding polymerized vimentin to desmoplakin PRD C and 
the envoplakin PRD using co-sedimentation pull down assays 
Commercially bought vimentin (Cytoskeleton, Inc) (stock concentration 0.5 mg/ml) was 
polymerized according to manufacturer’s instructions and incubated with desmoplakin PRD C or 
envoplakin PRD (stock concentration 10 mg/ml) for 1 h at room temperature (final 
concentrations were at a ratio of 2 to 1 PRD to vimentin). Tubes were then centrifuged at 100 
000g for 30 min on an Optima Max ultracentrifuge (Beckman-Coulter). The pellet was washed 
thoroughly three times with PBS to ensure that it was not contaminated with protein from the 
supernatant.  1: molecular weight marker, 2: vimentin (alone) pellet fraction, 3: vimentin (alone) 
supernatant fraction, 4: vimentin and desmoplakin PRD C pellet fraction, 5: vimentin and 
desmoplakin PRD C supernatant fraction, 6: vimentin and envoplakin PRD pellet fraction, 7: 
vimentin and envoplakin PRD supernatant fraction. It reveals that both the desmoplakin and 




5.84 Electrostatic analysis of the envoplakin PRD and modelling of vimentin 
binding 
It was originally proposed that the PRDs of desmoplakin bind to cytoskeletal proteins such as 
vimentin through a conserved positively charged groove. The envoplakin PRD exhibits a groove 
(approximately 16 Å wide, 26 Å long and 11 Å deep) that is similar to that of the desmoplakin 
PRDs B and C (Choi et al, 2002). To compare their grooves the envoplakin PRD and 
desmoplakin PRD C were subjected to electrostatic surface analysis with the PDB2PQR server 
using default parameters (Dolinsky et al., 2004).  The electrostatic surfaces are similar in some 
respects but different in others. Importantly the positively charged groove observed in 
desmoplakin is retained in the envoplakin PRD (Figure 5.74). For example, two previously 
identified positively charged side chains in desmoplakin (R2744 and K2668) are conserved in 
envoplakin (R1952 and R1876) and located in approximately the same orientation within the 
groove (Figure 5.74). In addition, the surface areas which could accommodate the proposed 
vimentin binding site are also similar.  
Interestingly, the original study did not highlight that the desmoplakin PRD C possesses a 
negatively charged patch consisting of 4 proximal surface exposed residues consisting of  
E2626, E2629, E2635 and E2638 from PR1 (Figure 5.74A) (Choi et al, 2002).  In contrast, the 
corresponding region in envoplakin displays a neutral patch as it encompasses residues T1834, 
N1837, T1843 and A1846 (figure 5.74B). Further comparisons of the molecular surfaces 
between envoplakin and desmoplakin revealed additional dissimilarities in their electrostatic 
properties. For instance, rotation of the envoplakin PRD approximately 180 ° from the proposed 
vimentin binding groove exhibits an electronegative charged patch (figure 5.74D). This is 
contributed by residues E1966, E1967, E1975 and E1979 from PR4 that is considerably larger 
than the patch observed in the corresponding region of desmoplakin PRD C (formed solely by 
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residues E2748 and E2749 from PR4) (figure 5.754C). Collectively, this suggests that although 
the positively charged putative binding groove is retained in each PRD solved to date (including 
the envoplakin PRD from this study) there appears to be subtle differences in other electrostatic 
surface regions. This may have an impact on cytoskeletal protein binding affinities, preferences 
or both since the structure of vimentin has provided hints as to how the cytoskeletal protein 
interacts with PRD containing proteins. Indeed, vimentin exhibits alternating charges on its 
surface and it is tempting to postulate that this could be an alternative / additive mode of binding 
in addition to the positively charged groove. The envoplakin-vimentin interaction warrants further 
investigation to validate whether the electrostatic patches play a key role in stabilising the 











Figure 5.74 Electrostatic surface representation of the envoplakin PRD and 
desmoplakin PRD C 
A: The electrostatic surfaces of both desmoplakin PRD C (A and C) and envoplakin PRD (B and 
D) were calculated using the PDB2PQR server (Dolinsky et al, 2004) and orientated in similar 
conformations. Residues conserved in the putative vimentin binding groove of desmoplakin PRD 
C (R2744 and K2688) are semi conserved in envoplakin (R1952 and R1876). Also indicated are 
other residues possibly involved in the interaction with vimentin such as the negative patches of 
desmoplakin PRD C (E2626, E2629, E2635 and E2638).  These residues are altered to non 
charged residues in the envoplakin PRD. When the surface representations of both desmoplakin 
and envoplakin are rotated 180 ° an alternative negatively charged patch is observed, especially 
for envoplakin in which E1966, E1967, E1975, E1979 and E1989 create a large patch which 
may bind to a positively charged patch on vimentin.  
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5.85 Modelling of vimentin binding to the envoplakin PRD  
The notion that vimentin binds to PRDs via their conserved positively charged groove was 
assessed by molecular modelling. The envoplakin PRD binding site on vimentin is unknown, 
although it has been proposed to reside in the rod domain based on previous studies (Favre et 
al., 2011, Choi et al., 2002). Interestingly, vimentin is dominated by a series of alternate negative 
and positive patches that may contribute to binding PRDs. The crystal structure of a fragment 
from the vimentin rod domain (PDB code: 1GK4) was used to assess the interaction between 
vimentin and the envoplakin PRD. Although it does not represent the entire rod domain, it was 
proposed that the rod domain contains homologous repeats of this crystallized fragment 
(Strelkov et al., 2002). This has since been proved by the very recent structural elucidation of 
three more fragments of the vimentin rod region (Chernyatina et al., 2012). Together with 
previous fragments elucidated, an atomic structure of the entire rod domain is now known. The 
1GK4 fragment was manually docked to the proposed groove on the envoplakin PRD and 
provided a relatively snug fit (Figure 5.75). This is in agreement with previous manual docking 
experiments on the desmoplakin PRDs B and C (Choi et al, 2002) and suggested the interaction 
between the two proteins is sterically feasible.  
To probe the interaction further, the High Ambiguity Driven DOCKing (HADDOCK) server was 
used to create a model of the envoplakin PRD-vimentin complex (Dominguez et al., 2003). As 
part of this process, the positively charged residues previously identified from the envoplakin 
PRD structure were selected as possible vimentin binding candidates based on manual 
modelling and previous suggestions (Choi et al, 2002).  These included residues that contribute 
to the positively charged groove (R1952 and R1876) as well as side chains proximal to the 
groove (R1985 and R1914).  Since the envoplakin PRD binding site on the vimentin rod domain 
has not been localized, two negative patches were identified on the crystallized fragment of 
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vimentin (PDB code: 1GK4) as possible binding sites. The most conserved negatively charged 
residues were present at E338, E341 and E348 since these residues were identical across 
vimentin full length sequences from multiple species from Homo sapiens to Xenopus laevis and 
semi conserved across other IF proteins desmin and keratin 8 when aligned by CLUSTALW 
(Thompson et al., 1994).   
The results from the HADDOCK server suggested that an electrostatic interaction between the 
two is highly plausible. The proposed complex was then analyzed visually, by the program PISA 
(which calculates buried surface areas) and by the program CONTACT (which allows 
quantitative analysis of the interactions between certain atoms of an amino acid in a complex). 
Overall the putative model appears to accommodate 4 electrostatic interactions between the 3 of 
the 4 selected amino acids of envoplakin and all 3 of vimentin (figure 5.76 and table 5.8). In 
addition two separate hydrogen bond interactions are observed (figure 5.76 and table 5.8). 
Interestingly, the residue R1952 from the putative flexible random coil region of PR4 described in 
5.63 is centrally located in this interaction. Furthermore, according to the program CONTACT it 
is involved in 2 electrostatic interactions between E338 and E341 of vimentin. This implies that 
R1952 may be critical to vimentin-envoplakin PRD complex formation. Finally, when the buried 
surface between the two proteins was analyzed by the program PISA (Krissinel and Henrick, 
2007) a value of 889.2 Å2 is given. Since this is significantly above the minimal level required of 
a physiologically relevant dimer it appears to suggest that the interaction between the two is 
entirely possible.  Collectively, this suggests that multiple electrostatic interactions most likely 





Vimentin Location Envoplakin Location 
K334NZ N/A D1822OD1 (*) 
E338OE1 N/A R1952NH2 PR4 (L) 
E341OE1 N/A R1952NH2 PR4 (L) 
E341OE2 N/A R1876 NH1 PR2 (S2) 
E348OE1 N/A R1895NH1 PR2 (H2) 
E348OE2 N/A Q1900NE2 PR5 (S2) 
 
Table 5.8 Calculated contacts between envoplakin PRD and vimentin based on 
HADDOCK binding 
A negative patch (E338, E341 and E348) from vimentin was selected as a potential binding to 
site for the envoplakin PRD using a crystallized fragment of the vimentin rod (PDB code: 1GK4). 
Amino acids selected from the putative positively charged groove of the envoplakin PRD were 
selected (R1876, R1985, R1914 and R1952) as a potential binding site for vimentin. Using 
HADDOCK a potential complex between the two proteins was predicted (figure 5.76) and using 
CONTACT potential interacting atoms from amino acid residues were calculated. It reveals that 
3 of the 4 residues selected for envoplakin bind to all 3 selected for vimentin. R1952 appears to 
be an important residue since it binds to both E338 and E341. Side chain atoms involved in 
binding are shown in superscript.    
 
 
This model is based on the premise that the envoplakin PRD has a positively charged binding 
groove, and since vimentin has multiple negatively charged patches, this proposed mechanism 
clearly requires further investigation. Due to time constraints this was not possible, but hopefully 









Figure 5.75 Manual docking of the envoplakin PRD-vimentin complex 
An excellent fit was obtained following manual docking of vimentin (rod shape) to the envoplakin 











Figure 5.76 HADDOCK automated docking of the envoplakin PRD (green)-vimentin 
(red) complex 
The complex reveals multiple electrostatic and hydrogen bond interactions. Vimentin side chains 
of K334, E338, E341, and E348 (highlighted in red text) interact with the envoplakin PRD side 
chains of D1822, R1876, R1985, Q1900 and R1952 (highlighted in green text) and are 
discussed further in the text. As shown in table 5.8 R1952 appears to be a critical residue in the 
formation of the complex since it is centrally located and interacts with both E338 and E341 of 








5.9 Chapter 5 Discussion 
Since a vital function of plakin family members is the recognition of cytoskeletal protein partners, 
understanding the mechanism of PRD and vimentin complex formation was investigated. It is 
well known that the C-terminal tail of plakin family members is required for binding to 
cytoskeletal proteins.  However, to date only two structures of PRDs from desmoplakin have 
been published (Choi et al, 2002). Understanding whether the structure and or function is 
conserved across other PRDs was therefore of interest. The envoplakin PRD was crystallized 
and its structure solved with the aim of gaining novel insights into vimentin binding and whether 
PRDs from different plakin proteins share similar structures and therefore binding properties. 
The experiments presented in this study revealed that the overall structures of PRDs are similar 
between different plakin family members. However, there appear to be minor differences in 
acquiring fold and potential binding mechanisms.  
It was originally suggested that PRDs require 4.5 PR motifs to acquire a globular fold and any 
less were suggested to result in an unstable fold (Choi et al, 2002).  The envoplakin PRD has 
4.5 PR motifs and adopted a similar fold to those observed for PRDs B and C of desmoplakin. 
However, a smaller envoplakin construct retaining the minimal 4.5 PR motifs failed to fold due to 
likely instability or insolubility upon E.coli expression. This construct had its N and C termini 
shortened as these regions were more divergent than those observed in the “core” region giving 
rise to the 4.5 PR motifs (figure 5.1). Closer inspection of the N and C termini from the 
envoplakin PRD crystal structure suggests that they were proximal to one another (figure 5.56). 
Multiple hydrophobic residues from PR1, the N-terminus and the C-terminus appeared to create 
a mini hydrophobic core. This formed a parallel sheet which allows the domain to complete its 
globular fold (figure 5.56). This feature appears to be critical to the fold of all PRDs since these 
residues were semi conserved in similar regions of the crystal structures of desmoplakin PRDs B 
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and C. In effect these results indicated that the residues at the N and C-termini are indispensible 
for folding of all PRDs.  
The mechanisms involved in acquiring the general fold therefore appear to be conserved 
between PRDs of different plakin family members. The same is true of individual PR motifs of 
the envoplakin PRD in which inter and intra domain hydrophobic and electrostatic interactions 
are required to acquire fold. Typically, amino acids present at position 4 (negatively charged 
amino acid) and position 19 (positively charged amino acid) of each PR motif engage in an 
electrostatic interaction. In addition to this interaction, multiple hydrophobic contacts are made 
between apolar residues situated between H1 and H2 (figures 5.54 and 5.55). These 
interactions are highly reminiscent to those observed in the desmoplakin PRDs B and C. In 
effect the envoplakin PRD utilizes similar mechanisms to those observed in the desmoplakin 
PRDs B and C for folding within the PRD domain and assembly of the PR motifs. 
The biophysical properties of the envoplakin PRD and desmoplakin PRD C were also 
investigated in solution by AUC and SAXS. AUC analysis revealed that both proteins were 
monomeric in solution (figure 5.2). SAXS confirmed this assumption when theoretical SAXS 
scattering curves were created for dimeric and monomeric models of the envoplakin PRD and 
superimposed onto the experimentally derived curve (figure 5.61). This confirmed that the 
monomeric state of the crystal structure was physiologically relevant. Given the corroboration 
between the ab-initio and crystal structure models, the electrostatic surfaces were also 
investigated and appeared to be conserved (figure 5.62). This included the putative positively 
charged vimentin binding groove. 
The putative binding groove of envoplakin’s PRD retains similar dimensions and charged 
residues to those observed for the desmoplakin PRDs B and C. Unfortunately, the binding sites 
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between vimentin and any PRD are yet to be experimentally mapped. One of the main aims of 
the experiments described in this chapter was to investigate how binding between a PRD and 
vimentin could be achieved. Firstly, unpolymerized unlabelled vimentin was titrated against 15N 
labelled envoplakin PRD and showed saturation at a ratio of 2:1 PRD to vimentin (figure 5.72). 
Similar findings were observed using 15N labelled desmoplakin PRD C and unpolymerized 
unlabelled vimentin in which a saturation was observed at a ratio of 2:1 (Unpublished findings: 
Miss Penelope Rodriguez-Zamora, 2012). This implies that the two different PRDs are capable 
of binding unpolymerized vimentin at similar affinities. This is the first time an unpolymerized 
cytoskeletal protein has been shown to interact with a PRD in vitro. The finding is of interest 
because the main physiologically relevant cytoskeletal state is polymerized vimentin which forms 
a large fibrous network (Bishr Omary and Coulombe, 2004). However, studies have indicated 
the presence of a pool of unpolymerized soluble cytoskeletal proteins which form a 
heterogenous group of dimeric, tetrameric and higher order oligomeric states (Blikstad, 1983, 
Quinlan et al., 1986, Bishr Omary and Coulombe, 2004). These pools of unpolymerized 
cytoskeletal proteins are thought to form the precursor molecules of a larger cytoskeletal 
network. However, once cytoskeletal networks have been formed why these unpolymerized 
pools of cytoskeletal proteins remain in the cell is unclear. In addition, it is known that proteins 
bind to cytoskeletal proteins to aid their polymerization (Bishr Omary and Coulombe, 2004). 
Binding of the envoplakin PRD to unpolymerized vimentin may therefore aiding vimentin 
polymerization or sequestering soluble vimentin precursors, depending on the state of the cell. A 
previous study found that a sequence in the C-terminal tail from plectin could inhibit filament 
assembly in a dose dependent manner and conversely disassemble polymerized IFs at high 
concentrations (Steinböck et al., 2000). This was suggested as a possible mechanism for 
envoplakin in which a previous study reported bundling of intermediate filaments by envoplakin 
in the presence of periplakin (Karashima and Watt, 2002).  
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Regulatory mechanisms have been proposed for PRD interactions. Phosphorylation of a non 
PRD based amino acid in the desmoplakin C-terminal tail significantly disrupted binding to 
vimentin and keratin (Stappenbeck et al., 1994, Meng et al., 1997b). Therefore, it appears there 
may be a complex interplay in the way IFs and PRDs (or at least plakin family member C-
terminal tails) interact with one another.  
In an effort to ascertain the interaction with the more physiologically relevant vimentin species, 
the polymerized state, the envoplakin PRD and desmoplakin PRD C were analyzed for their 
ability to bind polymerized vimentin in a co-sedimentation assay. It was shown previously that 
desmoplakin PRDs can bind to polymerized vimentin (Choi et al, 2002). This study has now 
confirmed that the envoplakin PRD can also bind to polymerized vimentin, in a similar affinity to 
that of desmoplakin PRD C (figure 5.73). Comprehensive analysis of the binding affinities 
between the PRDs and vimentin were not conducted in this study due to time constraints. This is 
in agreement with the findings of the envoplakin PRD binding to unpolymerized vimentin when 
analyzed by 2D-HSQC NMR (figure 5.72). Interestingly, the results contradict the finding of a 
previous study which suggested that the envoplakin PRD was unable to bind to vimentin directly 
(DiColandrea et al, 2000). The envoplakin constructs these authors used tended to aggregate in 
vivo, and hence may not give a clear indication of whether the envoplakin PRD is able to bind 
directly to vimentin or not.   
Ultimately, the results indicate no significant differences between the desmoplakin PRD C and 
envoplakin PRD in terms of their binding affinities to vimentin, either unpolymerized or 
polymerized. This may be reflected in the fact that their putative vimentin binding groove is 
similar both in terms of their charge and surface area.  When molecular modelling was used to 
further characterize the envoplakin PRD-vimentin interaction it suggested that binding was 
feasible (figures 5.75 and 5.76). This included parameters such as interaction surface area and 
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the type of amino acid interactions involved, which corroborated previously published findings 
(Choi et al, 2002).  
Regardless of the similarities between the envoplakin PRD and desmoplakin PRD C there are 
some subtle structural differences that may affect vimentin binding. A comparison of the 
molecular surfaces of desmoplakin PRD C and envoplakin PRD was investigated because the 
interaction between PRDs and vimentin were thought to be predominantly electrostatic (figure 
5.75). It revealed that although the putative positively charged binding groove was conserved, 
electronegative patches were present in alternative positions on the surfaces of desmoplakin 
PRD C and the envoplakin PRD. The importance of this is that vimentin exhibits alternative 
charges on its surface (Strelkov et al., 2002, Chernyatina et al., 2012) and these may represent 
an alternative/additive mode of binding to a PRD. Furthermore, the recently elucidated structure 
of a fragment from keratin’s rod domain, desmoplakin’s preferred cytoskeletal binding partner 
(Lee et al., 2012), revealed that keratin has interesting surface charge properties. In contrast to 
vimentin, keratin exhibits one face which is entirely negatively charged while the other is entirely 
positively charged. The differences of surface charge properties between both the PRDs and 
cytoskeletal proteins may therefore reflect a mechanism of cytoskeletal preference which 
warrants further investigation. This is based on previous observations indicating that 
desmoplakin has a preference for keratin K8/K18 over desmin/vimentin in non phosphorylating 
conditions (Meng et al., 1997b) while plectin has a preference for desmin/vimentin over 
cytokeratins 5/14 (Steinböck et al., 2000).  
At the amino acid level an interesting difference exhibited for the envoplakin PRD is the random 
coil feature (as opposed to the typical β-hairpin) of PR4. The electron density of this region in 
both asymmetric units was well defined which suggested this observation was real. In addition to 
this, the typical electrostatic interaction observed between the negatively charged residue on S1 
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and the positively charged residue on H1 was abolished in PR4. The positively charged residue 
at position 19 was instead replaced by a neutral serine (S1961). This is in contrast to other PR4 
motifs from other PRDs where this interaction is retained. It is also possible that this feature 
exhibits flexibility based on the differences in its orientation between the two different molecules 
of the asymmetric unit (figure 5.52B). The importance of this putative flexible region comes from 
the fact that R1952 was proposed to be centrally located in the putative vimentin binding groove 
by HADDOCK (figure 5.76). In addition to this R1952 is proposed to bind to two negatively 
charged residues from vimentin (table 5.8). The flexibility of this region may allow extra freedom 
in orientating itself between the two negatively charged residues. To ascertain whether this 
proposed flexibility is functionally important, the electrostatic interaction could be artificially re-
established by mutagenizing S1961 to a positively charged residue e.g. a lysine. The mutant 
construct could then be crystallized and its structure elucidated. If the β-hairpin motif is re-
established with no alteration to binding properties it would suggest that the random coil feature 
is just a serendipitous observation. Regardless, it appears to warrant further investigation given 
R1952’s putative central role in its binding to vimentin.  
Overall, the structural elucidation of the envoplakin PRD has revealed novel insights in terms of 
general PRD fold with the observation of a C-terminal strand that completes the fold. 
Furthermore, it has established that although there are a variable number of PRDs at the C-
terminal tails of plakin family members, they are highly likely to acquire similar folds. Regardless, 
there are subtle differences between desmoplakin PRD C and the envoplakin PRD to key 
regions such as those in PR4 and the alternative negatively charged surface areas. This 
suggests that differences between the two domains may explain differing cytoskeletal 
preferences between different plakin family members and therefore warrants further 
investigation.        
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Chapter 6 - Identification and flexibility of a structured domain in the 
C-terminal tails of plakin proteins 
The C-terminal tails of plakin family members tether the desmosome (or in some cases IFs) to 
IFs and disruption of this link can lead to a variety of diseases. While some PRD to IF binding 
mechanisms were proposed in chapter 5, other studies have highlighted the importance of the 
highly homologous linker domains in these interactions (Steinböck et al., 2000, Fontao et al., 
2003, Kazerounian et al., 2002, Meng et al., 1997b). These studies showed that different plakin 
family linker domains bind to a variety of IFs. Understanding the intricate interplay between linker 
domains and PRD binding to IFs requires further investigation in order to resolve the responsible 
domains, residues, and mechanisms underlying IF binding and preferences.  
The linker domains, as they are known in the field, typically tether PRD B to PRD C at the C-
terminal tails of plakin family member proteins. Recent work on plectin corroborates the 
suggestion that binding to cytoskeletal proteins can be conducted solely by the linker domains 
independently of the PRDs (Favre et al., 2011, Karashima et al., 2012). They are also thought to 
facilitate dimerization between full length envoplakin and periplakin proteins even with their rod 
domains deleted (Karashima and Watt, 2002). Furthermore, they are implicated in the disease 
paraneoplastic pemphigus (Kiyokawa et al., 1998, Mahoney et al., 1998). This disease is 
characterised by the presence of circulating autoantibodies directed against plakin family 
members.  The envoplakin and periplakin linker domains harbour major antigenic sites but as 
yet, it is unclear whether the targeting of linker domains is the cause or consequence of the 
disease. The periplakin linker domain is also known to bind protein kinase B in which the linker 
domain is thought to be used as a scaffold (Heuvel et al., 2002).   
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As suggested by their name, linker domains are viewed as flexible/disordered elements in some 
reviews (Leung et al., 2002, Jefferson et al., 2004). Unfortunately, to date there is no available 
biophysical data on the linker domains. Given their critical role in cytoskeletal binding it was felt a 
structural approach would give a clearer indication as to how these interactions occur. Some 
authors have reported the presence of up to 2 PR motifs in these linker domains using the 
SMART database (Leung et al., 2002, Jefferson et al., 2004) but these observations have never 
been explored fully. Other motif identification servers do not corroborate the possible presence 
of 2 PR motifs. Indeed it is unusual to observe single PRs in isolation. It was shown in the 
previous chapter and the original study on PRDs (Choi et al, 2002) that a fully folded domain 
must contain a minimum of 4.5 repeats and some hydrophobic elements at the N and C termini. 
Indeed, linker domains may be disordered, since intrinsically disordered regions of proteins are 
capable of binding multiple partners such as that of the cytoplasmic tail of DSG our lab 
previously reported (Kami et al., 2009).  
Three other groups involved in solving desmosomal protein structures (Weis, Sonnenberg/De 
Pereda/Wiche) typically use X-ray crystallography. The use of X-ray crystallography is 
predominantly suited to proteins with rigid globular structures and attempting to solve these 
linker domains by this method alone was presumably deemed too high a risk by these groups.  
This is based on the fact that if the linker domains were disordered it would have made their 
structural elucidation by X-ray crystallography refractory. However, alternative methods such as 
NMR and SAXS allow for basic structural analysis of folded or unfolded regions to be assessed 
with low risk. These include whether the protein is folded, basic structural properties and 
ascertain whether sequence derived models fit SAXS scattering data. Using NMR and SAXS it 
was hoped the following questions could be answered: 
1) Are the linker domains folded or unfolded? 
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2) Are there conformational differences between the plakin family member linker domains? 
3) What governs their binding preferences for cytoskeletal proteins? 
4) How do envoplakin and periplakin linker domains interact to form the proposed 
heterodimer of their full length proteins? 
By understanding these structural and functional properties it was hoped it would give a clearer 
insight into the role of the linker domains and their intricate interplay with the PRDs to bind to 
cytoskeletal proteins. 
Due to the results of this chapter being collected towards the end of my PhD, collection of some 
experiments were carried out in collaboration with Miss Penelope Rodriguez-Zamora or Dr 
Claudia Fogl and will be stated as such within the text or figures legends.  
6.1 Construct design and purification 
6.11 Construct design 
Construct lengths were based primarily on previous reports (Karashima and Watt, 2002). The 
alignment on which these linker domain constrcts were based is given in figure 6.11. As the 
linker domains were thought to be flexible or disordered, it was decided that all the constructs 
should be GST tagged to increase solubility. Constructs were therefore cloned into pGex6P-1 








Figure 6.11 Linker domain alignment used for construct design 
The linker domain is a well defined sequence and aligns well between all the plakin family 
members which include: periplakin (PPL), envoplakin (EVPL), desmoplakin (DP) and plectin. 
Dark blue residues represent semi conserved residues while light blue residues represent 
conserved residues. Each entire plakin linker domain sequence depicted here was used as the 














6.12 Purification of linker domains 
Each linker domain contained a GST tag and in addition, the envoplakin linker domain contained 
a non-cleavable his-tag at its C-terminal end (LGHHHHHH). The GST fused envoplakin linker 
domain was purified using a GST column (GE Healthcare). The GST tag was cleaved by 
PreScission protease and the linker domain purified by gradient-step his-trap elution. The 
periplakin and desmoplakin linker domains were also purified using GST columns. The GST tag 
was cleaved by PreScission protease and finally a gradient step anionic Q-sepharose column 
(GE Healthcare) was used to separate the linkers domains and GST. Following purification, 
each linker domain was judge to be 95% pure as judged by SDS-PAGE analysis and therefore 







Figure 6.12 Final purity of linker domains assessed by SDS-PAGE analysis 
Each domain is >90% pure. Des: desmoplakin linker domain, Peri: periplakin linker domain, Env: 









6.2 Sedimentation velocity AUC profiles of the linker domains 
The oligomeric state of the envoplakin and periplakin linker domains was unknown but both had 
been postulated to interact with one another (Karashima and Watt, 2002). Both the envoplakin 
and periplakin linkers were individually subjected to sedimentation velocity AUC to gauge their 
oligomeric states in solution in 20mM HEPES (pH 7.5) and 100 mM NaCl at 10 µM. In addition 
both were mixed at equimolar ratios to ascertain whether a complex (and therefore higher 
molecular weight species) could be observed. The results were analyzed by SEDFIT and shown 
in figure 6.2. It revealed two single peaks for both the envoplakin and periplakin linker domains 
at 11.5 and 11.8 kDa which suggested that each protein is monomeric. Although not shown, a 
complex of the two was not observed when the envoplakin and periplakin linkers were mixed 
together as only single species were observed which superimposed over the monomeric peaks 
of envoplakin and periplakin. This suggests that both linker domains are monomeric, and that a 
complex does not form at equimolar ratios unlike previous suggestions (Karashima and Watt, 
2002). The desmoplakin linker domain was also monomeric in solution (Personal 
communication: Miss Penelope Rodriguez-Zamora). To further characterize the fold of each 










Figure 6.2 Sedimentation velocity AUC of the envoplakin and periplakin linker 
domains 
The envoplakin and periplakin linker domains at 10 µM were subjected to AUC analysis in 20 
mM Hepes (pH 7.5) and 100 mM NaCl at 10 µM using a Beckman XL-1 ultracentrifuge at 25000 
rpm at 20 °C. A single species was observed for both proteins at 11.5 and 11.8 kDa for the 
periplakin and envoplakin linker domains respectively. The data reveal that both proteins are 
monomeric in solution. Molecular weights derived from AUC are within acceptable error ranges 
of sequence derived molecular weight estimations of 12.5 and 13.5 kDa for the periplakin and 





















6.3 2D-HSQC NMR analysis of the linker domains 
Bacteria transformed with linker domain constructs were grown and expressed in minimal media 
supplemented with 15N labelled ammonium chloride. Expression and purification of the linker 
domains revealed no significant differences in yield or purity when compared to their unlabelled 
counterparts. Following purification they were analyzed by 2D-HSQC NMR analysis to gauge 
their overall fold.   
6.31 2D-HSQC NMR analysis of the envoplakin linker domain 
Since it was anticipated the linker domains were unstructured/disordered an HSQC was 
conducted in the presence of the GST tag to retain solubility in solution. Typically the combined 
size of monomeric GST and the envoplakin linker (38 kDa) is beyond the optimal size limit of 
NMR. NMR has previously been used as an effective strategy to deduce the structural integrity 
of a GST-tagged protein (Liew et al., 2008). The GST tag forms a homodimer independently of 
its fusion partner. The GST tag therefore tumbles at a rate unfavourable for NMR which results 
in most GST peaks broadening out. The remaining observable peaks from GST are often 
weaker in intensity than those of the fusion protein of interest. The vector sequence between 
GST and its fusion partner is elongated and flexible enough to allow independent tumbling of the 
fusion partner. The independent motion of the fusion protein can therefore tumble as if the GST 
was not present. This effectively means that the predominant peaks observed in the HSQC 
originate from the fusion partner of interest. The possibility exists that fusion proteins could be 
used for future structure determination of more challenging proteins.  
When the fusion-protein was analyzed by 2D-HSQC NMR a well dispersed spectrum was 
observed indicative of a well folded protein (figure 6.31). Peak intensities are not isotropic which 
merely reflect the differences in observed origins of the peaks e.g. loop regions in GST (low 
intensities) and the linker domain itself (high intensities). To confirm that the high intensity peaks 
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observed in the dispersed regions originate from the envoplakin linker domain, the GST tag was 
cleaved, removed and run again by 2D-HSQC NMR and analyzed. Figure 6.32 shows the 
envoplakin linker domain in isolation (without GST) which again indicated that the original high 
intensity peaks observed in figure 6.31 originated from the envoplakin linker domain. Closer 
inspection by eye of the HSQC also facilitates the qualitative assessment of the secondary 
structure content. Proteins of high α-helical content contain peaks which disperse well between 
7.5 ppm and 8.5 ppm on the 1H chemical shift axis (see SR78 for an example – figure 3.73). 
Proteins of mixed α-helical and β-sheet content exhibit contain dispersion between 7 ppm and 
9.5 ppm (see envoplakin PRD – figure 5.3). The envoplakin linker domain appeared to have the 
dispersion of a mixed α-helical and β-sheet containing protein. Overall this confirmed that the 
envoplakin linker domain was not a flexible/unstructured tether as previously presumed and was 
actually a well folded protein with a stable tertiary fold. Whether the periplakin and desmoplakin 











Figure 6.31 2D-HSQC of GST-fused envoplakin linker domain 
The GST-fused envoplakin linker domain was analyzed by 2D-HSQC NMR analysis. The protein 
was analyzed using an Agilent 600 MHz spectrometer in 20 mM Hepes (pH 7.2) and 100 mM 
NaCl at 250 µM with a temperature at 298 K. The spectrum is indicative of a well folded protein 
as revealed by its well dispersed peaks between 7.5 ppm and 9.7 ppm. The peaks are not 
uniform in intensity; this is to be expected given that some low intensity peaks will be observed 








Figure 6.32 2D-HSQC of the envoplakin linker domain 
The envoplakin linker domain in isolation was analyzed by 2D-HSQC NMR analysis. The protein 
was analyzed using an Agilent 600 MHz spectrometer in 20 mM Hepes (pH 7.2) and 100 mM 
NaCl at 200 µM with a temperature at 298 K. Since these peaks correspond with the high 
intensity peaks observed in the GST-fused variant of the envoplakin linker domain, it confirms 









6.32 2D-HSQC NMR analysis of the periplakin linker domain 
Since the envoplakin linker domain was folded and all linker domains are highly homologous it 
was highly likely periplakin would similarly be folded without the presence of GST. It was 
therefore decided that the HSQC experiment would be conducted post GST cleavage. The 
periplakin linker domain was analyzed by 2D-HSQC NMR and a well dispersed spectrum was 
observed (figure 6.43). This suggested that the periplakin linker domain was well folded with a 
stable tertiary fold. Both the envoplakin linker domain and the envoplakin PRD have spectra 
indicative of mixed α-helical and β-sheet secondary structure content. Since the periplakin linker 
domain shares a similar HSQC to both the envoplakin linker domain and the envoplakin PRD it 













Figure 6.33 2D-HSQC NMR analysis of the periplakin linker 
The periplakin linker domain was analyzed by 2D-HSQC NMR analysis. The protein was 
analyzed using an Agilent 600 MHz spectrometer in 20 mM Hepes (pH 7.2) and 100 mM NaCl at 
250 µM at a temperature at 298 K. A well dispersed spectrum is observed indicative of a protein 







6.33 2D-HSQC NMR analysis of the desmoplakin linker domain     
Since both envoplakin and periplakin linker domains were folded, it was highly likely the 
desmoplakin linker domain was similarly folded. The high sequence homology to other plakin 
family linker domains also suggested that the fold would be retained in the desmoplakin linker 
domain. This was investigated by 2D-HSQC NMR analysis. Once again a well dispersed 
spectrum was observed (figure 6.44). The spectrum was similar to those of envoplakin and 
periplakin also implying mixed α-helical and β-sheet secondary structure content. This therefore 






Figure 6.34 2D-HSQC of the desmoplakin linker domain 
The desmoplakin linker domain was analyzed by 2D-HSQC NMR analysis. The protein was 
analyzed by an Agilent 600 MHz spectrometer in 20 mM Hepes (pH 7.2) and 100 mM NaCl at 
100 µM at a temperature of 298 K. A well dispersed spectrum is observed indicative of well 
folded protein. Protein purification and NMR analysis conducted in collaboration with Miss 








6.4 Modelling and SAXS analysis of the linker domains 
Due to time constraints crystallization trials and further NMR experiments of the plakin linker 
domains were not possible. Since the linker domain fold of any plakin protein was unknown, it 
was decided that a modelling approach in combination with SAXS could be used to ascertain its 
structure. Based on the high homology between the linker domain plakin sequences it was 
highly likely that they share the same overall fold. Firstly, the sequences of each linker domain 
were fed to the I-TASSER server in order to acquire an atomic resolution model and in parallel, 
their sequences aligned to ascertain potential motifs. This data was then combined with SAXS 
scattering curves which were acquired for the desmoplakin and periplakin linker domains. 
6.41 Sequence based modelling of the envoplakin, desmoplakin and periplakin 
linker domain 
Modelling of the envoplakin linker domain was carried out first. The I-TASSER server selected 
desmoplakin PRD C and PRD B as templates (PDB codes 1LM5 and 1LM7 respectively) for the 
envoplakin linker domain with 14 and 11% identity respectively. Five models were created based 
on these templates. Although the sequence identity was low, it revealed the possible presence 
of two plakin repeat like motifs separated by a short flexible region which I have tentatively called 
the “WEE box” since it contains a highly conserved Trp, Glu, Glu, motif (figure 6.1). Being 
centrally located in the domain sequence and separating the two PR motifs it was envisaged that 
the WEE box would be an important feature of each linker domain. Superimposition of the 5 
models generated by I-TASSER revealed a high level of convergence between the plakin repeat 
motifs of the different models. There was however a large degree of deviation observed between 
the WEE box of each model (figure 6.41). The convergence of the plakin repeat motif models 
suggests a measure of confidence in their general structure, however the ambiguity surrounding 
the modelling of the WEE box suggested it was potentially disordered. Models created for 
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desmoplakin and periplakin revealed a similar fold. To evaluate how similar these PR like motifs 
resembled actual plakin repeats motifs, all three linker domain sequences were aligned against 
canonical motifs of known structure (figure 6.42). Each of the proposed linker domain PR like 
motifs reveals a striking similarity to a canonical PR motif of known structure, which inferred a 
similar topology or fold. 
In the first proposed PR motif the obligatory negatively charged residue at position 4 is 
conserved as Glu and Asp in envoplakin and desmoplakin respectively. At the same position a 
negatively charged residue is not observed in periplakin and consisted of a His. The negative 
charge is required for an interaction with a positively charged residue at position 19. The 
positively charged residue at position 19 is retained in envoplakin and desmoplakin as an Arg 
and Lys residue respectively, but is altered in periplakin to an Ala. This interaction is required to 
“fix” the β-hairpin into position. It suggests that periplakin, presumably devoid of this interaction, 
may allow the β-hairpin free movement. Alternatively, this putative PR motif β-hairpin may be 
observed as a random coil reminiscent to those of PR4 in the envoplakin PRD (see figure 5.52). 
The hydrophobic interaction between the two anti parallel α-helices is also retained whereby the 
Ile and Leu residues at positions 22 and 30 respectively are identical between the linker domains 
and the canonical plakin repeat motifs. This suggested that in all 3 linker domains the α-helical 
fold / topology is retained.  
The second proposed PR motif appears slightly more divergent than the first although does 
retain some general properties that can still class this region as a PR like motif. At position 4 the 
negatively charged Asp residue is conserved entirely in each linker domain sequence. 
Interestingly the positively charged residue required at position 19 is conserved in desmoplakin 
as a lysine but is shifted two amino acids (position 21) along in envoplakin and periplakin as an 
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Arg. Both the envoplakin and periplakin models suggested that, like the desmoplakin model this 
shifted Arg retained the ability to interact with the Asp residue at position 4 (figure 6.53).     
It therefore appears highly likely that the linker domains harbour two PR like motifs. This is 
consistent with the NMR data which suggests the presence of mixed α-helical and β-sheet 
secondary structure content. The WEE box which sits between the two PR motifs remains could 
not be modelled effectively. Whether this motif is disordered or contains secondary structure was 
of interest. SAXS was therefore used by building low resolution models to resolve the structure 















Figure 6.41 Superimposition of 5 models of the envoplakin linker domain by I-
TASSER 
Five models created by I-TASSER based on the envoplakin linker sequence were created using 
desmoplakin PRD B and PRD C as templates (pdb codes: 1LM7 and 1LM5 respectively). 
Highlighted are the N and C termini, the plakin repeat β-hairpin (PRxβ, where x is the plakin 
repeat it belongs to – see text) and the plakin repeat antiparallel α-helices (PRxα, where x is the 
plakin repeat it belongs to – see text). It reveals a strong convergence between the plakin repeat 
motifs but divergence between the WEE box separating the two repeats. The WEE box between 









Figure 6.42 Identification of two plakin repeat motifs within the linker domain 
sequences of envoplakin, periplakin and desmoplakin 
Linker domain sequences of envoplakin (Env_Link), periplakin (PP_Link) and desmoplakin 
(Des_link) were aligned with the fourth PR motif of PRD C (Des_PRD_C_PR4) and the third of 
PRD B (Des_PRD_B_PR3) of desmoplakin by CLUSTALW (Thompson et al., 1994) which had 
both been structurally elucidated. N.B The entire sequence of the linker domains is not shown 
(as in figure 6.1). Secondary structure elements expected at particular positions are shown (S1: 
strand 1, S2: strand 2, H1: helix 1, H2: helix 2). Furthermore the numerical position of each 
amino acid within the 38 amino acid motif is highlighted. Semi colons represent high homology, 
full stops represent some homology and asterisks represent identical residues. Highlighted in 
yellow are residues involved in “fixing” the β-harpin in position. Highlighted in red are 
hydrophobic residues involved in the correct orientation and folding of the anti parallel α-helices 










Figure 6.43 Superimposition of plakin repeats 1 and plakin repeats 2 of the 
desmoplakin, envoplakin and periplakin linker domains 
PR motifs from sequence derived models of desmoplakin (yellow), envoplakin (red), and 
periplakin (blue) linker domains. PR1 of each linker domain is superimposed on the left and PR2 
is superimposed on the right. The typical β-harpin and anti-parallel α-helices for canonical 38 












6.42 SAXS analysis of the desmoplakin and periplakin linker domains 
SAXS provides experimental low-resolution structural information in the absence of high 
resolution NMR or X-ray crystallography data. Given the high sequence similarity and well 
dispersed 2D-HSQC spectra of each linker domain, it was anticipated that the linker domains 
would be good candidates for SAXS analysis.  For the SAXS analysis, purification was carried 
out in collaboration with Miss Penelope Rodriguez-Zamora and Dr Claudia Fogl. SAXS 
scattering curves were successfully acquired for the desmoplakin and periplakin linker domains. 
SAXS was attempted on the envoplakin linker domain but the protein experienced radiation 
damage and was subsequently omitted from the analysis.  
Signal to noise ratios of buffer subtracted SAXS scattering curves for both the desmoplakin and 
periplakin linker domains were excellent and superimposed and compared in figure 6.44. Rg 
values as calculated by GNOM were 1.8 and 2.3 nm for desmoplakin and periplakin 
respectively. Dmax values were calculated by GNOM as 5.8 and 8.3 nm for desmoplakin and 
periplakin respectively (table 6.1). Since the Rg and Dmax values significantly differ between the 
desmoplakin and periplakin linker domains it is immediately clear that given the low resolutions 
permitted by SAXS, both domains exhibit considerable differences in their structures. This can 
be more clearly observed in the overlay of their respective SAXS scattering curves in figure 6.44. 
Interestingly the Rg and Dmax values of desmoplakin and periplakin are similar to that shown for 
the envoplakin PRD (1.9 and 5.6 nm respectively) (section 5.7), which is twice the size of the 
linker domains by molecular weight. To ascertain the structures of both domains, ab-initio 






Figure 6.44 SAXS scattering curves of the periplakin and desmoplakin linker 
domains 
Final scaled and merged SAXS scattering curves of the periplakin (yellow) and desmoplakin 
(red) linker domains are superimposed and shown (utilizing 10 mg/ml data sets). The scattering 
curves reveal a degree of heterogeneity suggesting their overall conformations in solution are 







Rigid body ab-initio modelling of the desmoplakin and periplakin linker domains were conducted. 
It revealed an extended conformation for both domains which corroborated the Rg and Dmax 
values (figure 6.45). Both structures are similar except that periplakin is larger. When a 
sequence derived I-TASSER model was superimposed onto the ab-initio model by SUPCOMB it 
revealed a large proportion unoccupied for both periplakin and desmoplakin (data not shown). 
This is further highlighted by theoretical SAXS scattering curves achieving χ2 values of 1.74 and 
4.03 for desmoplakin and periplakin respectively (table 6.1). This suggested that rigid 
monomeric models were not valid for both desmoplakin and periplakin. However, since the linker 
domains appeared to adopt similar Rg and Dmax values to the envoplakin PRD it was possible 
that in solution they may be forming dimers.  
Using the ab-initio models as “starting points”, two molecules from the model were manually 
inserted into their respective SAXS derived ab-inito models. A theoretical SAXS scattering curve 
was created based on the manually derived dimeric model for desmoplakin and was 
superimposed onto the experimental curve. Using CRYSOL a χ2 value of 2.44 was achieved 
(figure 6.46). This suggested that the dimeric model is less likely to exist in solution compared to 
that of the monomeric model given the increase in the χ2 value and poorer fit to the SAXS 
scattering curve. Collectively, this suggests that the desmoplakin linker domain is neither a rigid 
monomeric or dimeric protein and further modelling would be required to ascertain its fold 
(discussed further in 6.5).  
A similar approach was applied to the periplakin linker domain. A rigid dimeric model achieved a 
significantly lower χ2 value of 0.84 and also fit the data well (figures 6.47 and 6.48). This 
suggests that the periplakin linker domain in solution is highly likely to be a dimer. This is in stark 
contrast to the findings of section 6.2 where AUC analysis suggested the domain was 
monomeric. AUC analysis for this study was typically conducted at far lower concentrations than 
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those required for SAXS, NMR and X-ray crystallography. AUC could have been performed at 
higher concentrations however, was not conducted due to time constraints. However, it is 
possible to gauge whether this phenomenon was a concentration dependent effect using the 
SAXS scattering curves at a range of different concentrations and superimpose them on top of 
one another. When the desmoplakin SAXS scattering patterns were superimposed onto one 
another, it revealed no differences for desmoplakin at 3.2, 5 and 10 mg /ml (appendix G). 
Similarly when the SAXS scattering patterns of periplakin were superimposed onto one another 
it revealed no differences at 1, 5 and 10 mg/ml (appendix H). This suggests that the findings of 
the linker domain oligomeric states by SAXS analysis and modelling are valid. It also implies that 
for periplakin the dimerization process is concentration dependent whereby dimerization occurs 
at a concentration between 10 µM (0.1 mg/ml) and 80 µM (1 mg/ml). Therefore, the dimeric 
model of the periplakin linker domain appears to represent its structure in solution although the 
models produced for that of the desmoplakin linker domain did not fit the data and required 
further exploration. 





Desmoplakin linker 1.8 5.3 1.74 2.44 
Periplakin linker 2.3 8.3 4.03 0.84 
 
Table 6.1 GNOM and CRYSOL derived SAXS parameters for the desmoplakin and 
periplakin linker domains 
Rg and Dmax values were calculated for the desmoplakin and periplakin linker domains by 
GNOM. The data revealed significant differences between the two domains. Sequence derived 
models were created by I-TASSER and were superimposed by CRYSOL. I-TASSER derived 
monomeric models gave poor fits with high χ2 values which suggest these models do not 
represent the proteins in solution. Similarly a dimeric model fit poorly for the desmoplakin linker 
domain.  A dimeric model however fit well for the periplakin linker with a low χ2 value suggesting 






Figure 6.45 Ab-initio models of the periplakin and desmoplakin linker domains 
 
Ab-initio bead models for periplakin (yellow) and desmoplakin (red) were created based on 
previously described methods and visualised using PYMOL. A: Periplakin linker domain shown 
in two orthogonal views. B: desmoplakin linker domain shown in two orthogonal views. C: mesh 
models of desmoplakin (red) manually superimposed onto periplakin (yellow). It reveals a large 
degree of heterogeneity between the two domains and corroborates the differences observed for 














Figure 6.46 SAXS scattering curve of the desmoplakin linker domain 
The SAXS scattering curve for the desmoplakin linker domain was created from scaled and 
merged buffer subtracted data from 10, 5 and 3.2 mg/ml samples (black) in 20 mM Hepes (pH 
7.5) and 100 mM NaCl. When a monomeric sequence derived model from I-TASSER had a 
theoretical SAXS scattering curve superimposed over the experimental curve (red) a poor fit is 
observed. Similarly, when a dimeric model was created (see text) the fit is even poorer (yellow). 
The data analysis and purification was conducted collaboratively with Miss Penelope Rodriguez-






Figure 6.47 SAXS scattering curve of the periplakin linker domain 
The SAXS scattering curve for the periplakin linker domain was created from scaled and merged 
buffer subtracted data from 10 mg/ml, 5 mg/ml and 1 mg/ml samples (black) in 20 mM Hepes 
(pH 7.5) and 100 mM NaCl. When a sequence derived monomeric model from I-TASSER had a 
theoretical SAXS scattering curve superimposed over the experimental curve (red) a poor fit is 
observed. However, when a dimeric model was created (see text) the fit is significantly 
improved. This suggests that the dimeric model is more representational of the protein in 













Figure 6.48 Dimeric periplakin linker domain model based on the ab-initio 
envelope 
A dimeric model (molecule 1: cyan, molecule 2: red) for the periplakin linker domain was based 
on the ab-initio envelope created by SAXS analysis and visualised by PYMOL. The manually 
inserted model represents the best possible fit by visual inspection. Interestingly the N-terminal 





Two approaches were attempted to structurally characterize the desmoplakin linker domain in 
order to investigate the possibilities of dynamics, an extended structure or both. The “starting 
point” for each approach used the sequence derived model by I-TASSER. The first approach 
assumed that protein was compact (the compact model) while the other assumed the protein is 
extended (the extended model). Alternative rigid models and flexible ensembles utilized the 
programmes CRYSOL and EOM respectively. A flow diagram elaborating the two different 
















Figure 6.49 A flow diagram representing the approaches to be used for assessing 
the fold of the desmoplakin linker domain. 
To further elucidate the fold and dynamics of the desmoplakin linker domain two approaches 
were used, utilizing SAXS analysis by EOM and CRYSOL. The first approach “the compact 
model” assumed the protein adopts a compact conformation. Two models were created using 
this approach in which one (A) contains a flexible WEE box and the other (B) contained flexible 
termini (residues indicated), while the rest of the protein was set as rigid. The other approach 
“the extended model” assumed the protein adopted an extended conformation which was 
manually extended to fit around the ab-initio model in which one model (C) was entirely rigid and 
the other (D) contained flexible termini (residues indicated) whereas the rest of the domain was 
set as rigid.  
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6.5 Modelling alternative approaches to ascertain the fold of the desmoplakin 
linker domain  
6.51 Modelling dynamics of the proposed compact desmoplakin linker domain 
model 
The first approach assumed the protein was compact based on the sequence based modelling. 
Plakin repeat motifs were set as structured on the basis of the observation of a mixed α-helical 
and β-sheet content indicated by 2D-HSQC NMR (figures 6.32-6.34), modelling results (figure 
6.41) and sequence alignments to canonical motifs (figure 6.42). This left the N terminus, C 
terminus and the WEE box, which were of a more ambiguous topology. Two models were 
therefore created. In the first, the termini were designated as flexible. In the second the WEE 
box was set as flexible and the rest of the domain as structured. The aim was to investigate 
which of the two models is more representative of the SAXS scattering data and therefore 
indicate approximate flexible or extended regions in the linker domain sequences.  
The precise residues selected to ascertain flexibility in the two desmoplakin linker domain 
models are indicated in figure 6.51. The flexible termini model appears to fit relatively well, and 
has a χ2 value lower than that of the original compact model fit (1.5 as opposed to 1.7). This 
suggests that some flexibility is likely to occur within the sequence. However, the fit does not 
exactly match the SAXS scattering data, and is therefore unlikely to give a significant 
contribution to the proposed flexibility of the domain. The flexible WEE box model however, 
matches perfectly throughout the SAXS scattering curve and gives a χ2 value of 0.74. This 
suggests that this model is more representative of the data when compared to the original 
compact model and a flexible termini model. An ensemble of the best 20 models calculated by 
RANCH and GAJOE is given in figure 6.52. Interestingly, the programme GAJOE appears to 
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select an ensemble in which the WEE box is predominantly extended and present within the 
core of the protein. This implied that extension and flexibility of the sequence derived model 
through the WEE box fitted the data well and was corroborated by the higher than expected Rg 
and Dmax values by GNOM. This suggests that the WEE box was significantly contributing to the 
flexibility of the protein and suggested that the linker domain contains a mix of structured and 
unstructured elements.  It must be stressed again, that given the low resolution of SAXS, the 
precise amino acid sequence contributing to the flexibility cannot be located. It does suggest 
however, that the flexibility and extension may be internally located within the core of the domain 
and that given the WEE box is of unknown structure it was a strong candidate. A second 
approach was also used to counter this argument by assuming that the entire protein may be 














Figure 6.51 Flexibility of the compact model 
The compact model was assessed for flexibility using the EOM suite discussed earlier using two 
different variants. One model had a flexible WEE box and rigid plakin repeat motifs and termini 
(yellow), while the other had a rigidified WEE box and plakin repeat motifs and flexible termini 
(red). Indicated are schematic diagrams of the two models, the WEE box and regions of 
flexibility and their sequences. 10000 random models were created by RANCH and a subset of 
20 models were selected by GAJOE that best fit the SAXS scattering curve using the ATSAS 
online web server (Petoukhov et al., 2007). This revealed that the model containing the flexible 
WEE box fits the data better than the flexible termini model. This is indicated by the χ2 values of 






Figure 6.52 Selected ensemble of the flexible WEE box compact model 
A subset of the 20 best flexible compact models representative of the SAXS scattering data was 
superimposed by CHIMERA. For ease of viewing the models were superimposed at the WEE 
box sequence (purple) with PR1 and PR2 shown in red and green respectively. It reveals 












6.52 Modelling dynamics of the proposed extended desmoplakin linker domain 
model 
To ascertain the orientation of a putative extended model the sequence derived model was used 
as the starting point. The sequence derived model of the desmoplakin linker domain was 
remodelled manually about the WEE box keeping it within the core of the protein so that the 
model fit the ab-initio envelope better (figure 6.53). To gauge whether this was representative of 
the SAXS data, a theoretical SAXS scattering curve of the extended desmoplakin linker domain 
was superimposed onto the experimental data by CRYSOL. When compared to the original 
sequence based model this revealed a significant improvement in the χ2 value which dropped 
from 1.5 to 0.89 (figure 6.54). However, closer inspection reveals that at higher angles the fit still 
did not match the SAXS scattering data. This suggested that when compared to the compact 
model, extension around the WEE box improved the fit to the SAXS scattering curve, but further 
improvements were still required. Since the N and C termini were set as rigid in this model it was 
decided that these may by disordered based on the secondary structure predictions. A second 
extended model was created whereby the core region of the linker domain was set as a 
structured element (PR1+WEE box+PR2), and the termini were set as flexible. This revealed an 
excellent fit throughout the SAXS scattering curve with a χ2 value of 0.74 and suggested this 
model is also representative of the protein in solution (figure 6.54). An ensemble of the best 
flexible extended 20 models representative of the SAXS scattering data is shown in figure 6.55. 
This revealed a modest degree of flexibility in the termini suggesting that the termini may 
possess secondary structure elements since the termini appear to “cap” the rigid domains. The 
same ability is retained in PRDs where the non-PR N and C termini are used to cap and 
correctly fold the PRD (as was the case with the envoplakin PRD). Unfortunately, until structural 
determination of the termini has been completed this cannot be validated.   
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Overall, modelling of both a flexible WEE box compact model and a flexible termini extended 
model both fit the data well. They appear to corroborate each other in that the flexible compact 
model sets the WEE box as centrally located within the core of the protein, while the flexible 
extended model also suggested this is required to extend the protein. 
Model 2 Fit to the data Flexible residues 
Sequence derived I-TASSER 
model (monomer) 1.73 No None 
Sequence derived I-TASSER 
model (dimer) 2.44 No None 
Flexible WEE box compact model 0.74 Yes 2497-2506 
Flexible termini compact model 1.51 No 2454-2462 and 2557-2565 
Rigid extended model 0.89 No None 
Flexible termini extended model 0.74 Yes 2454-2462 and 2557-2565 
 
Table 6.2 Final modelling and SAXS statistics of the desmoplakin linker domain 
CRYSOL (rigid models) and EOM (flexible models) based fitting of the desmoplakin linker 
domain to its SAXS scattering curves. Important considerations include low χ2 values (~1) and 
whether the curve fit the experimental data set. Also indicated are regions selected for flexibility 






Figure 6.53 Creation of the extended desmoplakin linker domain model based on 
the ab-initio envelope 
An extended model was manually created based on the ab-initio envelope created from the 
SAXS data, using the sequence derived compact model as the starting point in PYMOL. The 
WEE box was kept centrally located based on the information from the flexible model in 6.52 and 
also on the fact that it allowed most of the envelope to be occupied by structural regions. 
Indicated are plakin repeat repeat 1 β-hairpin (PR1β), plakin repeat 1 anti parallel α-helices 
(PR1α), both in red, the WEE box (in gold), plakin repeat repeat 2 β-hairpin (PR2β) and plakin 




Figure 6.54 Assessment of flexibility using the extended desmoplakin linker 
domain model 
The extended model was assessed for flexibility using the EOM suite discussed earlier using two 
variants. Both were based on the extended model created in figure 6.53. One was left entirely 
rigid (yellow), while the other was predominantly rigid with flexible termini (red). Indicated are 
schematic diagrams of the two models, the WEE box and regions of flexibility and their 
sequences. 10000 random models were created by RANCH and a subset of 20 models was 
selected by GAJOE that best fit the SAXS scattering curve using the ATSAS online web server 
(Petoukhov et al., 2007). It revealed that the model containing the flexible termini best fit the data 
when compared to the entirely rigid extended model. This is indicated by the χ2 values of 0.74 




Figure 6.55 Selected ensemble of the flexible termini extended model 
A subset of the 20 best flexible termini extended models representative of the SAXS scattering 
data was superimposed at the rigid PR1, WEE box and PR2 region (blue) by CHIMERA. The 
rigid PR1, WEE box and PR2 region are shown in blue. It revealed a modest degree of flexibility 
with the termini folding over to “cap” the rigid region. Also indicated is the N terminus (red), and 







To determine whether similar models were also representational of the periplakin linker domain 
the same approach used to estimate the conformation of the desmoplakin linker domain was 
also applied to periplakin. Table 6.3 reveals that the rigid dimeric conformation originally 
discussed in section 6.42 is still the most valid conformation based on the SAXS analysis. 
 
Table 6.3 Final modelling and SAXS statistics of the periplakin linker domain 
CRYSOL (rigid models) and EOM (flexible models) based fitting of the periplakin linker domain 
to its SAXS scattering curves. Important considerations include low χ2 values (~1) and whether 
the curve fit the experimental data set. Also indicated are regions selected for flexibility during 




6.6 2D-HSQC NMR binding studies using vimentin and the envoplakin and 
periplakin linker domains 
6.61 Investigating the interaction between the envoplakin and periplakin linker 
domains by 2D-HSQC NMR 
Full length periplakin and envoplakin are hetero-dimers (Ruhrberg et al., 1997). The domain 
responsible for this, the rod domain, is also responsible for homo-dimerization in desmoplakin. 
Karashima and Watt (2002) suggested that although the rod domain was important for hetero-
Model 2 Fit to the data Flexible residues 
Sequence derived I-TASSER model 
(monomer) 4.03 No None 
Sequence derived I-TASSER model 
(dimer) 0.84 Yes None 
Flexible WEE box compact model 1.95 No 1689-1698 
Flexible termini compact model 4.97 No 1646-1655 and 1748-1756 
Rigid extended model 3.72 No None 
Flexible termini extended model 2.02 No 1646-1655 and 1748-1756 
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dimerization the linker domains of periplakin and envoplakin could also interact and facilitate 
dimerization even when the rod domains were deleted. As the experiment was conducted in vivo 
it was felt that this interaction would benefit from being studied in vitro as it would show a direct 
interaction and if possible identify residues important to this interaction. A complex of both the 
envoplakin and periplakin linker domains was not observed by sedimentation velocity AUC (in 
section 6.2). To confirm that complex formation does not take place NMR spectroscopy was 
used. Using a 2D-HSQC, unlabelled envoplakin linker domain was titrated against 15N labelled 
periplakin linker domain. The same experiment was conducted again except that the labelling 
strategy was reversed.  Both titrations indicated that a direct interaction between the envoplakin 
linker and periplakin linker domains was unlikely to occur due to the lack of any chemical shifts 
or line broadening (figures 6.61 and 6.62). This was the case even when either unlabelled linker 
protein was present in molar excess. The results suggested that the findings of Karashima and 
Watt either needed further investigation or that dimerization was dependent on interaction with 
another ligand, most likely vimentin. This was suggested as a possibility by Karashima and Watt 
but was never validated. To confirm this result was valid it was important to verify the functional 
properties of either the periplakin or envoplakin linker domain. This is due to the possibility of 
non-native folding caused by in-vitro expression in E.coli which is devoid of post-translational 
modifications often required to fold proteins or domains in eukaryotes. To validate the lack of 
interaction between the periplakin linker and envoplakin linker, unlabelled vimentin was titrated 
against 15N labelled periplakin linker. This is based on previous observations of the periplakin 
linker domain binding to vimentin by different labs (Karashima and Watt, 2002, Kazerounian et 




Figure 6.61 15N labelled periplakin linker titration with unlabelled envoplakin linker 
domain 
A titration of 15N labelled periplakin linker domain against unlabelled envoplakin linker domain 
was conducted and analyzed by 2D-HSQC NMR analysis. The titration was analyzed on an 
Agilent 600 MHz spectrometer in 20 mM Hepes (pH 7.2) and 100 mM NaCl at 298 K with 
periplakin linker at 150 µM alone (blue) and at 150 µM in the presence of 150 µM envoplakin 
linker domain (maroon). At a ratio of 1:1 an interaction between the two is not observed – as 






Figure 6.62 15N labelled envoplakin linker titration with unlabelled periplakin linker  
A titration of 15N labelled envoplakin linker domain against unlabelled periplakin linker domain 
was conducted and analyzed by 2D-HSQC NMR analysis. The titration was analyzed on an 
Agilent 600 MHz spectrometer in 20 mM Hepes (pH 7.2) and 100 mM NaCl at 298K with 
envoplakin linker at 250 µM alone (blue) and at 250 µM in the presence of 250 µM periplakin 
linker domain (red). At a ratio of 1:1 an interaction between the two is not observed – as shown 





6.62 Investigating the interaction between the periplakin linker domain and 
vimentin by 2D-HSQC NMR 
As stated in the previous chapter vimentin was purified from insoluble inclusion bodies although 
the folded nature of vimentin was not investigated. Once urea was completely removed vimentin 
had previously been shown able to independently fold and forms a mixture of monomers and 
tetramers in vitro (Quinlan et al., 1986). For simplicity the following titrations were conducted in 
the absence of salt (i.e. binding to monomeric/tetrameric vimentin).  
Previous reports have shown that the periplakin linker domain is capable of binding to vimentin 
(Karashima and Watt, 2002, Kazerounian et al., 2002). As well as validating the functional 
capability of the in-vitro purified periplakin linker domain, it was important to validate experiments 
that had been conducted in vivo by an in vitro study as it would show a direct interaction. Using a 
2D-HSQC, unlabelled vimentin was titrated against 15N labelled periplakin linker in an attempt to 
document a direct interaction and if possible identify residues important to this interaction. Due 
to the lack of time and protein only one titration point was used. The first time point used 
periplakin linker at 100 µM alone. The second used the periplakin linker domain and vimentin at 
200 µM and 100 µM respectively, in Tris pH 7. 
As expected the periplakin linker domain bound to unpolymerized vimentin. This can be 
observed by the extreme line broadening of the periplakin linker peaks in the HSQC due to 
complex formation, which is unresolvable by NMR. Even when the periplakin linker domain to 
vimentin ratio was as low as 2:1, a significant portion of the peaks disappeared (~80%). The 
extreme line broadening suggested two possibilities: firstly, the interaction is extremely strong 
i.e. nanomolar or tighter. This is because if the interaction was weak i.e. in fast exchange, on the 
NMR time scale, this would be observable by seeing gradual chemical shift perturbations. In 
addition this it may be a reflection of the fact that interaction of the periplakin linker domain with 
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vimentin would lead to a complex of molecular weight of at least 65kDa (monomeric vimentin is 
53kDa) and the complexed proteins would tumble too slowly for peaks to be observed in an 
HSQC spectrum.  As significant line broadening occurred upon binding of the linker domain to 
vimentin it was impossible to locate peaks, and so identify residues critical to this interaction. 
The possibility that the periplakin linker domain binds strongly to vimentin may explain why 
periplakin has no plakin repeat domain at its C-terminal end. Envoplakin has both a linker 
domain and a plakin repeat domain (shown in the previous chapter to bind to vimentin). To test 
whether the ability of the periplakin linker domain to bind vimentin was unique or a common 
property of all linker domains, the envoplakin linker domain was 15N labelled and titrated against 







6.63 Titration of unlabelled vimentin to 15N labelled periplakin linker 
The proteins were analyzed by an Agilent 600 MHz spectrometer in 20 mM Tris (pH7) with 
periplakin linker domain alone at a concentration of 100 µM (red) and in the presence of 50 µM 
vimentin (green). In the presence of vimentin approximately 95% of peaks observed for the 
periplakin linker alone broaden out. This suggests that at a 2:1 (periplakin linker to vimentin) 







6.63 Investigating the interaction between the envoplakin linker domain and 
vimentin by 2D-HSQC NMR analysis 
Karashima and Watt (2002) suggested that in the absence of other domains, the envoplakin 
linker domain cannot bind to vimentin. To confirm this, unlabelled unpolymerized vimentin was 
titrated against 15N labelled envoplakin linker domain. The 2D-HSQC showed that the envoplakin 
linker domain is unable to bind vimentin directly (figure 6.64). This can be shown by the lack of 
any significant chemical shift perturbations or broadening. Closer inspection suggested that 
some peaks broaden out. However, this may be an artefact of the decreased concentration of 
the envoplakin linker domain in the presence of vimentin relative to the envoplakin linker domain 
HSQC alone. Therefore it is likely that even at a ~1:1 ratio, (which had broadened out the 
signals of envoplakin PRD and the periplakin linker domain) the envoplakin linker domain and 








6.64 Titration of unlabelled vimentin to 15N labelled envoplakin linker 
A titration of 15N labelled envoplakin linker domain against unlabelled vimentin was conducted 
and analyzed by 2D-HSQC NMR analysis. The proteins were run on an Agilent 600 MHz 
spectrometer in 20 mM Tris (pH 7) with envoplakin linker at 100 µM alone (blue) and at 80 µM in 
the presence of 80 µM vimentin (red). In the presence of vimentin, even at a ratio of 1:1, 
significant line broadening does not occur. Approximately 10% of peaks do broaden out or 
encounter chemical shift perturbations in the HSQC in the presence of vimentin.  However this 
may be an artefact of the decreased concentration of the envoplakin linker domain. Regardless, 
it appears that the envoplakin linker domain does not bind significantly to unpolymerized 





6.7 Identification of a putative flexible and highly variable “spacer” sequence 
proceeding the linker domain 
The experiments presented in this chapter suggest that the linker domains within the plakin 
family are folded protein domains. However, in some plakin family members a preceding amino 
acid sequence (of about 40 residues) separates the linker domain from the PRD C domain 
suggesting a specialized element (see figure 6.71). When the sequences of each of the plakin 
family members were aligned it becomes evident that some members do not possess this 
sequence and that the sequence is relatively divergent (figure 6.71). The sequence is absent in 
both periplakin and BPAG1. This is unsurprising for periplakin given that the linker domain is 
located at the extreme C-terminal end of the protein. However, it is surprising that the spacer 
region is absent in BPAG1 meaning that its linker domain is directly adjacent to its proceeding 
PRD C with no other sequence separating the two domains. Furthermore, this sequence in the 
remaining plakin family members desmoplakin, envoplakin and plectin are not homologous, the 
lengths are variable for desmoplakin (48), envoplakin (37) and plectin (34) and are 
predominantly made up glycines and serines. The lack of homology, variability in length and 
predominance of glycines and serines (amino acids which are typically found in intrinsically 
disordered regions (Dyson and Wright, 2005)) suggest that this region is in fact a 
flexible/intrinsically disordered region. When the sequences were individually input into the 
GLOBPLOT server (Linding et al., 2003), they were predicted to have a high propensity of 
disorder (data not shown). Finally, when this sequence from a variety of species from the 
envoplakin protein was aligned, it revealed this region for lower order eukaryotes (such as 
Xenopus Laevis) is much more divergent (figure 6.72). Again this is another indication of 
flexibility since regions with high conservation from lower to higher order eukaryotes are often 
structured and folded domains. Collectively this suggests that this region - that I would like to 
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tentatively call the “spacer” – (as it separates the linker domain from the PRD C domain) is a 




















Figure 6.71 Alignment of the “spacer” region from the plakin family members 
Full length human protein sequences from the plakin family members: periplakin 
(PEPL_HUMAN), desmoplakin (DESP_HUMAN), envoplakin (EVPL_HUMAN), plectin 
(PLEC_HUMAN), and BPAG1 (DYST_HUMAN) were aligned using CLUSTALW (Thompson et 
al., 1994). Highlighted are the C-terminal end of the linker domain (red), the spacer region 
(yellow) and the first 55 residues of PRD C domain (cyan). The sequence is absent in periplakin 
and BPAG1 and reveals a large degree of heterogeneity between the remaining plakin family 
members. The “spacer” region is predominantly made up of glycines and serines indicating 












Figure 6.72 Alignment of the “spacer” region from varying species of envoplakin 
Full length protein sequences from varying species of envoplakin were aligned using 
CLUSTALW (Thompson et al, 1994). Highlighted are the linker domain (red), the spacer region 
(yellow) and the PRD C domain (cyan). The sequence is highly conserved from human 
(EVPL_HUMAN) to turkey (G1MZ10_MELGA) however is divergent in Xenopus Laevis 
(F6V862_XENTR) – indicated by red arrowheads. Since structured domains are often highly 
conserved from higher to lower order eukaryotes (and occasionally yeast), the divergence in 










6.8 Chapter 6 conclusions 
The C-terminal tails of plakin family members are crucial to interacting with cytoskeletal proteins. 
Previous studies have highlighted the interdependent nature of the PRDs and linker domains 
with relation to cytoskeletal binding (Choi et al., 2002, Fontao et al., 2003, Lapouge et al., 2006, 
Meng et al., 1997b, Stappenbeck et al., 1993, Stappenbeck and Green, 1992). Further studies 
have shown that the linker domains in isolation are the most critical determinant of cytoskeletal 
preference (Favre et al., 2011, Karashima et al., 2012, Karashima and Watt, 2002, Kazerounian 
et al., 2002). To date no biophysical data is known of the linker domains, and they are simply 
viewed as “tethers” linking PRDs B to PRD C. However, some reviews have suggested the 
presence of up to 2 PR motifs (Leung et al., 2002, Jefferson et al., 2004). By analyzing the 
biophysical properties of linker domains from 3 plakin family members it was hoped a better 
understanding into how cytoskeletal preference is created would be observed. This study used a 
combination of solution based biophysical techniques, including NMR and SAXS, which allowed 
for the biophysical properties of linker domains to be probed. The novel results presented in this 
study indicate that unlike previous reports, the linker domains are fully folded PR motif 
containing domains with differential folding capabilities between desmoplakin, periplakin and 
envoplakin. A number of functional aspects of the linker domains were also corroborated which 
included cytoskeletal binding and lack of hetero-dimerization of envoplakin and periplakin linker 
domains, unlike previous suggestions. An additional highly variable and putatively flexible 
“spacer” region was also identified. Finally it must be noted that due to time constraints the PR 
motifs of the linker domains investigated in this thesis were not independently verified using 
experimental atomic resolution data. However, recent NMR backbone assignments of the 
desmoplakin linker domain have revealed the presence of 2 PR motifs concordant with the 
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suggested secondary structure in figure 6.42 (unpublished findings: Miss Penelope Rodriguez-
Zamora).   
Previous reports had suggested that the linker domains may possess up to 2 PR motifs. The 
possibility of which was initially investigated by sequence alignment and modelling which 
revealed the presence of two PRs based on the canonical 38 amino acid sequence (figure 6.42). 
The models suggested that the PR motifs retain their abilities to form intra-domain and inter-
domain hydrophobic and electrostatic binding for correct fold in a manner reminiscent to those 
observed of the envoplakin PRD in chapter 5 (figure 6.43). The presence of a mixed -helical -
sheet structure was also indicated in the 2D-HSQCs of each of the linker domains (figures 6.32-
6.34). Furthermore the high quality dispersion and isotropic peaks suggested the domain was 
well folded. This confirmed that unlike previous reports the linker domains from 3 different plakin 
family proteins are independently folded. The presence of 2 putative PR motifs also implied that 
they must adopt novel mechanisms to assume their fold given the results of chapter 5 which 
suggested that a typical PRD must contain a minimum of 4.5 PR motifs. Unfortunately, time 
constraints did not allow for a full structural determination of any of the linker domains to be 
conducted. However, when analyzed by SAXS the linker domains of desmoplakin and periplakin 
revealed some novel insights which suggested that regardless of their high sequence homology 
they adopted different topologies.  
Based on the SAXS data an unexpected extended or flexible conformation for both desmoplakin 
and periplakin were implied. This is in contrast to the I-TASSER sequence derived models 
produced for the linker domains. The extended nature was more pronounced for the periplakin 
linker domain relative to the desmoplakin linker domain (table 6.1). Given that the linker domains 
are half the size of a typical PRD (in terms of their sequence derived molecular weight) it is 
interesting to observe that the envoplakin PRD had similar Rg and Dmax values. Collectively, this 
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implied the linker domains were extended with the extension being more prominent in periplakin. 
Modelling of a monomeric and dimeric structure for the desmoplakin linker domain revealed that 
neither fit the data, implying a more complex structure (figure 6.46). However, a dimeric model 
for the periplakin linker domain fit the data well which implied that it was a dimer in solution 
(figure 6.47). The specific molecular mechanisms underlying periplakin linker domain 
dimerization is beyond the resolutions permitted by SAXS. However, the N-terminal regions may 
play a role as implied by the dimeric model (figure 6.48). Further inspection of the N-terminal 
sequence of the periplakin linker domain did not clarify the situation. The N-terminal region of 
periplakin contains charged residues which may interact in an electrostatic manner between the 
two molecules of the dimer. However, the same residues are semi-conserved in the 
desmoplakin sequence, which did not form a dimer. Conversely, it is possible that the periplakin 
linker domain undertakes dimerization using its WEE box. The importance of the WEE box has 
been further highlighted by protein insolubility upon bacterial expression caused by the 
mutagenesis of the tryptophan to an alanine (Personal communication: Miss Penelope 
Rodriguez-Zamora). Furthermore this is corroborated by the in vivo binding studies of Karashima 
and Watt (2002), which showed the deletion of the WEE box plus the proceeding isoleucine, 
prevented binding of the periplakin linker to vimentin. Regardless of the mechanism that may be 
adopted to create a periplakin linker domain dimer its size similarity to a PRD suggested that it 
may in effect adopt a PRD-like topology. Unfortunately, the possibility of a dimeric periplakin 
linker domain raises a concern in terms of its in vivo behaviour. The full length periplakin protein 
is typically observed as a heterodimer with the envoplakin protein (Ruhrberg et al., 1997). Homo-
dimerization would therefore not be possible since another periplakin protein would be required. 
There are reports of a periplakin homo-dimer (Kalinin et al., 2004, Ruhrberg et al., 1997) 
however, the functional differences between this state and the hetero-dimer are unknown. The 
presence of a functional dimeric periplakin linker domain therefore raises concerns about which 
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periplakin protein (homo/hetero-dimer) is the functionally active protein. While Ruhrberg et al 
(1997) implied the formation of homo/heterodimers of periplakin (and envoplakin) by sequence 
homology, Kalinin et al (2004) confirmed that periplakin is typically observed as a heterodimer 
with envoplakin. Kalinin et al also observed that envoplakin was insoluble without the presence 
of periplakin. Finally, they also observed the presence of higher order oligomers of the 
periplakin/envoplakin complex in vivo. If true, it may explain the homodimerization of the 
periplakin linker domain by stabilization of the tetrameric periplakin/envoplakin oligomers (and 
higher). This clearly needs more work to validate. Interestingly, the known homo-dimeric protein 
desmoplakin in contrast is likely to contain a monomeric linker domain.     
To clarify the fold and topology of the desmoplakin linker domain two different modelling 
approaches were used, based on the differences observed in the SAXS scattering curve 
between desmoplakin and periplakin. One such approach adopted the ab-initio envelopes 
generated by DAMMIF and manually constructed an extended model whereby the core region 
was rigid yet extended at the same time (figure 6.53). This model revealed a very good fit when 
the N and C termini were set to disordered by EOM (figure 6.54). Unfortunately a compact model 
with a flexible WEE box model similarly gave good fits for the desmoplakin linker domain. 
Therefore, it is not possible to confirm one model over the other due to the low resolutions of 
SAXS analysis. However some assumptions can be made. The first, being that the desmoplakin 
linker domain is highly likely to be monomeric given the consistently lower χ2 values observed for 
monomeric models (table 6.2). The second, that the desmoplakin linker domain is likely to utilize 
a form of inter-domain interaction divergent from that of the periplakin linker domain and that 
observed of typical PRDs. The cause of this structural divergence may linked to the architecture 
of their respective C-terminal tails. The periplakin linker domain is the only domain present at its 
C-terminal tail. In contrast, the C-terminal tail of desmoplakin contains a PRD A, PRD B, the 
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linker domain and PRD C. The architecture and the fact that the C-terminal tails of both 
desmoplakin and periplakin interact with different affinities to cytoskeletal proteins implies 
possible redundancy in the structured domains of the desmoplakin C-terminal tail. The 
desmoplakin linker domain is not required to bind to cytoskeletal proteins as shown by Weis and 
colleagues (2002) while the periplakin linker domain is required for cytoskeletal binding. 
Therefore these differences may be explained by the different folds they adopt as demonstrated 
by this study. The differences in possible functional outcomes of the linker domains were 
therefore further investigated.  
The linker domains of periplakin and envoplakin were investigated for their ability to bind 
vimentin and interact with one another as previously described (Karashima and Watt, 2002). A 
2D-HSQC titration series of 15N labelled periplakin to unlabelled envoplakin was conducted and 
vice versa (figures 6.61 and 6.62). Both titrations revealed that the two linker domains cannot 
bind to one another even in molar excess of the titrated ligand. This is in stark contrast to the 
findings of Karashima and Watt (2002) which suggested that when the rod domain (the domain 
involved in hetero-dimerization of the two full length proteins) was deleted, binding could still 
take place. Closer inspection of the constructs used to test this interaction in the original study 
revealed that an approximately 50 amino acid sequence derived from the rod domain was 
present in the rod domain “deleted” full length sequence. They conceded that the presence of 
this sequence may have artificially allowed hetero-dimerization and based on the titration results 
of this study is likely to be the case. The matter is further complicated when the cytoskeletal 
protein vimentin is involved in binding.  
The linker domains of envoplakin and periplakin were tested for their ability to bind to 
unpolymerized vimentin by 2D-HSQC NMR. This revealed differential binding abilities between 
periplakin and envoplakin which showed that periplakin was the only linker domain capable of 
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binding to vimentin. It showed saturation of binding at a ratio of 2:1 (periplakin to vimentin) 
(figure 6.63). In stark contrast, envoplakin showed no binding at a ratio of 1:1 (figure 6.64). 
Binding of the desmoplakin linker domain to vimentin was not tested but showed no binding to 
the heart cytoskeletal protein desmin in its unpolymerized state (Personal communication: Miss 
Penelope Rodriguez-Zamora). The lack of interaction between desmin and the desmoplakin 
linker domain corroborates the idea that the presence of PRDs leads to redundancy in 
desmoplakin C-terminal domains. However, previous reports had shown that the desmoplakin 
linker domain is critical for cytoskeletal preference (Lapouge et al., 2006). While this has not 
been explored in this study it is likely to be true as implied by the structural differences between 
the periplakin and desmoplakin linker domains. 
The periplakin linker domain had previously been shown to bind to vimentin in vivo (Karashima 
and Watt, 2002, Kazerounian et al., 2002). Karashima and Watt (2002) proposed that the 
envoplakin and periplakin linker domains co-localise to vimentin with periplakin enhancing the 
binding propensity of envoplakin to this trimeric complex. The findings reported in this thesis 
corroborate the earlier results of Karashima and Watt as it is possible that the periplakin linker 
domain firstly binds to vimentin which allows a conformational change in either vimentin and/or 
periplakin that is more conducive for envoplakin linker domain binding.  
The matter is further complicated by the observation of a putatively flexible and highly variable 
“spacer” region observed in envoplakin, desmoplakin and plectin (figure 6.71). Flexibility was 
proposed to be involved in increased affinity to cytoskeletal proteins by Weis and colleagues 
(2002). This was deduced based on a series of interactions using different constructs from the 
desmoplakin C-terminal tail. A construct encompassing PRD B, the linker domain, the spacer 
region and PRD C had the highest affinity for binding to vimentin compared to the domains in 
isolation (Choi et al, 2002). Given the high sequence divergence between the observed spacer 
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regions, it may reflect another structural mechanism for cytoskeletal preference and/or binding 
affinities. Indeed, intrinsically disordered regions have been reported to enhance or coordinate 
binding of their adjacent structured domains to ligands (Nagulapalli et al., 2012, Vuzman and 
Levy, 2012). Constructs encompassing PRD B to PRD C from desmoplakin and the linker 
domain to PRD C from envoplakin (which each contain a spacer region) were relatively unstable 
during purification (Personal communications: Dr Claudia Fogl and Miss Penelope Rodriguez-
Zamora). This is likely to reflect spontaneous degradation or non-specific cleavage of the spacer 
region typical of highly disordered regions and corroborates the idea that this region is flexible. 
These constructs require further investigation, possibly by SAXS. It is possible that their roles in 
the overall structure topology and functional implications of the C-terminal tails can be 
investigated, since it is possible to purify these domains to homogeneity as shown by Weis and 
colleagues (2002).   
Overall, this study has highlighted that the linker domains are fully folded domains with 2 
putative PR motifs. They also show different folding capabilities which may reflect the 
cytoskeletal preferences observed in the literature between different plakin proteins. In addition a 
putative and highly variable “spacer” region may further contribute to the functional implications 
of C-terminal tails. This work may therefore highlight the differences in plakin protein cytoskeletal 












Chapter 7- Biophysical implications of ARVC missense mutations in 
desmoplakin: the traffic light system 
ARVC is a complex disease, characterized by fibrofatty replacement in the right ventricle which 
is often life threatening and can lead to sudden cardiac death. The symptoms of ARVC include 
dizziness, fatigue, breathlessness and ECG abnormalities, amongst others (Marcus et al., 2010, 
McKenna et al., 1994). ARVC is a genetic disease caused by mutations in proteins expressed in 
the cardiac desmosome (Awad et al., 2008). However, the link between these mutations and the 
phenotype is unclear. The matter is further complicated by the disease being difficult to diagnose 
due to its phenotypic similarities to other cardiomyopathies (such as long QT syndrome) which 
can lead to incorrect diagnosis of a patient (although great improvements have been made in the 
past 10 years). Furthermore, ARVC mutations are thought to have incomplete penetrance 
meaning that one member of a family who has a disease causing mutation may not be affected, 
while another with the same mutation may be affected. Diagnosis of ARVC requires the usage of 
the taskforce criteria where some symptoms are classed as “major” while others are classed as 
“minor” (McKenna et al., 1994). Furthermore symptoms which fulfil classic criteria of ARVC may 
only arise at a later age i.e. beyond their 20s, as highlighted by one study on 3 Dutch sisters 
(Otterspoor et al., 2007). A mutation in a cardiac desmosome gene has recently been increased 
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to a major criterion for fulfilling ARVC diagnosis further highlighting the need to understand the 
link between a mutation and the phenotype (Marcus et al., 2010).  
At the genetic level there are a plethora of studies which suggest certain mutations are disease 
causing, but there are very few papers on the mutations’ direct impacts on their protein products. 
The ARVC database which contains details of over 800 mutations is the sole primary source of 
information on these mutations (van der Zwaag et al., 2009). Unfortunately, the ARVC database 
is likely to harbour many polymorphisms as there appears to be little (if any) regulation as to 
what is included. Furthermore, the ARVC database classifies each mutation using the 
“Grantham score” a scoring system which calculates the proposed difference in amino acid 
structure caused by a mutation. The problem with the Grantham score is that it disregards the 
amino acid’s position in the tertiary structure of the protein (Grantham, 1974). The lack of a link 
between the genotype and clinical phenotype therefore appeared to require further attention.  To 
date only a few studies have investigated the functional and/or structural consequences of 
mutations at the molecular level. 
Yang et al investigated the direct functional consequences of 2 ARVC mutations at the extreme 
N-terminus of desmoplakin (V30M and Q90R) (Yang et al., 2006).  The study found that 
plakophilin binding was adversely affected but plakoglobin binding was unaffected (Yang et al, 
2006). This was the first study to directly show the adverse functional consequence of an ARVC 
mutation at the molecular level.  Another very recent study investigating the biophysical effects 
of ARVC mutations on the ARM domain of PKP2a (where the majority of desmosomal ARVC 
mutations are reported) has recently been published (Kirchner et al., 2012). The authors 
suggested that ARVC mutations had varying degrees of biophysical effects on the ARM domain 
of PKP2a. The authors crystallized a WT fragment from the ARM domain of PKP2a which 
showed homology to the previously crystallized ARM domain of PKP1 (Kirchner et al, 2012). 
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This allowed them to investigate the effects of the mutations on the entire PKP2a ARM domain 
by modelling. They showed that some ARM domain constructs with disease causing ARVC 
mutations (I487S and V453I) could be purified in similar amounts to the WT protein. However, 
ARM domain constructs incorporating the disease causing ARVC mutations C752R, S571F and 
C649fsX697, were unstable, resulting in degradation of these proteins. They concluded that the 
altered amino acids I487S and V453I which resulted in stable ARM domain constructs were not 
involved in structural stabilization/folding events. However, the mutations that resulted in protein 
degradation (C752R, S571F and C649fsX697) were essential for inter and intra domain 
stabilization/folding effects. The study showed for the first time that some ARVC mutations were 
more deleterious than others. Therefore, it appears that ARVC mutations can cause functional 
as well as structural consequences at the molecular level which may rationalise their 
pathogenecity. The recent study on PKP2a also highlights the possible presence of 
polymorphisms which may have previously been incorrectly suggested to “cause” ARVC. 
The two studies discussed above focused on specific regions of their target proteins; the 
desmoplakin extreme N-terminal and the PKP2a ARM domain. The main focus of both studies 
was on specific domains as opposed to investigating different mutations present in varying 
structural domains which adopt different folds. The experiments described in this chapter 
investigated mutations in desmoplakin across a variety of domains and therefore it was hoped 
that by gauging their biophysical implications it would answer the following questions: 
1) What is the structural consequence of ARVC mutations in desmoplakin?  
2) Are certain mutations more deleterious to protein structure than others? 
The ultimate aim of the experiments described in this chapter was to gauge whether some 
information could be used to aid cardiologists in facilitating diagnosis based on genetic 
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screening results of the patient. Part of the findings presented in this chapter was published in 
the Journal of Molecular Biology (see appendix A1). 
7.1 Mutation selection criteria 
Over 800 mutations are reported to date in the ARVC database (van der Zwaag et al., 2009) and 
the choice of which mutations to investigate needed to be narrowed down. It appeared more 
pertinent to investigate those more susceptible to deleterious effects physiologically and 
therefore only mutations classed as “pathogenic” were selected. So that direct comparisons 
could be made between the WT and mutant variants only missense mutations were selected.  
Next, since the focus of this study was the plakin family and only mutations in desmoplakin (as 
opposed to envoplakin or periplakin) have been reported to cause ARVC, this was the selected 
as the target protein. Finally the mutations were selected based on the constructs to hand. Using 
this approach allowed for a wide variety of different domains and amino acid substitutions to be 
compared.  The final mutations selected for biophysical analysis were: K470E, R808C, G2375R, 
R2541K and R2639Q. A modified table based on the ARVC database with the selected 
mutations is given in table 7.1. A schematic diagram representing the positions of these proteins 



















K470E 1408 A>G SH3 4
*




Basso et al (2006) 
R808C
+
 2422 C>T SR8 1 0/1200 Presyncope 
and VT 
Al-Jassar et al (2011) 
G2375R 7123 G>C PRD B 8 0/180 VT, SCD, Skin 
fragility wooly 
hair syndrome 
Alcalai et al (2003) 




 0/500 SCD Bauce et al (2010) 
R2639Q 7916 G>A PRD C 1 0/200 VT Yu et al (2008) 
  
Table 7.1 Selected desmoplakin ARVC mutations for biophysical analysis 
The table highlights the alterations and physiological consequences of each mutation. * and $ 
represent incorrectly reported number of patients affected with ARVC from the ARVC database, 
however on closer inspection of the reporting papers more likely to be 1. VT = ventricular 
tachycardia, SCD = sudden cardiac death. + A R808H mutation has also been reported 







Figure 7.1 Schematic diagram showing the positions of the mutations studied in 
the full length desmoplakin sequence 
Mutations K470E and R808C originate within the plakin domain and were analysed in the 
context of full length plakin domain and SR subdomain proteins. Mutations G2375R and 
R2639Q originate in the PRD B and PRD C subdomains respectively and were analysed in the 













7.2 Purification of ARVC mutant proteins 
All amino acid substitutions were carried out by site directed mutagenesis using the Lightning 
quick change kit (Stratagene). Amino acid substitutions of K470E and R808C were carried out 
on the full length plakin domain construct and their component structural domains (SR56 and 
SR78 respectively). G2375R was mutated in the PRD B construct of desmoplakin. R2541K was 
mutated in the desmoplakin linker domain. R2639Q was mutated in the PRD C construct of 
desmoplakin. Purification was carried out in the same fashion as their WT counterparts. With the 
exception of the PRD mutant constructs, expression and purification of the mutants gave no 
significant differences in yield, purity or final stability at 4°C. 
Interestingly proteins with mutations in the two PRDs were entirely insoluble when expressed in 
bacteria (figure 7.2). Even when a variety of different expression conditions were altered 
(temperature, expression time, IPTG concentration) the proteins remained insoluble when 
compared to their WT counterparts which remained soluble in nearly all conditions (data not 
shown). This suggested that a single amino acid substitution in both constructs was significant 
enough to alter its folding and/or stability and therefore its expression profile.  
The following sections will therefore concentrate on plakin domain and linker domain mutants. 
The final section will attempt to model the possible structural differences caused by each mutant 









Figure 7.2 Comparison of expression profiles of wt and mutant PRD proteins 
A: SDS-PAGE analysis of PRD B and the mutant variant G2375R. B: SDS-PAGE analysis of 
PRD C and the mutant variant R2639Q. WT and mutant variants of the PRDs B and C were 
expressed, lysed and analysed for solubility. Both mutant proteins are insoluble.  WTL: wt lysate, 
WTS: wt soluble fraction, WTI: wt insoluble fraction, ML: mutant lysate, MTS: mutant soluble 




7.3 Comparison of gel filtration elution profiles of SR56 and SR78 subdomains 
During the purification of the plakin domain subdomain mutants a Superdex S75 size exclusion 
column was used to separate them from contaminants of different molecular weights. This 
method can also be used to determine the molecular weight and oligomerization state when 
compared to known standards. This was not conducted for this thesis as AUC was used instead 
(e.g. see 7.4). During size exclusion purification the molecular weight determination is heavily 
influenced by the hydrodynamic radius of the protein. Therefore, if the hydrodynamic properties 
had altered due to an amino acid substitution it would be observed as a significant shift in the 
elution profile of the mutant. When wild type and mutant SR56 and SR7-8 proteins were 
subjected to size exclusion chromatography a single peak was observed in the elution profile. 
When superimposed, the peaks of SR56 and its mutant variant SR56-K470E matched (figure 
7.3). The same applied to the wt and mutant variants of SR78 (figure 7.3). This suggested that 
the wt and mutant variants match in terms of the hydrodynamic radius and therefore their 
molecular weight. Therefore, it appears the amino acid substitutions have had no effect on the 
hydrodynamic radius of the proteins. Although the hydrodynamic radius had not been altered it 
wasl possible that the oligomerization state of the protein had been altered by the mutation. This 








 Figure 7.3 Gel filtration elution profiles of wt and mutant subdomain proteins 
WT and mutant variants of SR56 and SR78 were subjected to size exclusion chromatography in 
20 mM sodium phosphate (pH 7.2) 100 mM NaCl. The elution profiles were scaled to 250 mAU 
and superimposed. SR56 wt (black) and SR56-K470E (yellow) match closely indicating that they 
are the same size and have a comparable hydrodynamic radius. The same applies to SR78 wt 










7.4 Sedimentation velocity AUC profiles 
To gauge the oligomerization state further AUC was conducted on wt and mutant SR56 and 
SR78 proteins. Size exclusion chromatography showed that K470E and R808C ARVC mutations 
had no affect on hydrodynamic radius so for simplicity only oligomerization state was analysed 
by AUC.  SR56 wt and SR56-K470E AUC profiles were acquired using SEDFIT (Brown and 
Schuck, 2006). A sedimentation profile with a single peak estimated to be 28.0 kDa was 
obtained for SR56-K470E (figure 7.41). This is in good agreement with SR56 wt profile which 
gave an estimated size of 31.6 kDa. This suggested that the protein remained monomeric in the 
presence of a predicted pathogenic ARVC causing mutation. The slight variations in size and 
distribution may represent a slight difference in hydrodynamic properties or an artefact created 
by slightly different processing. An alternative explanation may be that the SR56-K470E has 
decreased heterogeneity in the sample by increasing intra-molecular stability. SR78 wt and 
SR78-R808C were also analysed by sedimentation velocity AUC. Both gave matching 
sedimentation velocity profiles when scaled with single peaks estimated to 25.1 and 25.1 kDa for 
SR78 wt and SR78-R808C respectively (figure 7.42). Hence it appears that neither the K470E 










Figure 7.41 Sedimentation velocity profiles for SR56 and SR56-K470E 
SR56 wt (black) and SR56-K470E (red) were subjected to sedimentation velocity AUC at 20000 
rpm on a Beckman XL-1 in 20mM sodium phosphate (pH 7.2) and 100 mM NaCl and analyzed 
by SEDFIT (Brown and Schuck, 2006) then scaled. Both revealed a single peak around 
approximately 30 kDa which matches closely to the predicted sequence derived molecular 











Figure 7.42 Sedimentation velocity profiles for SR78 and SR78-R808C 
SR78 wt (black) and SR78-R808C (red) were subjected to sedimentation velocity AUC at 20000 
rpm on a Beckman XL-1 in 20mM sodium phosphate (pH 7.2) and 100 mM NaCl and analyzed 
by SEDFIT (Brown and Schuck, 2006) and scaled. Both revealed a single peak around 









7.5 Comparison of far-UV CD profiles 
CD is a method used to analyse the secondary structure content of proteins and was used to 
analyse the SR56 and SR78 subdomains. As observed in figure 7.51 and 7.52, the ARVC 
mutations do not appear to change the CD profile shown by the superimposition of the wt and 
mutant spectra. My conclusions were independently validated by Professor Alison Rodger 
(Warwick University, 2010), Dr Matthew Hicks (Warwick University, 2010) and Dr Raul Pinchero-
Gomez (University of Birmingham, 2010) all experts in the use of CD. This suggested that both 
K470E and R808C do not alter the secondary structure content of the protein when compared to 
their wt counterparts. Since subdomain secondary structure was not altered, full length plakin 
domain mutants were not compared to the wt counterparts by far-UV CD, although were 














Figure 7.51 Typical far-UV CD profiles of SR56 WT versus SR56-K470E 
SR56 wt (black) was compared to the K470E variant (red). Comparisons were run multiple times 
at the University of Birmingham and the University of Warwick at 0.1 mg/ml in 20mM sodium 
phosphate (pH 7.2). The K470E mutation did not cause any significant alterations to the far-UV 











Figure 7.52 Typical far-UV CD profiles of SR78 WT versus SR78-R808C 
SR78 wt (black) was compared against the R808C variant (red). Comparisons were run multiple 
times at the University of Birmingham and the University of Warwick at 0.1 mg/ml in 20mM 
sodium phosphate (pH 7.2). The R808C mutation did not cause any significant alterations to the 











7.6 Thermofluor melting temperature comparisons between wt and mutants 
Although secondary structure content was not altered by either of the mutants it is possible that 
intra and inter molecular stabilization events (i.e. amino acid interactions) may have been altered 
as observed by Kirchner et al for PKP2a (2012). This could lead to a less stable structure which 
can be analyzed by thermal stability assays as the melting curves correlate with the general 
stability of the protein. Circular dichroism is the preferred choice of analyzing melting 
temperatures by structural biologists. Typically, a sharp transition from ordered to disordered is 
correlated with temperature and a melting curve is created. Unfortunately, CD analysis for 
ascertaining melting curves of each subdomain and respective mutants were attempted at the 
University of Warwick but both wt and mutant variants of SR56 and SR78 aggregated at 
temperatures above 60°C. An accurate melting curve could not be created as a result. It was felt 
that although the proteins may not be aggregating themselves the proteins could have 
aggregated on the glass present in the cuvette (Personal communication: Dr Matthew Hicks, 
University of Warwick, 2010). Indeed when a water only solution was added to the (thoroughly 
washed) cuvette immediately after analysis of SR56, an anomalous CD signal was observed 
owing to the presumed aberrant aggregation of SR56 on the glass of the cuvette. As an 
alternative, wt and mutant variants were subjected to thermofluor analysis where a plastic 96 
well plate is used instead and a different signal acquired by means of fluorescence.  
Wild type and mutant variants were analysed at three different pH value ranges.  Different pHs 
were used due to the fact that both the original wt amino acids (K470 and R808) were charged 
and may have required a certain chemical environment to stabilize an intramolecular interaction. 
The program XLFit was chosen for thermal shift analysis as it is the gold standard for 
thermofluor analysis and gives accurate melting temperatures when dealing with multiple data 
sets (to 1°C) (Ericsson et al., 2006). These were replicated 6 times to gain a more accurate 
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melting temperature. SR56 and the mutant variant revealed superimposable melting curves at all 
pHs attempted (data not shown). This suggested that the mutation had no effect at all on the 
general stability of this subdomain. SR78 and SR78-R808C revealed differences in melting 
temperature at all pHs attempted (table 7.2). When analysed by XLFit, a decrease of 2 °C in 
melting temperature was observed for the mutant protein at both pH 6.5 and pH 7.1.  A larger 
decrease of 4 °C was observed at pH 8.2 (figure 7.6). This suggested that at a range of different 
pHs thermal stability was consistently lower in the R808C variant when compared to the wt.  















6.5 57 55 -2 
7.2 59 57 -2 
8.2 60 56 -4 
 
Table 7.2 Thermofluor melting temperatures as ascertained by XLFit.  
Maximum and minimum points were ascertained by XLFit and the midpoints were calculated as 
the melting temperature with the caveat of an accuracy of no more than 1 °C. In each case a 
negative shift is observed.  The most pronounced affect is observed at pH 8.2 where the 








Figure 7.6 Thermofluor analysis of SR78 wt and SR78-R808C 
SR78 (black) and SR78-R808C (red) at 4 µM were analysed by thermofluor in A) 20 mM Bis Tris 
(pH 6.5), 100 mM NaCl; B) 20mM sodium phosphate (pH 7.1), 100 mM NaCl; C) 20 mM Tris (pH 
8.2), 100mM NaCl. Each experiment was repeated 6 times. For each condition replicates 
superimposed very well. This was then input into XLFit and a sigmoidal fit was applied in line 
with previously published methods (Ericsson et al., 2006). In each curve a negative shift is 
observed for the mutant when compared to the wt which suggested a decrease in thermal 
stability with the most pronounced effect observed at pH 8.2. See table 7.2 for detailed 
differences as recorded by XLFit. 
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7.7 SAXS analysis of wt and mutant proteins 
Although secondary structure content alteration was not observed as a direct consequence of an 
amino acid substitution, a global change may still have occurred. For instance, since both K470E 
(large positively charged residue to a negatively charged residue) and R808C (large positively 
charged residue to a small sulphur containing residue) mutations are dramatic changes it was 
hypothesized that they could have an effect on the tertiary fold. Wt and mutant full length (plakin 
domain) and subdomain variants were compared by SAXS.    
SR56 wt and the K470E mutant variants were analysed by SAXS analysis. Using PRIMUS their 
merged data sets (using similar concentrations for signal to noise ratio comparison) were 
superimposed to ascertain global structural differences. As observed in figure 7.71 their 
scattering curves superimpose very well. This is true for the entire scattering curve range (figure 
7.71A) and importantly at low angles (figure 7.71B) where the size and shape is predominantly 
calculated from the Guinier region. Thus the K470E mutation has had no observable effect on 
the globular shape of the SR56 subdomain at the low resolutions permitted by SAXS analysis. 
SR78 WT and R808C mutant variants were similarly analysed by SAXS using the same protocol 
as described above.  The scattering curves of the SR78 wt and mutant proteins superimposed 
very well (figure 7.72). This was the case across the entire scattering curve range (figure 7.52A) 
and at lower angles (figure 7.72B). Thus it appears that the R808C mutation has had no 
significant effect on the globular shape of the SR78 subdomain.  
 To independently verify that these mutations did not significantly alter globular fold, the raw data 
sets were sent to Dr Dmitri Svergun (DESY, Hamburg, 2010) for analysis. He confirmed that 
these data sets do indeed superimpose and described any differences as “marginal” and that the 
curves in general “practically coincide”. The independent analysis of the wt versus mutant SAXS 
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scattering curves corroborated the previously suggested lack of globular change within the 
subdomains.  
WT and mutant counterparts were also compared using the full length plakin domain proteins. 
Since the SH3 domain was known to be folded in the recently crystallized SR3-6 fragment (Choi 
and Weis, 2011) it was hypothesized that the K470E mutation could disrupt fold and/or the 
interaction with SR4. Similarly for R808C it was possible that the mutation had an effect on the 
entire plakin domain. Wild type plakin domain was compared to its mutant counterparts by SAXS 
analysis. As shown in figure 7.73 neither the K470E or R808C mutants cause a significant 
alteration in the globular structure of the plakin domain. SAXS is also sensitive to differences in 
degree of flexibility and changes in flexibility can also be ruled out (Personal communication: Dr 
Pau Bernadό, Montpellier University, 2012).  
Overall it appears that the global structures of the subdomain and full length plakin domain 
proteins are not altered by the ARVC mutations investigated. Although global structure appears 
not to have been altered within the low resolutions permitted by SAXS, it is entirely possible that 
local conformational changes could have occurred especially as each of the amino acid 
substitutions are dramatic. 2D-HSQC NMR is sensitive to local conformational changes since 
the position of each peak within a HSQC is determined by its local chemical environment. Due to 
the size limitations of NMR (<30 kDa) comparisons of wt and mutant proteins of the full length 
plakin domain were not possible. Instead the subdomain wt and mutant variants were compared 







Figure 7.71 SAXS analysis of SR56 subdomain wt and mutant counterpart 
SR56 and its mutant variant were subjected SAXS analysis in 20mM sodium phosphate (pH 7.2) 
and 100 mM NaCl at 1.0, 2.5 and 3.8 mg/ml for SR56 WT and 1.0, 2.5 and 4.2 mg/ml for SR56-
K470E. Each scattering profile was scaled and superimposed on to one another.  Shown are the 
full scattering range (A) and the Guinier region (B) for each protein. The scattering curves of the 
wt and mutant proteins were similar suggesting that the mutation does not affect overall 
structure at the low resolutions permitted by SAXS. This was also the case in the Guinier region 







Figure 7.72 SAXS analysis of SR78 subdomain wt and mutant counterpart 
SR78 and its mutant variant were subjected to SAXS analysis in 20mM sodium phosphate (pH 
7.2) and 100 mM NaCl at 1.0, 2.5 and 3.7 mg/ml for SR78 WT and 0.8, 1.2 and 2.4 mg/ml for 
SR78-R808C. Each were then scaled and superimposed on to one another.  Shown are the full 
scattering range (A) and the guinier region (B) for each protein. The scattering curves of the wt 
and mutant proteins were similar suggesting that the mutation does not affect overall structure at 
the low resolutions permitted by SAXS. This was also the case in the Guinier region in (B) which 






Figure 7.73 SAXS analysis of the plakin domain wt and mutant counterparts 
The plakin domain and both its mutant variants were subjected SAXS analysis in 20mM sodium 
phosphate (pH 7.2) and 100 mM NaCl. Shown are the full scattering range (A) and (C) and the 
Guinier region (B) and (D). Merged SAXS scattering curves of approximately the same signal to 
noise ratio from each of the wt and mutant variants were superimposed. This is also the case in 
the Guinier regions (B) and (D) which is the predominant determinant of overall protein 
dimensions. This suggested that the K470E and R808C mutations did not alter the globular 







7.81 2D-HSQC NMR analysis of the plakin domain mutants 
It was shown in chapter 3 that both SR56 and SR78 contained tertiary fold by 2D-HSQC NMR, 
with SR78 being the more dispersed of the two subdomains. Mutant variants were analysed by 
2D-HSQC NMR under the same conditions (spectrometer, buffer conditions, spectral widths) as 
their wt counterparts.  The 2D-HSQC of SR56-K470E was superimposed onto the SR56 wt 
variant. It revealed a similar degree of dispersion when compared to the wt indicating that the 
mutation neither increased nor decreased tertiary structure (figure 7.81), consistent with the 
SAXS data. On closer inspection however, approximately 25% of the observable peaks of the 
mutant exhibited chemical shift perturbations. This indicated a local conformational or 
electrochemical change as a direct result of the amino acid substitution. Unfortunately, due to 
the lack of assignment data, the precise way in which the local conformation had been altered 
could not be identified.  The same process was then applied to the SR78-R808C mutation. 
SR78-R808C revealed a similar degree of dispersion and chemical shift perturbations (~30% of 
observable peaks) (figure 7.82).  Overall it appears that mutations cause local conformational 










Figure 7.81 2D-HSQC NMR analysis of SR56 and its mutant counterpart 
Both the wt (red) and mutant (black) variant of SR56 were subjected to 2D-HSQC NMR analysis 
at 100 µM in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl using a Agilent 600 MHz 
spectrometer. The HSQC shows that overall dispersion remains similar although chemical shift 
perturbations occur due the movement of some peaks (~25%). The box represents the expected 
positions of the NεH resonance of tryptophans 493, 537 and 550 with only one being observable. 
A schematic diagram of the full length plakin domain with SR56 highlighted in red is shown.  The 




Figure 7.82 2D-HSQC NMR analysis of SR78 and its mutant counterpart 
Both the wt (purple) and mutant (orange) variants of SR78 were subjected to 2D-HSQC NMR 
analysis at 100 µM in 20 mM sodium phosphate (pH 7.2) and 100 mM NaCl on an Agilent 800 
MHz spectrometer. The HSQC reveals that overall dispersion remains similar however, chemical 
shift perturbations occur due the movement of some peaks (~30%). The box represents the 
expected positions of the NεH resonance of tryptophans 667, 867, 879. A schematic diagram of 
the full length plakin domain with SR78 highlighted in purple and the mutant in orange is 







7.82 2D-HSQC NMR analysis of the desmoplakin linker domain mutant 
It was shown in chapter 6 that the desmoplakin linker domain was folded and well dispersed by 
2D-HSQC NMR analysis. Mutant variant expression and purification of the 15N labelled 
desmoplakin linker domain yielded no significant differences in yield or purity when compared to 
those grown in LB.  
The two spectra were superimposed to analyse chemical shift perturbations as a direct result of 
the mutation. The degree of dispersion appeared to be similar between the wt and mutant 
counterparts indicating the mutation has had little/no effect on the overall fold of the protein 
(figure 7.83). Closer inspection revealed that a few peaks (~10%) have chemical shift 
perturbations. This suggested that some local chemical environments or conformations had 
been altered although the majority remain unchanged. Due to the low number of chemical shift 
perturbations relative to the changes observed in SR56 and SR78 it suggested that this mutation 
is less deleterious in its effects on the conformation of the protein. The precise way in which the 
local chemical environments or conformations have been altered will require a high resolution 









Figure 7.83 2D-HSQC NMR analysis of the desmoplakin linker domain and its 
mutant counterpart 
Both the wt (blue) and mutant (red) variant of the desmoplakin linker were subjected to 2D-
HSQC NMR analysis at 100 µM in 20 mM HEPES (pH 7) and 100 mM NaCl on an Agilent 600 
MHz spectrometer. The HSQC shows that overall dispersion remains similar although a few 
chemical shift perturbations occur due the movement of some peaks (~10%). The box 
represents the expected position of the NεH resonance of tryptophan 2503. A schematic diagram 
of the desmoplakin C-terminal tail with the linker domain highlighted in blue is given.  The 
position of the R2541K mutation is indicated. Purification and NMR analysis conducted in 




7.91 Modelling of ARVC mutants  
To further evaluate the effects of each mutant modelling was performed. Three of the mutations 
analyzed in this chapter already have their wt structures elucidated.  One of the mutations 
R808C within SR78 can be modelled using human erythroid spectrin, repeats 8 and 9 (pdb 
code: 1S35) as a template as it was shown that SR78 is a canonical spectrin repeat in chapter 3. 
A high quality model for the desmoplakin linker domain cannot be created due to the lack of 
structural information and therefore will not be discussed. 
K470E in the desmoplakin plakin domain resides in an exposed position on the RT loop of the 
SH3 domain. It is not directly involved in the SH3-SR4 binding interface that has been shown to 
rigidify the SR3-6 fragment (Choi and Weis, 2011). The SH3 domain does not have a known 
ligand. Chemical shift perturbations in the 2D-HSQC of SR56-K460E compared to the wt 
suggested flexibility based on the non-isotropic dispersion. This may be due to the fact that it 
requires SR4 for stabilization. When a model for the SR3-6-K470E mutant was created 
superimposition to the wt fragment suggested few (if any) changes (figure 7.91). The mutant 
does however lie next to Y469 which is directly involved in the SH3-SR4 binding interface with 
W360. Since local conformational / electrochemical changes were observed in the HSQCs of 
SR56 WT and SR56-K470E it is possible that the mutation has altered the position of Y469 and 
therefore altered the binding propensity to W360 previously suggested (Choi and Weis, 2011). 
The mutant model however suggested this was not the case. Structural determination of the 
K470E mutant will validate this, with the use of SR3-6 as the preferred construct of choice since 
SR56 and the full length plakin domain were refractory to crystallization.  
SR78 has not been structurally determined and therefore a PHYRE model based on erythroid 
spectrin, repeats 8 and 9 (pdb code: 1S35) was used. It revealed that the side chain of R808 
had a potential electrostatic interaction with a spatially adjacent glutamic acid (E882) (figure 
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7.92). This was present in all 5 models (based on 5 different spectrin repeat templates from the 
PDB) created by I-TASSER which revealed an average distance of 2.7 Å between the carbonyl 
and amide groups. This is well within maximum distance required to form such an interaction. 
Electrostatic interactions throughout spectrin repeats are a typical feature known to stabilize their 
overall fold (Broderick and Winder, 2005, Djinovic-Carugo et al., 2002, Grum et al., 1999, 
Jefferson et al., 2007, Yan et al., 1993, Ylänne et al., 2001). The alteration to a cysteine (a small 
uncharged amino acid) amino acid would therefore abolish this proposed interaction. This idea is 
supported by the decreased thermal stability observed at a variety of pHs. Although 
unpublished, I received further information from a cardiologist specializing in cardiomyopathies 
identifying a desmoplakin R808H (histidine is a bulky residue) mutant as the sole determinant of 
ARVC in a patient (Personal communication: Dr Hennie Bikker, University of Amsterdam, 
Netherlands). This mutation would also abolish this interaction and indicates this residue is 
critical for stabilization of the spectrin repeat.  
The importance of the G2375R mutation to the PRD B fold is more “clear cut”. G2375 in PR3 is 
a highly conserved residue across all plakin family members at the end of PR1 and PR3. Its 
importance is highlighted by the fact that it creates a sharp bend which precedes the beginning 
of PR2 and PR4 (figure 7.93). Glycine is the only amino acid capable of a wide variety of 
backbone conformations. Amino acid substitutions would prevent this bend from occurring, 
which was indicated by the insolubility / instability of the protein upon overexpression in bacteria 
(figure 7.2).  
Furthermore the R2639Q mutation in PRD C of desmoplakin is similarly more “clear cut” than 
those of the plakin domain. In all plakin repeats an interaction is typically observed between the 
positively charged residue at position 19 and an aspartic acid at position 4 to set the position of 
the β-hairpin. R2639Q lies at position 19 of PR1 of PRD C, which interacts with D2624 which 
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lies at position 4 of PR1. As shown in figure 7.94 the alteration to a glutamine (a polar uncharged 
amino acid) could abolish this interaction. All together this suggests that this amino acid 
substitution is not tolerable in maintaining the overall fold of the domain as shown by insolubility 













Figure 7.91 Modelling of the K470E mutant versus the wt 
The desmoplakin plakin domain (pdb code: 3R6N) and a model of the K470E mutant protein 
were superimposed. Residue K470 is shown in blue and E470 in red.  SR4 and the SH3 domain 
are shown in purple. Also shown are residues Y469 (green) and W360 (magenta) that are 
thought to be involved in the SH3-SR4 binding interface.  The orientation of these residues is not 







Figure 7.92 Modelling the R808 residue in a SR78 model 
SR78 was modelled by the PHYRE server using erythroid spectrin, repeats 8 and 9 (pdb code: 
1S35) as a template shown in magenta. The positively charged side chain of R808 is shown in 
blue, which is present on the “A” alpha helix of SR8. The negatively charged side chain of E882 
is shown in red, which is present on the “C” alpha helix of SR8. This suggests that an 











Figure 7.93 Modelling of the G2375R mutation 
The crystal structure of the PRD B of desmoplakin (yellow) and a model harbouring a G2375R 
mutant created by I-TASSER (red) were superimposed. The second alpha helix of PR3 is 
highlighted as “α2” with the backbone of the critical bend created by G2375 depicted in 
magenta. Although both models superimpose well, (including a proposed bend created by the 
mutant R2375 amino acid) the bend in reality must be altered as R2375 cannot adopt as many 






Figure 7.94 Modelling of the R2639Q mutant 
WT (blue) and mutant (red) variants of the PRD C domain of desmoplakin were superimposed. 
The β-hairpin and first α-helix (“α1”) of PR1 where R2639 resides is shown. It clearly shows the 
importance of the interaction between the R2639 side chain (green) and the D2624 side chain 
(blue) which has been previously shown to set the position of the β-hairpin. Also shown is 
another residue E2629 (blue) which may also allow the arginine to set the β-hairpin. Depicted in 
magenta is the side chain of the R2639Q mutant which would abolish the interaction of R2639Q 









7.92 Chapter 7 Conclusions: The traffic light system? 
The experiments described in this chapter have for the first time highlighted the wide variety of 
differences ARVC mutations cause on the biophysical properties of desmoplakin domains. Since 
the function of proteins is intimately linked with their structure they show how a wide range of 
different types of mutations have a varying effect on the structure. It therefore appears critical to 
view each mutation individually for its proposed deleterious effect. The results indicate a wide 
variety of deleterious effects each mutation may have at least at the biophysical level. Therefore 
since the ARVC field is devoid of mutant-physiological effect correlations it may be beneficial to 
“class” certain mutations as highly deleterious (red), moderately deleterious (amber), and mildly 
deleterious (green) which the Overduin lab and I would like to call the “ARVC traffic light 
system”. G2375R and R2639Q would be classed as red mutants, K470E and R808C as amber 
mutants, and R2541K as a green mutant.   
7.93 Overall chapter 7 discussion 
Given the recent taskforce criteria upgrade of a desmosomal mutation as a major criterion 
(Marcus et al., 2010), it was important that the mutation-phenotype correlation was explored 
further. The experiments of this chapter and the creation of the ARVC traffic light system 
hopefully show that mutations could be considered in terms of their ability to affect the overall 
fold of the protein. 
Mutations from both N and C termini of the desmoplakin protein were investigated. K470E and 
R808C from the N-terminal plakin domain, G2375R from the desmoplakin PRD B domain, 
R2541K from the desmoplakin linker domain and R2639Q from the desmoplakin PRD C domain 
were analyzed in their respective subdomains. Both mutations from the plakin domain (K470E 
and R808C) were soluble and comparable to their WT counterparts in terms of their purification. 
While SAXS revealed no global alterations their structures, 2D-HSQC NMR revealed probably 
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localized chemical shift perturbations indicative of local electrochemical changes. SR56-K470E 
gave no differences in terms of its thermal stability profile compared to its WT counterpart. 
SR78-R808C however, did reveal a difference in its thermal stability profile compared to its WT 
counterpart, at a variety of different pHs. The difference in their behaviour may underlie the type 
of construct used. SR56 consists of a tandem spectrin repeat and a SH3 domain which 
appeared to contain some internal flexibility or disorder based on the CD and 2D-HSQC NMR 
data (chapter 3). In contrast SR78 is solely a tandem spectrin repeat construct, contained the 
highest thermal stability of all plakin domain constructs and was a well folded as shown by CD 
and 2D-HSQC NMR. With the aid of modelling, how the mutants affected the structure may 
complement the experimental observations.  
The SR78 models clearly indicated that the side chain of R808 on alpha helix A was in close 
proximity to that of E882 on alpha helix C (figure 7.92). The proximity between the two charged 
side chains implied an electrostatic interaction between the two is feasible and is within the 
distances required to form. Electrostatic interactions between the α-helices of individual SRs are 
critical throughout all structures known to date for stabilization (Pascual et al., 1996, Yan et al., 
1993). As a result the interaction is likely to exist and as such the mutation from R808 to a 
cysteine would disrupt this. Given that thermal stability is lower in the mutant variant it suggested 
that a destabilization event has occurred and corroborated the suggestion that the R808C 
mutation had disrupted the R808-E882 interaction. How this correlates to the clinical 
manifestation of ARVC is less clear. It was originally suggested in section 3.9 that SR78 may be 
acting as a “shock absorber” given its relatively high thermal stability. The destabilization may 
therefore result in an aberrant ability to resist mechanical force and possibly result in inadequate 
desmosomal formation or mechanotransduction. Confirmation of this hypothesis would require 
structural characterization of the SR78 domain.  
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The other plakin domain mutant analyzed (K470E) appeared to have less significant alterations. 
The most pronounced affect was observed when the K470E mutant was compared to its WT 
counterpart by 2D-HSQC NMR. This revealed a shift perturbation in the spectrum. While this 
suggests an alteration in the local chemical environment of the residue affected, the lack of 
assignment data and the slightly poorer dispersion (relative to that of SR78) suggests caution in 
interpreting the cause of the K470E mutation on the structure. However, the recent crystal 
structure revealed the position of the mutation to within the SH3 domain and may explain some 
of the observations. The K470 residue resides in an exposed position on the RT loop and is not 
directly involved in the SH3-SR4 interface implicated in rigidifying the SR3-6 domain (Choi and 
Weis, 2011, Ortega et al., 2011). It is difficult to interpret its biophysical or functional implication 
of the K470E mutation given its innocuous position on the RT loop. However, K470 resides next 
to Y469 which is directly implicated in the SH3-SR4 interface (Choi and Weis, 2011). Given this 
residue is critical to the interface, the K470E mutation may alter the backbone orientation of 
Y469 and prevent interaction with W360. This may explain the chemical shift perturbations in the 
2D-HSQC spectrum.  However the mutation is not sufficient enough to unfold the protein given 
the lack of an increased number of broadend signals. At present no known ligands are known for 
the plakin SH3 family. Although the typical binding region for SH3 domains is occluded in 
desmoplakin and plectin (Choi and Weis, 2011; Ortega et al, 2011) alternative modes of binding 
have been shown for other SH3 domains (Mongiovı et al., 1999). However, with the lack of 
ligand binding data only the structural implications can be assessed. Given that SR56 did not 
behave as well (biochemically) as the larger SR3-6 construct, a more pertinent way of 
addressing the ambiguity in the observations would be to crystallise SR3-6 in the presence of 
the K470E mutation. Regardless, the observations for the K470E mutation may also suggest 
that it is a polymorphism and others may be present throughout the ARVC database. Clearly 
other explanations may be involved in leading to ARVC from the K470E mutation (such as 
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preventing of binding to an unknown ligand) but the evidence from this study suggests 
otherwise.  
The G2375R mutation was assessed in the PRD B of desmoplakin. It revealed that in stark 
contrast to the WT variant it turned the protein entirely insoluble. In context, the WT variant 
expresses in large amounts and is entirely soluble. Furthermore, the wt behaviour in solution 
makes it a relatively easy protein to purify. Therefore, this mutation is clearly causing a 
significant alteration to the overall fold or stability of the protein. With the aid of a crystal structure 
and bioinformatic analysis the biophysical effect on the fold of the protein by this mutation can be 
explained. G2375 resides at the end of PR3 of PRD B. Glycines are critical in this position to 
create a sharp bend for PR1 and PR3. There is an absence of a glycine at the end of PR2 and 
PR4 which results in an alternate conformation for the proceeding PR motif. Glycine is the only 
amino acid capable of creating such a sharp bend as the ones observed at the ends of PR1 and 
PR3. Mutagenesis of this residue to an arginine would therefore prevent such a sharp bend 
occurring and more than likely alter the fold. Since the protein was predominantly located in the 
insoluble fraction the altered conformation of the proceeding PR motif is likely to have had an 
effect on the overall conformation of the protein and destabilized the overall fold. The other PRD 
subdomains A and C were reported to bind vimentin with the same affinity as PRD B and the 
entire C-terminal tail encompassing all 3 (Choi et al, 2002). It is possible that misfolding of PRD 
B is unlikely to affect the fold of its neighbouring PRDs given that they can each be individually 
expressed and fold correctly. This would need validation with the full length desmoplakin C-
terminal tail construct. However, what still remains to be answered is whether all 3 are required 
for desmin (the predominant heart cytoskeletal protein) binding and whether (for example in this 
particular instance) PRDs A and C are sufficient to substitute the destabilized fold in PRD B. 
Clearly this mutation has a profound effect on the patient as a reported 8 members of the same 
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family were affected and resulted in sudden cardiac death at an early age (Alcalai et al., 2003). 
Since the main function of the PRD is to bind to cytoskeletal proteins it is highly likely that PRD B 
will not be able to do so. Another possibility is that the expression of the entire full length 
desmoplakin protein may result in partial aggregation rendering the full length protein less able 
to conduct its role to its full potential. Indeed altered gene expression of plakoglobin was shown 
to lead to ARVC like symptoms in endurance-trained mice (Kirchhof et al., 2006). Interestingly a 
study looking at a G2056R mutation which similarly is involved in bend formation at the end of 
PR1 of PRD A resulted in less profound effects (Christensen et al., 2010a). The authors reported 
that the patient had mild skin defects such as skin blistering with no other cardiac associated 
problems. Clearly then for a mutation to be deleterious to life it must destabilize the overall fold 
but the domain it is located in may be more functionally important than others. This implies that 
while the G2375 residue is critical, the G2056 residue may not be, although causes skin 
problems which are tolerable.  
The R2639Q mutation in PRD C of desmoplakin appears to have a similar affect on the 
subdomain fold in a similar fashion to that of G2375R. Mutation of R2639 to a glutamine results 
in the protein being expressed into inclusion bodies. As explained in the previous paragraph 
expression into inclusion bodies implies a destabilization event which is directly linked to the 
mutation. Again, similarly to the G2375R with the aid of the crystal structure and bioinformatics, 
the critical nature of the R2639Q mutation can be explained. R2639 is located in PR1 of PRD C 
at position 19. Residue 19 of each PR motif is usually occupied by a positively charged residue 
(typically arginines or lysines), although exceptions are observed. The positively charged residue 
is required for interaction with a negatively charged amino acid at position 4 of the motif. In this 
case the R2639 residue interacts with D2624 in an electrostatic manner. These interactions are 
required so that the β-hairpin is “locked” in position. Disruption of this interaction by 
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mutagenizing the arginine to a glutamine is therefore presumably deleterious to the conformation 
of the protein so that it results in a destabilized fold and causes the protein to be sequestered in 
inclusion bodies. As in the case of the G2375R mutation it is unlikely to have a direct effect on 
the folds of the other neighbouring PRDs. However, it cannot be discounted that the destabilized 
fold of the PRD C may result in aggregation of the full length desmoplakin protein in vivo. 
Furthermore, binding to cytoskeletal proteins may be disrupted although it should be noted that 
the G2375R and R2639Q mutations do not reside in the proposed vimentin binding groove. 
Furthermore to date no mutations have been reported in any of the PRD binding grooves. 
Instead it appears that the mutations studied in the PRDs of desmoplakin destabilize the fold 
resulting in ARVC.  
The R2541K mutation was analyzed within the desmoplakin linker domain. Although a full 
biochemical analysis was not conducted due to time constraints, the relative differences 
observed were far less significant than those of the other mutations studied. The mutant variant 
of the protein was stable, soluble and no significant alterations were observed in its final yield or 
purity. Furthermore, the 2D-HSQC of the desmoplakin linker mutant variant superimposed onto 
the WT variant revealed very few chemical shift perturbations relative to those observed for the 
plakin domains. Although approximately 10% of the peaks experience chemical shift 
perturbations this is likely to be a reflection of an NMR artefact whereby minor backbone 
alterations reorientate the amides slightly. In contrast to the 2D-HSQCs observed for the plakin 
domain mutants, the slight reorientations are likely to be highly localized. As a result, although 
10% of peaks had chemical shift perturbations the actual number of amino acids experiencing 
backbone conformational change is likely to be lower. Therefore, altogether this suggests that 
the R2541K mutation is having a minor effect on the biophysical aspects of the desmoplakin 
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linker domain. Unfortunately, to date the atomic structure of the linker domain is unknown and 
therefore the effect of the mutation on the fold remains to be seen.  
Another possibility is that since so few chemical shift perturbations were observed R2541 may 
not be involved in folding but may in fact be surface exposed. This in turn would reduce the 
number of other amides the mutation would have an effect on. It was previously shown that the 
desmoplakin linker domain can bind to desmin (Lapouge et al., 2006) and therefore if the 
R2541K mutation was surface exposed could prevent binding to cytoskeletal proteins. The test 
whether the mutation affected desmin binding titrations of WT and mutant desmoplakin linker 
against unpolymerized desmin were conducted (unpublished results, Miss Penelope Rodriguez-
Zamora, 2012). No binding was observed for either the WT or mutant variant which suggested 
that R2541K does not significantly affect fold, nor is the desmoplakin linker domain involved in 
binding to unpolymerized desmin. All together the biophysical data imply that this mutation may 
in fact be a polymorphism. Given it was previously shown to bind to polymerized desmin, it may 
have affected binding to only the polymerized variant of desmin and therefore needs 
investigating. Interestingly, the lead author who published the original R2541K mutation said the 
descendents of the deceased with whom also had the mutation were currently middle-aged and 
reported no signs of ARVC (Personal communication: Dr Alessandra Rampazzo, University of 
Padova, 2012). This was despite routine checkups with their doctors and highlights the need for 
caution for over interpreting the importance of mutations. Dr Alessandra Rampazzo conceded 
that the R2541K may be a mutation in which incomplete penatrance may be at play.  
Recently it has become apparent that those with ARVC may in fact harbour multiple mutations 
across different genes in the desmosome (Xu et al., 2010). Xu et al highlighted the need for all 
cardiac expressed genes of the desmosome to be sequenced. Many previous studies have 
investigated only up to two genes and would therefore suggest that many mutations in the ARVC 
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database may not represent the “causative” mutation. Xu et al also suggested that currently it 
would be difficult to assess which of the mutations may/may not be contributing to the 
pathogenesis of ARVC. They concluded however, that it is highly likely that they presence of two 
or more mutations would significantly increase the chances of harbouring ARVC. Furthermore 
the prevalence of possible polymorphisms in the ARVC database was highlighted by two 
independent studies which suggest that some mutations reported as pathogenic are prevalent in 
the general population (Posch et al., 2008, Christensen et al., 2010b). Both authors conclude 
that while mutations may be disease modifying, they cannot be clearly extrapolated to being 
disease causing. To date the DSG2 mutations originally reported as pathogenic have been 
altered in light of this data in the ARVC database while, unfortunately, the same cannot be said 
for those reported as unknown pathogenecity in PKP2. This therefore presents a new problem in 
which scientists are overzealous in their reporting of novel “disease causing mutations” in 
desmosomal genes. Regardless, the presence of an ARVC database to discuss these sorts of 
phenomena is likely to be beneficial to the field as it allows healthy debate to further understand 
the ambiguities involved in the diagnosis of ARVC and the correlation between the genotype and 
phenotype. 
The ARVC mutations investigated in this study represent a wide variety of types of mutants, in a 
diverse range of domains. It suggested that some mutations are more deleterious than others. 
Furthermore, and most importantly, it highlights the need for caution in terms of interpreting the 
importance of a desmosomal mutation which recently has been upgraded as a “major” criterion 
for the revised task force criteria (Marcus et al., 2010). It is highly likely that each mutation at the 
biophysical level will have a highly specific effect on the structure of the protein (like that 
observed for the mutations studied in PKP2a by Kirscher et al (2012)). Unfortunately, the speed 
at which new mutations are reported and the level of work required to interpret these proteins at 
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the biochemical level will never balance. However, this study on ARVC mutations lays a 
foundation that suggests that some mutations can be classified in a certain way. It was earlier 
suggested that a traffic light system could be used in which some mutations (G2375R and 
R2639Q) are highly deleterious or red, others are moderately deleterious or amber (K470E and 
R808C) and some are mildly deleterious or green (R2541K). Furthermore the grantham score 
(Grantham, 1974), a common tool used to quantify the deleterious effect on the protein in the 
ARVC database appears to have no correlation with the suggested traffic light system (figure 
7.95). This highlights the need for rather looking at the amino acid substitution solely, its position 
in the three-dimensional fold of the domain to be taken as the predominant determinant of its 
effect. While the traffic light system is clearly an over-simplification it can set some ground rules 
for how mutations can be classed in the future based on their amino acid position, which 
ultimately would be helpful for diagnosis and prognosis. For example if a residue known to be 
critical to fold was mutagenized (i.e. W360 involved in the SH3-SR4 interface) it would likely 
cause the SH3 domain to detach from SR4 and become unfolded based on the evidence 
presented in chapter 3. A patient with a W360 mutation would be a mutation of top priority for 
cardiologists to maintain careful observation of.  Unfortunately, very few mutations within the 
known atomic structures of desmoplakin have such mutations. Indeed 50% of the classified 
missense “pathogenic” desmoplakin mutations in the entire ARVC database reside in the plakin 
domain, yet the few examined in the C-terminal tail within this study resulted in the most 
deleterious effects. This therefore implies that some mutations are more tolerable than others, 
with those who have these mutants reaching an age where they can be passed on. The G2375R 
mutant is particularly fatal with most of the patients not reaching even 25 (Alcalai et al., 2003). 
This therefore implies that through natural selection the most deleterious of ARVC mutations are 
eliminated. However, it is clear that even ARVC mutations that are “tolerable” present a huge 
challenge to cardiologists treating those with ARVC. Clearly there are many questions that 
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remain unanswered and these are likely to come from understanding the biology of the 
desmosome further. These include desmosomal assembly and binding domains of one 














Figure 7.95 The Grantham score does not correlate with the traffic light system 
Grantham scores were calculated for mutations investigated.  Bars are coloured according to the 
traffic light system. The figure indicates a lack of correlation between the Grantham score for 











































Chapter 8 – Overall conclusions 
This study has shed light on the biophysical properties of the functional N and C-termini “arms” 
of the desmosomally located plakin proteins desmoplakin, envoplakin and periplakin. Using a 
variety of biophysical techniques such as NMR, X-ray crystallography and SAXS (amongst 
others) it has provided a plethora of information which no individual technique could have given. 
Using SAXS and NMR the N-terminal plakin domain was shown to have a modular organization 
with rigid SR3-6 and SR78-CT regions separated by a flexible hinge.  This was the case in all 
plakin domains examined. X-ray crystallography allowed for the first time atomic resolution 
comparisons of a non desmoplakin PRD from envoplakin, which SAXS confirmed was a 
monomer in physiological solution. Furthermore SAXS and NMR shed light on the plakin linker 
domains (which were previously thought of as semi-structured/disordered tethers).  The data 
showed they were actually fully folded domains with PR motifs capable of binding IFs with 
differential abilities. Finally, using all the above mentioned major techniques, this study revealed 
the highly specific biophysical impacts of desmoplakin ARVC missense mutations. Overall it 
reveals a highly complex architecture for the plakin proteins, which is likely to impart protein 
specific functions such as cytoskeletal binding preferences.  
The N-terminal head region of plakin proteins had previously been shown to be essential for 
desmosome assembly (Bornslaeger et al., 2001, Kowalczyk et al., 1997). The N-terminal region 
has also been shown to bind to plakophilin1, plakoglobin and weakly to desmoglein. This 
highlights its critical role in desmosome formation. Unfortunately, the binding site for these 
proteins has not been further narrowed down within the N-terminal region with the exception of 
plakophilin1. In a study published with my colleagues, we showed that plakophilin1 was unable 
to bind to SR56 and SR78-CT, and therefore deduced by inference that the plakophilin 1 binding 
site is located within SR34 (Al-Jassar et al, 2011). Unfortunately, this could not be directly 
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validated since the SR34 construct was insoluble upon expression in E.coli (chapter 3). Despite 
this the question remained – how does the N-terminal head region of desmoplakin bind to 
multiple binding partners and what is the role of the plakin domain? To answer this, the plakin 
domain architecture was assessed. It revealed that SR3-6 is a protease resistant, rigid entity 
(Choi and Weis, 2011; Al-Jassar, et al, 2011) which is followed by a flexible hinge region and a 
thermally stable SR78 domain. Indeed, SAXS analysis of each plakin domain revealed flexibility 
and excluded the possibility that plakin domains are linear rigid elements. Given that SRs are 
often exposed to mechanical stress and the N-terminal head region binds to multiple binding 
partners it opens up the possibility that the plakin domain could bind to certain partners 
depending on the mechanical stresses imposed on the cell. In a beautiful study under the 
umbrella of a new field termed “intracellular mechanotransduction” conducted by Michael 
Sheetz’s lab, they investigated the two proteins vinculin and talin. Together they are functionally 
similar to plakin proteins in that they tether anchoring junctions (in this case focal adhesions) to 
the cytoskeletal network (Ziegler et al., 2008). The study showed, using a variety of single 
molecule techniques (such as magnetic tweezers, total internal reflection, fluorescence, and 
atomic force microscopy), that upon mechanical stimulation (i.e. stretching) of talin, vinculin was 
able to bind to cryptic binding sites on talin (del Rio et al., 2009). Although no protein has been 
directly implicated in mechanotransduction in the desmosomal field, the plakin protein plectin 
has been shown to have an influence on the mechanical stability of cells (Na et al., 2009). 
Furthermore it is well established that desmosomes experience mechanical stress and are 
expressed in tissues known to encounter mechanical stress (such as the epidermis and 
myocytes). Sheetz’s findings have implications for the observations presented in this study. 
Firstly, all plakin domains were found to be non-linear in-vitro. Secondly unpublished in-vitro 
findings by Dr Martyn Chidgey showed that plakophilin1 was able to bind to desmoplakin but a 
number of different plakoglobin constructs could not. This is contrary to previous in-vivo 
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experiments which showed that both plakophilin1 and plakoglobin could bind to desmoplakin (Al-
Jassar et al, 2011). Collectively, it could be argued that the N-terminal head region is acting as a 
“mechanosensor” to the cell’s mechanical situation. The flexible plakin domain could potentially 
linearize (as opposed to being U or L-shaped in chapter 4) and the SRs could withstand the 
mechanical stress to compensate for the altered mechanical state of the cell. This could then 
initiate a change in conformation for desmoplakin where cryptic sites could be exposed for PG. 
PG is known to be important for stability in desmosomes (Kirchhof et al., 2006, Palka and Green, 
1997). Finally, plakophilin1 could be released upon aberrant mechanical stresses and 
translocate to the nucleus to initiate downstream effects, something it is known to do (Mertens et 
al., 2001, Sobolik-Delmaire et al., 2010). These potential mechanisms may underpin the 
dynamic assembly of the desmosome in which it is proposed to disassemble under high 
mechanical stresses (Green and Gaudry, 2000). Exploring these possibilities would need a lab 
competent in single molecule techniques.  
Given the possibility of a dynamic role in desmosome assembly at the N-terminal region, a 
similar process may occur at the C-terminal tail in terms of plakin proteins’ cytoskeletal binding 
preferences and aiding IF assembly. The crystal structure of the envoplakin PRD and SAXS 
structures of the desmoplakin and periplakin linker domains were deduced in this study. In 
addition to this NMR titrations were conducted using unlabelled unpolymerized full length 
vimentin which revealed differential abilities to bind vimentin. The envoplakin PRD retained a 
conserved structure similar to that of its crystallized homologue, the desmoplakin PRD C. The 
putative positively charged vimentin binding groove was also preserved in the structure. Subtle 
differences were observed in the envoplakin PRD’s ability to fold when compared to the 
desmoplakin counterpart. These included the presence of a random coil feature in PR4 which is 
centrally located in the putative vimentin binding groove and a negatively charged patch in a 
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different position found in desmoplakin which may also play a role in vimentin binding. The 
envoplakin PRD was also shown to be able to bind to polymerized vimentin with the same 
binding affinity as the desmoplakin PRD C. Although few structural differences were observed, 
the biophysical data obtained for the plakin linker domains may explain why differences are 
observed in cytoskeletal binding of full length plakin proteins as previously reported.  
The linker domains of desmoplakin, envoplakin and periplakin were analyzed by NMR and 
SAXS. They revealed they are fully folded domains with a likely novel fold encompassing 2 PR 
motifs separated by a highly conserved WEE box. Unfortunately, the envoplakin linker domain 
was not analyzed by SAXS. However, the two remaining linker domains from desmoplakin and 
periplakin were successfully analyzed by SAXS and the data revealed significant differences. 
The desmoplakin linker domain was shown to be a flexible monomeric protein (figure 6.55). In 
contrast the periplakin linker domain was shown to be a rigid dimeric protein (figure 6.48). When 
unpolymerized vimentin was titrated against periplakin it saturated at a ratio of 1 to 2 (vimentin : 
linker domain) ratio. Binding between the envoplakin linker domain and vimentin was not 
observed under similar conditions. In addition to this unpolymerized desmin was unable to bind 
to the desmoplakin linker domain (unpublished results: Miss Penelope Rodriguez-Zamora). 
Previous reports have shown that linker domains from a variety of plakin proteins are the sole (or 
at least in combination with a PRD) determinants of cytoskeletal binding (Favre et al., 2011, 
Fontao et al., 2003, Kazerounian et al., 2002, Lapouge et al., 2006, Steinböck et al., 2000). 
Therefore, although binding was not observed for desmoplakin and envoplakin, linker domains 
are likely to have a significant effect on binding to polymerized cytoskeletal proteins. 
Furthermore, a heterogeneous sequence of a likely flexible “spacer” region was also identified 
which was present in desmosomal located proteins desmoplakin, plectin and envoplakin but not 
the hemidesmosomal protein BPAG1. Again this may reflect a determinant of cytoskeletal 
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preference. Collectively, given the large heterogeneity of their structural and binding capabilities 
it suggests that the linker domains are in fact the domains that dictate the cytoskeletal binding 
preferences of plakin proteins at their C-terminal tails. The heterogeneity between the PRDs and 
linker domain binding capabilities could allow the C-terminal tails of plakin proteins to be viewed 
as “hands”. The similar binding capabilities of the desmoplakin and envoplakin PRDs suggest 
they may act as a “palm”, while the linker domains act as the “fingers” to specify the plakin 
protein’s cytoskeletal preference. The binding of both unpolymerized and polymerized vimentin 
also implies they have a role in IF assembly too, although would need to be validated. 
The greater understanding of the highly specialized structural domains from the N and C-termini 
of plakin proteins may therefore reflect the ambiguity surrounding the genotype-phenotype link in 
ARVC, especially in terms of missense mutations. Before this study was conducted no data was 
available regarding the biophysical impact of ARVC missense mutations on desmosomal 
proteins. The data presented in this study suggests that the precise location (as opposed to the 
type of substitution) of the ARVC mutation is highly likely to reflect how damaging it would be to 
the protein. For instance the G2375R and R2639Q had predicted to have the most destabilizing 
effect on the fold of the PRDs B and C of desmoplakin respectively. In contrast, R2541K and to 
a lesser extent K470E had the least significant effects. As a result, the Michael Overduin lab and 
I have proposed the “traffic light system”. The system proposes that the likelihood of a missense 
mutation's deleterious effects can be inferred from the mutation’s position in the fold of the 
domain. For instance if the amino acid is surface exposed, not conserved and non-critical to fold 
it would be classed as a “green mutation”. While an amino acid critical to fold, highly conserved 
or is involved in a binding pocket would be classed as a “red mutation”. This is particularly 
important now that a mutation within a desmosomal protein is classed as a major criterion given 
the recent revision of the taskforce criteria (Marcus et al, 2010). The lack of any significant 
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effects on some domains by some mutations raises the question of potential polymorphisms in 
the ARVC database, which although may be disease related, are not disease causing. The 
possibility of polymorphisms in the ARVC database has been raised by other labs (Posch et al., 
2008, Christensen et al., 2010b). This is also corroborated by a very recent study from Kirchner 
et al (2012) which showed that some ARVC mutants in plakophilin2a caused destabilization of 
protein fold whereas others produced no observable effects. However, clearly some mutations 
may not have a significant impact on the structure or biochemistry of the domain yet alterations 
of binding grooves to as yet unknown ligands may occur. This therefore highlights the 
importance of combining biochemical, structural and medical studies in future ARVC research. 
There are however some limitations to the proposed traffic light system. For instance the 
mutagenesis of a glycine at the end of PR1 or PR3 in any PRD would destabilize the fold of 
most PRDs in vitro (as seen for the G2375R mutant in PRD B of desmoplakin). However, a 
G2056R mutant in desmoplakin PRD A at the end of PR1 in a middle aged patient caused only 
minor skin abnormalities. Using the system it would suggest it would be a severe problem to the 
patient at the molecular level, as for the patients who harboured the G2375R mutant could not 
reach beyond the age of 25 (Alcalai et al., 2003). However, clearly the patient with a similar 
mutation (G2056R) suggests that severity of the disease could not be extrapolated using the 
traffic light system.  Thus caution should be applied when using the traffic light system.   
Interestingly, the G2056R data raises another question – why do some desmoplakin mutants 
cause skin defects while others cause skin and/or heart defects? Unfortunately, the answer to 
this is not clear based on the evidence in the literature or this study. The answer may lie in the 
two desmoplakin isoforms, DPI and DPII. DPI and DPII are expressed at similar levels; however, 
DPII is expressed at lower levels in the heart. It would be interesting to investigate whether 
expression patterns and/or protein function between the two desmoplakin isoforms differ with or 
without the presence of skin/heart causing mutants. Again this proposed investigation would 
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allow cardiologists to make more informed decisions about how to go about maintaining care for 
a patient and whether other relatives should similarly be screened. The presence of over 800 
“disease causing” mutants in the ARVC database suggests that rather than focus on finding new 
mutants, the paradigm should be shifted towards new ways of dealing with the medical and 
genetic information to hand in order to help those afflicted with ARVC. Hopefully the traffic light 
system, in addition to biochemical studies on ARVC mutants, will take the first few steps in 
translating the vast amount of medical and genetic information to channelling research efforts to 
help maintain and treat those with ARVC.  
Overall this study has shed light into the biophysical properties of the functional N and C-termini 
“arms” of plakin proteins. It suggests a complex interplay in the way the N-terminal region is 
organized as well as potential determinants of protein specific functions at the C-terminal tail. 
This study hopefully sets a foundation of work which can be built upon to further elaborate the 
mechanisms of plakin protein functions of tethering the desmosome to the IF cytoskeletal 











A number of limitations were present in this study and will be discussed.  
Firstly since the work was conducted in vitro, it is possible that previously documented 
interactions in vivo that were not observed in this study are unlikely to reflect a real lack of an 
interaction. Rather an alternative view would be to interpret lack of interaction (as was the case 
with the envoplakin linker domain and vimentin) down to a requirement of an intermediary or 
synergistic interaction with another protein. 
Secondly, although attempts were made to correlate structural/biophysical information of ARVC 
mutations with patient outcome in chapter 7 the picture is likely to be far more complex. 
Evidence which suggests this is the case include: the likely presence of polymorphisms in the 
ARVC database, incomplete genetic profiling of ARVC patients (i.e. multiple rather than single 
mutations in cardiac desmosomal genes), and as yet unknown binding sites for cardiac 
desmosomal proteins to one another. Other complexities include the possibility of misdiagnosis 
of ARVC due to its inherent difficult nature to diagnose.  
Thirdly was the lack of AUC data on the effect of high concentrations on potential protein 
oligomerization. Throughout the study proteins were tested at low concentrations (typically 0.1 – 
1 mg/ml) by AUC. However, as was the case with the periplakin linker domain it was evident that 
at low concentrations the protein was monomeric but this model did not fit very well when 
compared to a dimeric model when analyzed by SAXS at higher concentrations.  
 Finally another limitation was the lack of data confirming that the recombinant vimentin purified 
for this thesis was independently folded. Although the case, the divergent functional ability to 
bind between the different c-terminal structural domains of envoplakin, periplakin and 




Clearly much work needs to be conducted to elaborate the findings presented in this study. The 
study aimed to investigate the biophysical mechanisms of plakin families that allowed 
desmosomal assembly, tethering to IFs as well as identifying how cell specific function was 
created. Since PKP and PG binding to the N-terminal of desmoplakin is imperative to 
desmosomal integrity, how these proteins interact should be investigated further. Whether there 
are cryptic sites for PG or whether both PG and PKP are able to bind together to desmoplakin 
should be looked into. This could be conducted by pull down assays as well as NMR titrations 
such as those used in this study.  
The identification of the plakin linker domains as structured elements is an important discovery. 
Clearly their structural elucidation is of top priority and has almost been completed by other 
members of the Chidgey/Overduin lab as this thesis is being finalised. Importantly, why and how 
there are structural differences between the linker domains will also need to be investigated, as 
is whether this causes plakin protein cytoskeletal preferences.  
Finally, how the PRDs and linker domains bind to IFs will be an important priority as currently 
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Appendix – A2  
Buffer list 
Recipes for GST purification buffers: 
0.5M-sodium phosphate (pH7.2)                    5ml 
1M-NaCl                                                               10ml 
                                                                              ------- 





Glutathione                                                            80mg 
1M-Tris.Cl (pH8.0)                                                2ml 
1M-NaCl                                                                2.5ml 
Water                                                                      5.5ml 
                                                                                ------ 








His-trap binding buffer:  
20mM Hepes, 500mM NaCl, 10mM Imidazole (pH 7.5) 
 
His-trap wash buffer:  
20mM Hepes, 500mM NaCl, 30mM Imidazole (pH 7.5) 
 
His-trap  Elution Buffer: 
20mM Hepes, 500mM NaCl, 250mM Imidazole (pH 7.5) 
 
Ion-exchange Q sepharose buffers 
Binding buffer: 
20mM Hepes pH 7.5 
 
Elution buffer 
20mM Hepes pH 7.5 and 500mM NaCl 
 
 
Recipes for vimentin refold buffers 
 
 
Triton Wash buffer:  
(for 1L), 5ml Triton X-100 (100%), 50ml 4M NaCl, 20 ml 0.5 M EDTA (pH8), 10 ml 10 % Na 
Azide, 50 ml 1M Tris (pH 8) 
Non-Triton wash buffer:  
(for 1L), 20 ml 0.5 M EDTA (pH 8), 10 ml 10 % Na Azide, 50 ml 1M Tris (pH 8) 
Solubilization buffer:  
383 
 
20ml of 10mM Tris-HCl pH 8, 0.2mM EGTA/EDTA (Optional), 5mM DTT (optional), and 8M Urea 
NMR expression media: 
 
M9 media salts (1 l) 
 
6 g   Na2HPO4 
3g   KH2PO4 




10 µl  1 M CaCl2 
2 ml  1M MgSO4 
400 µl  1M FeCl3 
1 ml  20 mg/ml Thiamine 
1 g  15NH4Cl 
0.5 ml  “Metal Mix” 
 
Metal mix (100 ml) 
 
0.115 g ZnSO4 
0.0169 g MnSO4 
0.029 g H3BO3 
0.0175 g CuSO4 
 
 






















Appendix - C 
         character*3  wed 
         character*5  xmodel 
 
         dimension g1mat(11000,3) 
         dimension v654mat(11000,3) 
         dimension F8767mat(11000,3) 
         dimension Q447mat(11000,3) 
 
         dimension mat_d1(1000) 
         dimension mat_d2(1000) 
 
         dimension mat_d1sel(1000) 
         dimension mat_d2sel(1000) 
 
         dimension d1_vec(11000) 
         dimension d2_vec(11000) 
    
         OPEN(1,FILE='P1.txt',STATUS='OLD') 
         OPEN(2,FILE='G523.txt',STATUS='OLD') 
C        OPEN(3,FILE='F8767_coord.txt',STATUS='OLD') 
C        OPEN(4,FILE='Q447_coord.txt',STATUS='OLD') 
 
         OPEN(5,FILE='best_curve001.txt',STATUS='OLD') 
 
C        Definition of the histrogram 
 
         start=20.0   !holaaaaa 
         fin=400.0 
         width=2.0 
 
         nbins=(fin-start)/width 
 
         do i=1,nbins 
          mat_d1(i)=0 
          mat_d2(i)=0 
         enddo 
 
100      format(i5,7x,f8.3,f8.3,f8.3) 
101      format(i5,7x,f8.3,f8.3,f8.3) 
         do k=1,10000 
          read(1,100) ista,xc,yc,zc 
          g1mat(ista,1)=xc 
          g1mat(ista,2)=yc 
          g1mat(ista,3)=zc 
 
          read(2,101) istb,xc,yc,zc 
          V654mat(istb,1)=xc 
386 
 
          V654mat(istb,2)=yc 
          V654mat(istb,3)=zc 
 
C          read(3,100) istc,xc,yc,zc 
C          F8767mat(istc,1)=xc 
C          F8767mat(istc,2)=yc 
C          F8767mat(istc,3)=zc 
 
C          read(4,100) istd,xc,yc,zc 
C          Q447mat(istd,1)=xc 
C          Q447mat(istd,2)=yc 
C          Q447mat(istd,3)=zc 
 
         enddo 
 
         do kk=1,10000 
C  Distance between G1 and V654           
 
          xx=g1mat(kk,1)-V654mat(kk,1) 
          xx2=xx*xx 
          yy=g1mat(kk,2)-V654mat(kk,2) 
          yy2=yy*yy 
          zz=g1mat(kk,3)-V654mat(kk,3) 
          zz2=zz*zz 
 
          d1=sqrt(xx2+yy2+zz2) 
 
C          print *, d1,kk 
 
          d1_vec(kk)=d1 
 
C  Let's put d1 into a histogram 
    
          do j=1,nbins 
           xmin=start+width*(j-1) 
           xmax=start+width*j 
           if(d1.gt.xmin .and. d1.le.xmax) then 
              mat_d1(j)=mat_d1(j)+1 
           endif 
          enddo 
 
C  Distance between G1 and F8767 
 
C          xx=g1mat(kk,1)-F8767mat(kk,1) 
C         xx2=xx*xx 
C          yy=g1mat(kk,2)-F8767mat(kk,2) 
C          yy2=yy*yy 
C          zz=g1mat(kk,3)-F8767mat(kk,3) 




C          d2=sqrt(xx2+yy2+zz2) 
 
C          d2_vec(kk)=d2 
 
C  Let's put d2 in a histogram 
 
C          do j=1,nbins 
C           xmin=start+width*(j-1) 
C           xmax=start+width*j 
C           if(d2.gt.xmin .and. d2.le.xmax) then 
C              mat_d2(j)=mat_d2(j)+1 
C           endif 
C          enddo 
 
         enddo 
 
          read(5,*) wed 
          read(5,*) xmodel 
 
          do while (.true.) 
           read(5,*,end=999) nstr,ifreq 
C           print *, nstr,ifreq 
 
           do j=1,nbins 
           xmin=start+width*(j-1) 
           xmax=start+width*j 
           if(d1_vec(nstr).gt.xmin .and. d1_vec(nstr).le.xmax) then 
              mat_d1sel(j)=mat_d1sel(j)+ifreq 
           endif 
          enddo 
 
          do j=1,nbins 
           xmin=start+width*(j-1) 
           xmax=start+width*j 
           if(d2_vec(nstr).gt.xmin .and. d2_vec(nstr).le.xmax) then 
              mat_d2sel(j)=mat_d2sel(j)+ifreq 
           endif 
          enddo 
 
          enddo 
 
102      format(2X,f5.1,5x,4(i4,3x)) 
999      do j=1,nbins 
           print 102, start+width*(j-1)+width/2.0,mat_d1(j), 
     &       mat_d1sel(j),mat_d2(j),mat_d2sel(j) 






         stop 








































SR78 (Crysol fit) 
SR78 experimental data 
SR78 (DAMMIF fit) 
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